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Alzheimer’s disease (AD) is an age-related neurodegenerative disease that mainly 
affects elderly individuals. The disease is characterised clinically by cognitive decline 
and neuropsychiatric symptoms, while its pathological features are the accumulation 
of senile plaques and neurofibrillary tangles in the brain. Aβ pathology is a central 
component of the disease. Early aggregated forms of Aβ known as “soluble 
oligomers” are believed to be a potent neurotoxic agent responsible for nerve cell 
damage and loss of synapses, so contributing to memory and learning deficits. 
Therefore, inhibiting the formation of these early aggregates could provide a novel 
approach to the treatment of AD. 
 
A retro-inverso peptide, RI-OR2-TAT, has been developed previously in Lancaster, 
and this demonstrated good inhibition of early-stage Aβ aggregation, but only at high 
concentrations of inhibitor relative to Aβ. An improved peptide system was 
subsequently developed involving attachment of RI-OR2-TAT onto the surface of a 
lipid nanoparticle scaffold (nanoliposome). The resulting “Peptide inhibitor 
nanoparticles” (PINPs) demonstrated much more potent inhibition of aggregation, 
and could penetrate through an artificial BBB. In this project, RI-OR2-TAT, PINPs and 
a novel retro-inverso peptide, RI-OR2-NAG, were examined for their ability to cross 
the intact and functional blood-brain barrier (BBB) of WT mice. Their accumulation in 
the brain, distribution in peripheral tissues, and possible modes of excretion, were 




In fluorescent imaging studies, fluorescein-labelled versions of RI-OR2-TAT, RI-OR2-
NAG and PINPs all demonstrated effective penetration across an integral BBB and 
accumulation in the cortex, hippocampus, and dentate gyrus of the brain, where they 
were mainly co-localised with glial cells. Luminex technology was used to study the 
distribution of the first two peptides in the brain, heart, lungs, stomach, liver, spleen, 
kidneys and small intestine. The results of this study confirmed that these peptides 
accumulate in small amounts in the brain, but they are mainly found in the small 
intestine, suggesting a possible elimination route through bile secretions into the 
duodenum, followed by excretion through the faeces or reabsorption back into the 
general circulation, for possible excretion through the urine. Finally, as part of the 
project, the anti-aggregatory properties of the RI-OR2-NAG peptide were 
investigated, and this proved to be a more effective inhibitor of Aβ aggregation than 
RI-OR2-TAT. 
 
In conclusion, the use of liposomes as an effective carrier nanosystem for targeted 
delivery could be extended to the RI-OR2-NAG peptide. The results of this PhD thesis 
project are encouraging and it is hoped that a version of these peptides can progress 
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Chapter 1: Introduction 
 
1.1. Alzheimer’s disease 
Alzheimer’s disease (AD) is an age-related neurodegenerative disorder delineated 
mainly by cognitive impairment, and neuropsychiatric symptoms, as well as 
restriction in daily independence of living activities. AD is the leading and most 
common cause of dementia as it accounts for about two-thirds of all dementia cases 
(WWW, Alzheimer’s Research UK), and affects mainly elderly individuals. Dementia is 
a general term used to describe a broad set of symptoms as a result of the damage 
present in the human brain caused by various degenerative diseases. Generally, 
dementia is a slow progressive condition, denoting that the symptoms will gradually 
become worse and more severe over time, resulting eventually in incapacitation. In 
particular, dementia symptoms comprise memory loss, confusion, mood changes, 
and difficulties with thinking, expression, language and problem-solving (WWW, 
Alzheimer’s Society). 
 
1.1.1. Alzheimer’s first case 
AD was first identified more than 100 years ago by a German psychiatrist and 
neuropathologist, Alois Alzheimer (1864 – 1915) (Alzheimer, 1907). In his first report 
published in 1907, Alzheimer described the symptoms of a 51-year-old female 
patient, Auguste Deter, who suffered from progressive memory impairment, reduced 
cognitive function, distorted and aggressive behaviour, language problems, 
hallucinations and disorientation (Alzheimer, 1907). Histological samples taken from 
the brain of the patient post-mortem showed widespread thinning of  
cerebrocortical grey matter, along with the presence of ‘miliary bodies’ between 
nerve cells and ‘dense bundles of fibrils’ inside nerve cells which today are known as 
the principal neuropathological and pathognomic hallmarks of AD (Blennow et al., 
2006). These distinguishing focal lesions of the disease are respectively termed as 
senile or neuritic plaques which form as extracellular deposits of amyloid-β peptide 
(Aβ) in the grey matter of the brain, and neurofibrillary tangles (NFTs) that are 
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Figure 1.1. The neuropathological hallmarks of Alzheimer's disease. 
Microscopic image of AD neuropathology showing a senile or neuritic plaque (lower left-hand 
corner) and a NFT (upper right-hand corner), which are known to be the pathognomic 
hallmarks of the disease (Bird, 2008). 
 
1.1.2. Global prevalence and incidence rate 
Currently, there are about 10 million people globally that suffer from 
neurodegenerative diseases each year, a figure that is expected to rise by 20% over 
the following decade due to the increased life expectancy of the population (OECD, 
2010). What is more, neurodegenerative diseases are currently the fourth leading 
cause of death following the diseases of the heart, cancer and stroke (WWW, 
Organisation for Economic Co-operation and Development). With reference to AD, 
currently there are 46.8 million people worldwide who are believed to be living with 
the disease or related dementias; a number that is anticipated to increase to 74.7 
million by 2030 and 131.5 million by 2050 (WWW, BrightFocus Foundation). 
Naturally due to the aging of the world population, AD is reaching an epidemic 
magnitude. It afflicts at least 6% of individuals over the age of 65, rising to 20% for 





1.2. Pathological aspects and clinical features of Alzheimer’s disease 
AD is considered as one of the most debilitating conditions of the current century. 
Analogous to dementia, AD is considered as a progressive disorder with numerous 
pathological, structural and functional alterations ensuing and becoming gradually 
and irreversibly advanced over time. 
 
1.2.1. Pathophysiological changes 
The two main pathological hallmarks of the disease are the senile plaques composed 
of amyloid deposits and NFTs that are formed by intracellular deposits of 
hyperphosphorylated tau protein (Figure 1.1.). These characteristic lesions are 
predominantly found in the frontal and temporal lobes, including the hippocampus, 
and other cortical areas of the brain at autopsy (Morgan, 2011). 
 
1.2.1.1. Senile plaques 
The amyloid deposits are arranged in aggregated and accumulated forms of Aβ fibrils 
and are primarily found at the core of the senile plaques, in association with metals 
such as copper, iron and zinc (Selkoe, 2004; Zatta et al., 2009), and surrounded by 
activated microglia cells, reactive astrocytes and dystrophic dendrites and axons. As a 
result, the entire complex forms a spherical structure with a diameter of 
approximately 200 μm which can inflame the surrounding area of the brain by 
initiating many downstream events (Blessed et al., 1968). 
 
1.2.1.2. Neurofibrillary tangles 
The NFTs on the other hand are composed of intracellular deposits of tau, a 
microtubule-associated protein, which aggregates to form paired helical filaments 
(PHFs) that consist of two 10 nm filaments twisted around each other to form a 
double helix (Kidd, 1963). These filaments are abundant inside the nerve cells and 
occupy most of the cytoplasm (Puglielli, 2008). Hyperphosphorylation of tau protein 
results in its disassembling from the microtubule and instead forming the NFTs. As 
hyperphosphorylated tau protein is present inside the nerve cells, the efficacy of 
axonal transport is impaired jeopardising the function of neurons and synapses (Iqbal 
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et al., 2005) resulting in many synaptic defects and memory impairments (Cowan et 
al., 2010).  
 
The brain of an AD patient exhibits global structural atrophy particularly in the 
hippocampus and temporal lobes (Figure 1.2.). Neuropathological changes of the 
disease include the loss of brain weight, dysfunction and degeneration of neurons 
and synapses, enlargement of ventricles, and widespread oxidative damage 
(Markesbery, 1997) and death of cholinergic neurons resulting in many downstream 




Figure 1.2. Comparison of a normal versus an Alzheimer brain. 
Contrast image of a normal adult brain (left) with an Alzheimer’s brain (right). During the 
progression of the disease, the structure of the brain becomes more damaged, showing 
marked diffuse cortical atrophy and enlargement of ventricles (Bird, 2008). 
 
1.2.2. Neurological characterisation 
The disease is clinically characterised by an insidious and vague onset along with 
progressive deterioration of selective cognitive domains, in particular short-term 
memory (primary/active memory). Specifically, memory decline initially establishes 
as a loss of episodic memory, which is considered as a subtype of declarative 
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(explicit) memory (LaFerla et al., 2007). Explicit memory with procedural (implicit) 
memory form the long term memory, which is severely affected during the late stage 
of AD. 
 
Due to the progressive nature of the disease, typical signs that characterise the 
disease include agnosia, the lack of recognition of objects; apraxia, the inability to 
make voluntary movements; and aphasia, the loss of the capability to speak and poor 
word recognition. Alzheimer’s patients often experience a plethora of cognitive 
symptoms due to the loss of cognitive function (the aptitude to think and reason 
clearly). These symptoms include disorientation, heighted aggression, agitation, 
impaired judgment, mood swings, sleep disturbances and hallucinations (Blennow et 
al., 2006). 
 
1.2.3. Clinical determination for disease progression 
The progression of AD and other dementias is commonly divided into three stages as 
defined by the mini-mental state examination (MMSE) score and include early, mild-
moderate and late-severe stages. Nevertheless, neurodegeneration in AD is thought 
to start 20 – 30 years before the clinical onset and the appearance of overt clinical 
symptoms (Davies et al., 1988). The symptoms only appear after the plaque and NFT 
deposition reaches a certain critical threshold. Conversely, during the preclinical 
stage termed as mild cognitive impairment (MCI) (Eckerström et al., 2013), 
individuals show greater than expected memory deficits, yet not severe enough to be 
diagnosed with dementia. This presymptomatic stage is a transitional stage between 
normal ageing and AD where individuals can either be stable or go on to develop the 
disease with a conversion rate of 10 – 15% per year (Petersen, 2004). Ultimately, 
during the early stage of the disease, minor changes are detectable in behaviour due 
to the limited loss of cognitive function. On the contrary, as the disease advances to 
the moderate and severe stages, the changes become more discernible due to the 
loss of functional independence and increased behavioural problems. In 
consequence of these facts, the estimated life expectancy following initial diagnosis 




1.3. Alzheimer’s disease as amyloidosis 
Numerous diseases, including AD, are characterised by the misfolding of one or more 
proteins which contribute, over a period of time, to extensive degeneration in 
specific brain regions, leading to the corresponding clinical and pathognomic features 
of each disease. These neurodegenerative diseases belong to a wider group of 
diseases termed as amyloidoses in which the central pathological characteristic is the 
deposition and accumulation of insoluble fibrillary proteins. Once formed, amyloid 
deposits remain resistant to proteolytic degradation; a process that normally allows 
the effective clearance of proteins from the organism and subsequently result in cell 
damage, organ dysfunction and ultimately death (Ghiso and Frangione, 2002).  
 
Characterised by the presence of localised amyloid deposits and aggregates in the 
brain and the central nervous system (CNS), AD is actually the most frequent type of 
amyloidosis in humans (Wisniewski et al., 1997; Selkoe, 2001). The deposition of the 
insoluble and mature amyloid fibrils in AD is a consequence of misfolding from native 
α-helix/random coil soluble peptides to β-sheet structure, 7 – 10 nm in width (Figure 
1.3.), with low molecular weight and ability to bind to dyes Congo red and ThT 
(Thioflavin T) (Gosal et al., 2006; Soto, 2003). Both Aβ and tau proteins are 
aggregated in AD composing parenchymal amyloid deposits in the form of 




Figure 1.3. Aβ fibrils and senile plaque formation. 
A. The Aβ peptide can be detected by in-vivo immunostaining at the core (centre) of the senile 
plaque. B. The in-vitro assembly of Aβ into 10 nm (in diameter) fibrils as detected by electron 
microscopy with rotary metal shadowing (courtesy of Dr. David Howlett – King’s College, 
London, U.K.) (Allsop, D., and Mayes, J., 2014). 
 
1.3.1. Aβ and Amyloid precursor protein 
The Aβ which is involved in AD as the main component of the amyloid plaques, is a 
36 – 43 amino acid residue peptide and is produced by the internal proteolytic 
cleavage of both N- and C- terminal domains of a larger type I integral membrane 
glycoprotein called amyloid precursor protein (APP). The gene encoding the APP 
protein is located on chromosome 21 (Kang et al., 1987; Goldgaber et al., 1987; 
Robakis et al., 1987). The Aβ peptide sequence arises from fragments of exons 16 
and 17 and contains a C-terminal hydrophobic tail composed of 12 – 14 residues that 
are derived from the intramembranous portion of APP, while the remaining resides 
are located outside of the membrane (Blennow et al., 2006; Barnham et al., 2003). 
 
Aβ is produced constitutively during normal cell metabolism (Haass et al., 1992). 
Proteolytic cleavage of APP by α-secretase between residues 16 – 17 of the Aβ region 
prevents the formation of Aβ peptide; however initial cleavage by β-secretase and 
sequential processing of the resulting peptide by γ-secretase leads to the generation 
of Aβ (Figure 1.4.) Normally, APP in 90% of the neuronal cells undergoes the non-
proteolytic pathway, denoting that the α-secretase pathway is predominant in APP 




Figure 1.4. Proteolytic processing of APP. 
In the non-amyloidogenic pathway (left-hand side) the APP is cleaved by α-secretase 
generating a large soluble sequence (sAPPα) and the C-terminal fragment (CTF) α (CTFα). 
Further processing of the CTFα sequence and cleavage by γ-secretase generates the p3 
fragment and the amyloid precursor protein intracellular domain (AICD); neither of which are 
involved in amyloid plaque formation. However, in the amyloidogenic pathway (right-hand 
side), initial cleavage of APP by β-secretase results in the sAPPβ and CTFβ fragments, while 
further cleavage of CTFβ by γ-secretase provokes the production of AICD and Aβ which is 
implicated in the senile plaque formation. Imbalanced cleavage of APP through the 
amyloidogenic pathway, and inadequate Aβ degradation and clearance result in the 
formation of amyloid plaques (adapted from La Ferla et al., 2007). 
 
Under physiological conditions, the Aβ peptide produced through the amyloidogenic 
pathway is cleared from the brain through degradarion by several peptidases 
including the insulin-degrading enzyme (IDE), neprilysin, and the endothelin-
converting enzyme 1 (ECE1) (Carson and Turner, 2002). Additionally, the low-density 











mediate the balanced efflux and influx, respectively, of Aβ across the BBB in order to 
remove the excess peptide from the brain (Tanzi et al., 2004). Therefore, AD can also 
be described as an imbalanced between Aβ productin and clearance. 
 
1.3.2. Amyloid cascade hypothesis 
Aβ is produced from APP processing as a monomer, yet it can rapidly aggregate and 
assemble into multimeric protein complexes with various molecular weights, ranging 
from dimers or trimers to higher order assemblies including protofibrils and mature 
fibrils (Figure 1.5.). Two forms of Aβ peptide are mainly produced, Aβ40 (amino acid 
residues 1 – 40) and Aβ42 (amino acid residues 1 – 42). Cumulative evidence 
suggests that Aβ42 is more inclined to aggregation as it undergoes more accelerated 
formation of Aβ oligomers, larger intermediate assemblies such as the protofibrils, 
and more insoluble mature amyloid fibrils (Jarrett et al., 1993; Iwatsubo et al., 1994). 
 
 
Figure 1.5. Aβ assembly and aggregation. 
Aβ exists in multiple states. Monomeric molecules can aggregate into oligomeric and 
protofibrilar complexes, that further form the mature amyloid fibrils present at the core of 
the senile plaques. The early soluble oligomeric forms of Aβ are considered as potent 
neurotoxic agents that result in the pathogenicity of AD (adapted from LaFerla et al., 2007). 
 
The “amyloid cascade hypothesis” initially proposed that imbalanced production 
and/or clearance of Aβ insoluble mature fibrils are central to AD pathology. 
According to the hypothesis, Aβ mature fibrils are responsible for the initiation of a 
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cascade of events in AD brain leading to a number of downstream consequences 
including neuronal cell death, NFT formation, and its aggregation and accumulation 
in senile plaques (Hardy and Allsop, 1991). Even though this hypothesis offers a 
broad description of AD pathogenesis, it was thought that it is lacking in detail and 
was more recently revised (Hardy and Selkoe, 2002). 
 
1.3.2.1. The “Oligomer hypothesis” 
Hardy and Selkoe (Hardy and Selkoe, 2002) reviewed the amyloid cascade hypothesis 
and shifted the emphasis away from the mature amyloid fibrils. They presented 
evidence that smaller and more soluble aggregates that embody a diversity of 
molecules, referred to as oligomers, ADDLs (amyloid β-derived diffusible ligands) or 
protofibrils, are the neurotoxic species of Aβ. The “oligomer hypothesis” (Figure 1.6.) 
thus suggests that intermediate Aβ oligomers are more potent brain toxins than the 
larger mature fibrils (Klein et al., 2001; Hardy and Selkoe, 2002; Varvel et al., 2008), 
resulting in synaptic dysfunction in AD brains, potent memory and learning deficits 
(Chromy et al., 2003; Bitan et al., 2003), and play a critical role in the progression of 
cognitive impairment in AD (Tomic et al., 2009) and its pathogenicity (Kayed et al., 
2003; Kayed et al., 2004). 
 
1.3.2.2. Oligomers and Reactive Oxygen Species generation 
Further evidence that the early oligomeric structures are the neurotoxic components 
in AD has included the fact that these molecules are able to generate reactive oxygen 
species (ROS). Elevated levels of redox-active transition metal ions, lipid 
peroxidation, DNA and protein oxidation and the introduction of carboxyl groups into 
proteins have been reported in a wide range of neurodegenerative diseases (Allsop 
et al., 2008; Riederer et al., 2013), including AD. With reference to AD, the oxidative 
brain damage has been reported to be predominantly an early event in the time 
course of the disease (Nunomura et al., 2001; Markesbery et al., 2005), and ROS have 
been reported to be generated at the initial stages of Aβ aggregation (Tabner et al., 
2005). Particularly, biometal ions have been found at enriched levels in the amyloid 
cores of the senile plaques in AD patients (Lovell et al., 1998; Huang et al., 2004; 
Smith et al., 1997). The soluble non-fibrillar oligomers have also been reported to 
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generate hydrogen peroxide (H2O2) from molecular oxygen through electron transfer 
interactions that involve strongly bound redox-active metal ions such as copper, iron 






Figure 1.6. Oligomer cascade hypothesis. 
Proposed sequence of the pathognomic events leading to Alzheimer’s disease through the 
“oligomer hypothesis” cascade. The curved arrow indicates that the soluble oligomers of Aβ 
may not only activate the microglia and astrocytes, but also directly damage the synapses 
and neurites of neuronal cells (adapted from Hardy and Selkoe, 2002). 
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1.4. Sporadic and familial Alzheimer’s disease 
As the disease is strongly correlated with age, it is primarily characterised by two 
types; late-onset AD, which is the most common form of the disease and is defined 
by age at disease onset later than 65 years, and early-onset AD, which accounts for 
about 1 – 6% of all cases and the age at onset ranges from 30 to 65 years. From a 
genetic point of view though, the disease is mainly differentiated into familial cases 
that follow Mendelian inheritance and are predominantly linked with the early-onset 
disease, and sporadic cases which mainly appear as late-onset AD (Bekris et al., 
2010), yet these two forms of the disease are clinically indistinguishable.  
 
1.4.1. Familial Alzheimer’s 
The familial form of AD is a rare autosomal dominant disorder and is usually due to 
mutations in one of three principal genes; APP on chromosome 21, presenilin 1 (PS1) 
on chromosome 14 and presenilin 2 (PS2) on chromosome 1 (Bertram et al., 2010). 
 
1.4.1.1. APP mutations 
Currently, 25 pathogenic APP mutations have been associated with the familial form 
of the disease, yet they only account for less than 1% of AD cases (Lambert and 
Amouyel, 2007). These mutations either affect residues within the Aβ amino acid 
sequence that are important for its self-association and aggregation, or cluster 
around the β- and γ-secretase cleavage sites, where in both cases they result in 
increased levels of Aβ release, or promote its aggregation. More specifically, disease-
causing mutations clustered around the β-cleavage site generate a better substrate 
for the production of Aβ40 (Mullan et al., 1992), while mutations around the γ-
cleavage site, favour the production of the more toxic Aβ42 (Ghiso and Frangione, 
2002). 
 
Importantly, a coding mutation (A673T) in the APP gene was found to protect against 
the disease and the cognitive decline in non-AD elderly individuals. This mutation is a 
result of an amino acid substitution next to the site where β-secretase cleaves the 
APP protein. Data obtained by Jonsson and colleagues demonstrate that the resulted 
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mutation decreases the in vitro formation of Aβ by 40%, suggesting that inhibition of 
β-secretase APP cleavage site may protect against AD (Jonsson et al., 2012). 
 
1.4.1.2. Presenilin mutations 
Mutations in the highly homologous genes PS1 and PS2 account for the majority of 
familial AD cases (Rogaev et al., 1995; Sherrington et al., 1995; Sorbi et al., 1995). The 
proteins encoded by these genes determine γ-secretase action as they compromise 
the active site of the enzyme (Gandy, 2005). Subsequently, mutations on PS1 and PS2 
genes can alter APP proteolysis and processing, increasing the levels of Aβ peptide 
generated and altering the ratio of Aβ42 to Aβ40 (Blennow et al., 2006; Schellenberg 
and Montine, 2012). 
 
1.4.2. Sporadic Alzheimer’s 
On the other hand, the majority of all AD cases, about 95%, are considered to be 
sporadic and are strongly associated (about 35% of sporadic cases) with the 
apolipoprotein E (APOE) ε4 allele (Corder et al., 1993; Poirier et al., 1993) which 
accounts for much of the genetic risk and pathology in this form of the disease 
(Raber et al., 2004). Interestingly though, over 60% of all sporadic cases are not 
associated with the APOE ε4 allele, suggesting that other genetic and environmental 
factors can contribute to the determination of the disease. It has been identified that 
a rare variant of the TREM2 gene is associated with late-onset sporadic AD 
(Guerreiro et al., 2013; Jonsson et al., 2013) and increases susceptibility to the 
disease with an odds ratio similar to that of the APOE ε4 allele (Jones, 2012; Niemitz, 
2012; Neumann and Daly, 2013; Guerreiro et al., 2013; Jonsson et al., 2013). 
 
1.4.2.1. Apolipoprotein E ε4 allele mutation 
APOE is the major apolipoprotein expressed in the brain and exists in a polymorphic 
form; it is a constituent of lipoproteins which are involved in cholesterol 
homeostasis. In connection with AD, the APOE ε4 allele, located on chromosome 19, 
increases the risk of the disease by 3-fold in the heterozygote form and by 15-fold in 
homozygotes (Farrer et al., 1997), and also modifies the age of onset (Meyer et al., 
1998) with each allele copy lowering the age of onset by approximately 10 years 
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(Corder et al., 1993). Even though the role of APOE in the predisposition of the 
disease is entrenched; the mechanism by which the protein is involved in the 
pathogenesis of AD is still unclear (Verghese et al., 2011). One possible mechanism 
suggested by Martins and colleagues (2006) proposes that the differences in the 
amino acid sequences of the three APOE isoforms (ε2, ε3 and ε4) induce a protein 
structure with altered functional properties resulting in abnormal cholesterol 
metabolism and defective redistribution of lipids, which would affect neuronal 
plasticity (Martins et al., 2006). Another potential mechanism of action described by 
Castano and colleagues (1995) suggests that based on the evidenced presence of 
APOE in both senile plaques and NFTs, APOE is associated with the conversion of 
monomeric Aβ to oligomeric and fibrillar forms that are deposited into plaques 
(Castano et al., 1995; Holtzman et al., 2000). In fact, the ε4 allele of the APOE gene 
plays a crucial role in AD as it is less effective in breaking down Aβ, thus increasing 
the risk of amyloid plaque formation and density (Corder et al., 1993) compared to 
the ε2 allele which has been linked with decreased risk for AD (Verghese et al., 2011). 
 
1.4.2.2. TREM2 mutation 
Encoding the triggering receptor expressed on myeloid cells (TREM) 2 protein, the 
TREM2 gene is expressed throughout the CNS and particularly in white matter, as 
well as the hippocampus and neocortex, while the encoded protein is present on 
macrophages, dendritic cells, osteoclasts and microglia (Colonna, 2003; Bouchon et 
al., 2000). The TREM2 protein has two normal functions; it is involved in the 
regulation of phagocytic pathways responsible for the removal of neuronal debris 
and also suppresses various inflammatory responses through the repression of 
microglia-mediated cytokine production and secretion (Takahashi et al., 2007; Frank 
et al., 2008; Piccio et al., 2007). It has been demonstrated that a rare missense 
mutation in TREM2 significantly increases the risk of AD by 3-fold. Considering the 
normal anti-inflammatory role of TREM2 protein in the brain, it is suspected that the 
mutated variant interferes with brain’s ability to prevent the build-up of amyloid 
plaques (Guerreiro et al., 2013, Jonsson et al., 2013).  
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1.5. Risk factors 
As a heterogeneous disorder, AD is associated with various risk factors that increase 
the frequency of its occurrence. Aside from ageing which is the most apparent risk 
factor, the disease is also linked with previous family history, even though only about 
5% of cases have clear genetic linkage. As mentioned previously, the APOE ε4 and 
TREM2 genotypes have been described as major risk factors for the development of 
sporadic AD. 
 
1.5.1. Low brain reserve capacity 
An alternative risk factor for the disease is the decreased reserve capacity of the 
brain which is determined by the number of neurons and their synaptic 
communications (Mayeux, 2003) and is described as the brain’s resilience to 
pathological damage and changes. A low reserve capacity of the brain correlates with 
reduced brain size, low educational achievement, and low mental and physical 
activity later in life, along with other lifestyle-related strategies (Mayeux, 2003; 
Mortimer et al., 2003). Evidence provided by Jellinger in 2004, shows that head 
injuries can result in reduced brain reserve capacity, and thus are considered as a 
hazardous factor for the occurrence of AD (Jellinger, 2004). Additionally, 
epidemiological studies by Roberts and colleagues have also shown that multiple and 
repeated head trauma can lead to plaque and tangle formation (Roberts et al., 1990). 
 
1.5.2. Type 2 Diabetes Mellitus 
It has also been reported that impairments in insulin signalling and Type 2 Diabetes 
Mellitus (T2DM) are important risk factors associated with early-onset sporadic AD 
(Strachan, 2005; Haan, 2006; Luchsinger et al., 2004; Ristow, 2004; Biessels et al., 
2006). Evidence suggests that hyperinsulinemia and insulin resistance, the hallmarks 
of T2DM, can lead to memory impairment (Ott et al., 1999; Kroner, 2009; Jiang et al., 
2008), thus T2DM patients are predisposed to AD (Akter et al., 2011). 
 
Other risk factors associated with AD include vascular diseases such as 
hypercholesterolaemia, hypertension, atherosclerosis, coronary heart disease and 
obesity (Mayeux, 2003). 
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1.6. Diagnosis of Alzheimer’s disease 
One of the main problems associated with AD is the limited availability of diagnostic 
methods and tools. The clinical diagnostic accuracy of the disease is around 80 – 
90%. Diagnosis is performed based on the known clinical history of the individuals 
along with clinical, neurological and psychiatric examinations in order to exclude any 
other possible causes of dementia such as alcohol problems, head trauma or 
cerebrovascular dementia. Additionally, confirmation of genuine cognitive 
impairment is available through memory tests and rating scales such as the MMSE 
score. 
 
Brain imaging (neuroimaging), computed tomography (CT) and magnetic resonance 
imaging (MRI) scans are sometimes used in the diagnosis of AD and can help with the 
exclusion of other causes of dementia such as brain tumours and strokes. The scans 
can also indicate neurodegeneration in the form of cerebral atrophy. It has also been 
identified that Pittsburgh Compound-B (PiB) can be used for imaging senile plaques 
in AD brains (Klunk et al., 2004). PiB is a radioactive analog of ThT which, when used 
in Positron Emission Tomography (PET) scans, can image amyloid plaques in the 
brain. Thus, PiB can potentially aid diagnosis of AD or be useful in clinical trials. 
 
Still, a definitive diagnosis can only be made by examination of the brain post-
mortem for the presence of senile plaques and NFTs (Blennow et al., 2006). 
 
 
1.7. Therapy and treatment of Alzheimer’s disease 
AD is becoming gradually more common as the global population ages, yet 
development of drugs that prevent, delay the onset, slow the progression, or 
improve the symptoms of the disease has proven to be difficult. A study conducted 
by Cummings and colleagues examining data from a public website that records 
ongoing clinical trials, during the period between 2002 and 2012, identified 244 
compounds in 413 AD clinical trials, of which; 151 (36.6%) were cognitive enhancers 
targeting the symptoms of the disease, 145 (35.1%) were small molecules with 
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disease-modifying potential, and 76 trials (18%) with immunotherapies; and an 
overall success rate of 0.4% (Cummings et al., 2014). Currently, four drugs are 
approved for AD treatment, which temporarily alleviate the symptoms of the disease 
and do not have a major impact on its progression, delineating the disease as an 
unmet medical and clinical need. 
 
1.7.1. Acetylcholinesterase inhibitors 
One approach implemented in symptomatic and palliative treatments for AD 
involves the acetylcholinesterase inhibitors which restore cholinergic activity through 
the inhibition of acetylcholinesterase. AD is associated with the loss of cholinergic 
neurons in the brain affecting the levels of the acetylcholine neurotransmitter (Lane 
et al., 2006). According to the cholinergic hypothesis in AD, degeneration of the 
cholinergic neurons, which are present in the basal forebrain nuclei, results in the 
disruption of the presynaptic cholinergic terminals, located in the hippocampus and 
neocortex, affecting the memory and consequently contributing to the cognitive 
decline present in AD (Terry and Buccafusco, 2003). Currently available 
acetylcholinesterase inhibitors approved for clinical use in AD, Donepezil, 
Rivastigmine and Galantamine, act by restoring both the levels and duration of action 
of acetylcholine, thus improving synaptic communication between nerve cells, and 
showing modest benefits in cognition and behaviour (Colovic et al., 2013). The 
acetylcholinesterase inhibitors are used to treat mild to moderate AD, however, 
these drugs show various adverse effects mainly with gastrointestinal symptoms, 
such as nausea, vomiting, diarrhoea, abdominal pain and dizziness (Inglis, 2002). 
 
1.7.2. NMDA receptor antagonist 
Another medication used for AD patients is Memantine, a NMDA (N-methyl-D-
aspartate) receptor antagonist, which has demonstrated a modest effect on 
moderate-to-severe AD (Reisberg et al., 2003). More specifically, Memantine is 
administered to patients with moderate AD who have a contraindication to or are 
intolerant of acetylcholinesterase inhibitors, or those with severe AD. Memantine 
demonstrates a moderate decrease in clinical deterioration with minor effects on 
cognition, behaviour and mood of AD patients (Areosa et al., 2006). Despite years of 
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research on this drug, there is only slight evidence of any effect on mild AD 
(Schneider et al., 2011). 
 
1.7.3. β- and γ-secretase inhibitors and modulators 
Increasing knowledge regarding the molecular pathogenesis of AD has led to the 
development of drugs that interfere with the secretase activity in APP processing. 
These drug candidates can either inhibit Aβ production and consequently the 
aggregation of the peptide in the brain or increase Aβ clearance from the brain. The 
secretase modulators would either target the inhibition of β-secretase or γ-
secretase; or stimulate the production of α-secretase. However, development of 
these inhibitors was proven difficult, especially for β-secretase or γ-secretase, as 
these secretases are involved in the clearance of multiple cell surface proteins – in 
addition to APP – thus resulting in various adverse side effects (Gandy, 2005). 
 
More precisely, initial therapeutic approaches that targeted the inhibition of total Aβ 
peptide production by directly inhibiting the action of γ-secretase equivalently 
blocked the formation of all major Aβ variants (Anderson et al., 2005) – not only 
Aβ42 – and also the formation of the APP intracellular domain and Notch-1 receptor 
that plays a key role in the differentiation of multiple cell types (De Strooper et al., 
1999). Semagacestat, a γ-secretase inhibitor that was tested in two Phase 3 clinical 
trials failed to show any effect on disease progression, compromised even more the 
performance of the patients on their daily activities as it induced further cognitive 
impairment (WWW, Lilly), and was also linked with an increased risk of skin cancer 
(Wagner et al., 2012). Further studies on drug candidates, called nonsteroidal anti-
inflammatory drug (NSAID)-like compounds that modulate the levels of the enzyme 
activity instead of inhibiting its action, showed no potency and poor brain 
penetration (Weggen et al., 2001; Green et al, 2009). Regardless of the minimal 
properties of γ-secretase modulators, R-flurbiprofen (Tarenflurbil) was tested in 
three large phase clinical trials demonstrating no effect (Green et al., 2009). 
 
On the other hand, inhibitors of β-secretase (BACE1) have been proven difficult to 
develop due to the large binding site of the enzyme. Additionally, because of the 
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numerous substrates that are cleaved by BACE1, inhibition of the enzyme may result 
in various side effects including impaired motor coordination (Cheret et al., 2013) 
and retinal pathology (Cai et al., 2012). 
 
1.7.4. Immunotherapy and vaccine development 
Studies associated with AD treatment using active and passive immunisation resulted 
in the development of various potential vaccine candidates for the disease. The idea 
of active Aβ immunisation was first proposed by Solomon and colleagues (Solomon 
et al., 1996; Solomon et al., 1997) suggesting that anti-Aβ antibodies can be used to 
prevent the mature fibril formation while also disaggregating any pre-existing fibrils. 
Schenk and colleagues then demonstrated that active immunisation against the full 
length of the peptide resulted in reduced load of amyloid plaques in vivo using AD 
transgenic mice (Schenk et al., 1999). Consequent studies proved that active Aβ 
immunisation promotes the generation of anti-Aβ antibodies able to bind on the 
amyloid plaques and reduce the cerebral Aβ load improving also cognition. The first 
active vaccine that was tested in clinical trials, AN1792, demonstrated reduction of 
Aβ deposition following autopsy of the responders’ brains after several years, 
however, the drug itself failed to pass the trials as it resulted in the development of 
meningoencephalitis (Gilman et al., 2005). 
 
The first approach of using passive immunisation was performed by Bard and 
colleagues (Bard et al., 2000) using an Aβ monoclonal antibody, 3D6 mAb, specific for 
the Aβ N-terminus. Systemic injection of the antibody in AD transgenic mice resulted 
in binding of the antibody onto amyloid plaques and induction of a Fc-receptor-
mediated microglial phagocytosis of Aβ deposits following distribution and uptake of 
the antibody into the brain (Bard et al., 2000). The same antibody was then used to 
develop a humanised mAb, Bapineuzumab, that was tested in Phase 1, 2 and 3 
clinical trials showing reduced Aβ load in PET scanning yet no other significant clinical 
benefits leading to the termination of the trials (Rinne et al., 2010). Further studies 
on Bapineuzumab demonstrated association with transient vasogenic oedema and 
microhaemorrhage with higher risk in AD patients with one or two APOE ε4 alleles 
(Sperling et al., 2012). 
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Another antibody reported for passive immunisation, m266, demonstrated low brain 
Aβ burden and increased levels of the protein in plasma suggesting that the antibody 
promotes Aβ clearance from the brain to blood (DeMattos et al., 2001). This 
antibody was used as a precursor for Solanezumab, an antibody tested in Phase 3 
clinical trials showing no association with vasogenic oedema or microhaemorrhages 
but indeed increasing plasma Aβ (Farlow et al., 2012). However, in January 2017, Lilly 
terminated the study on Solanezumab failing to show positive results (WWW, 
ClinicalTrials.gov). 
 
Currently on-going clinical trials on Gantenerumab and Crenezumab, show promising 
results (WWW, ClinicalTrials.gov). Gantenerumab, a fully humanised monoclonal 
antibody used in clinical studies (Bohrmann et al., 2012), binds to the fibrillar forms 
of Aβ and demonstrated 30% decrease of brain Aβ load in an antibody-dependent 
manner, using PET scanning (Ostrowitzki et al., 2012). Crenezumab demonstrated 
low possibility of causing inflammatory immune responses and reduced risk for brain 
microhaemorrhage and vasogenic oedema (Adolfsson et al., 2012; Garber, 2012). 
 
However, one major confine of all clinical trial results is the placebo effect in which 
the placebo recipient demonstrates condition-related improvements due to 
psychological expectations rather than the treatment itself. This response, along with 
the long duration of clinical trials which promotes the deterioration of the 
conditions, result in the failure of many clinical studies (Ito et al., 2013).  
 
 
1.8. The approach to an effective amyloid aggregation inhibitor 
Many aggregation inhibitors have failed to progress in clinical studies. Tramiprosate 
(Alzhemed), an aggregation inhibitor that interferes with the binding of 
proteoglycans to Aβ, has failed in clinical trials as it did not demonstrate any 
beneficial effects (Anand, 2014). However, inhibition of the Aβ oligomerisation 
process is an attractive therapeutic approach for AD, as the early soluble oligomers 
are believed to be the neurotoxic agents that drive neurodegeneration and neuronal 
cell death. One of the strategies employed in order to develop novel drug candidates 
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was the use of peptide-based inhibitors that target the oligomeric state of Aβ 
aggregation process rather than the late fibrillar forms (Sciarretta et al., 2006).  
 
1.8.1. The KLVFF region of Aβ 
The central region of the Aβ peptide composed of amino acids 16 – 20, KLVFF, is 
crucial for the self-association and aggregation of the protein (Hilbich et al., 1992; 
Tjernberg et al., 1996). As a result, this pentapeptide sequence has been used as the 
lead compound to develop inhibitory agents of the Aβ aggregation process (Lowe et 
al., 2001; Zhang et al., 2003). Modified synthetic peptides based on this central 
sequence have been reported to prevent the conversion of monomeric Aβ to β-
sheet-rich aggregated assemblies by binding to the homologous sequence in Aβ 
(Soto et al., 1996; Findeis et al., 1999; Ghanta et al., 1996; Gordon et al., 2001; 
Kokkoni et al., 2006; Watanabe et al., 2002). However, the design of these inhibitors 
was formulated on the inhibition of the late fibrillar mature aggregates rather than 
the early oligomeric assemblies and therefore they were only able to partially 
reverse the toxicity of Aβ. 
 
1.8.2. OR1 and OR2 peptides  
Austen and colleagues (Austen et al., 2008) designed peptide inhibitors of the 
oligomerisation assembly based on the corresponding KLVFF region of the Aβ 
peptide. Two synthetic inhibitors (Figure 1.7.) were initially developed, named OR1 
(RGKLVFFGR) and OR2 (RGKLVFFGR-NH2). Both modified peptides contained arginine 
(R) and glycine (G) amino acid residues (RG-/-GR) as a solubilising component (El-
Agnaf et al., 2004) added to the N- and C- terminal ends of the peptides. The cationic 
arginine was added to the peptide through the glycine spacer to aid the solubility of 
the inhibitor and also to prevent it from self-aggregating. The glycine residues 
between the arginine molecule and the pentapeptide were added to facilitate the 
interaction between the inhibitor peptides and native Aβ. The two peptides were 
only differentiated by the replacement of the carboxyl terminus of the OR1 with an 
amide group at the C-terminus of the OR2 inhibitor to render it less charged. As the 
peptide sequence arose from an internal part of Aβ, it was thought best to introduce 
the amide group at the end of the OR2 inhibitor to design a peptide that would be 
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more likely to be recognised as if it was a part of the whole protein from which the 
sequence was chosen (Austen et al., 2008).  
 
Data were obtained from ThT assay analysis and Transmission Electron Microscopy 
(TEM), showing that both OR1 and OR2 inhibitors were able to block the formation 
of Aβ mature aggregates. However, results from the enzyme-linked immunosorbent 
assay (ELISA) demonstrated that the OR2 inhibitor had a better inhibitory effect on 
Aβ soluble immature oligomer formation than the OR1 peptide. OR1 only had a slight 
blocking effect on oligomer formation at high concentrations signifying that it may 
act at a later point in the aggregation pathway than OR2 (Austen et al., 2008). As a 
control for their studies, the group also synthesised a modified KLVFF peptide alone 
containing an amide group at the C-terminus (KLVFF-NH2) which showed no effect on 
the aggregation, possibly due to the absence of the flanking residues (RG- and -GR) in 
the amino acid sequence and thus affecting the peptide’s tendency to self-aggregate 
(Austen et al., 2008). According to these results, blocking the C-terminus with an 
amide group was beneficial since OR2 is overall a more effective inhibitor of Aβ 
oligomer formation than OR1 (Austen et al., 2008). 
 
Further investigation in cytotoxicity studies revealed that only the OR2 inhibitor was 
able to protect cultured human neuroblastoma (SH-SY5Y) cells from Aβ toxicity 
(Austen et al., 2008). Consistent with previous research (Lambert et al., 1998; Kim et 
al., 2003; Kayed et al., 2003; Clearly et al., 2005; El-Agnaf et al., 2000; El-Agnaf et al., 
2001; El-Agnaf et al., 2003; El-Agnaf et al., 2006, ; Bucciantini et al., 2006; De Felice et 
al., 2004) the reported results provided clear evidence that the early non-fibrillar 
oligomers are the toxic species as the neuroprotective effects demonstrated by OR2 
were due to the inhibition of the oligomeric assemblies rather than the late mature 
aggregates (Austen et al., 2008). 
 
1.8.3. The retro-inverso OR2 peptide 
Even though the OR2 peptide inhibitor was proven to be an effective inhibitor 
against the formation of early soluble oligomers, it was unlikely itself to be a viable 
drug candidate as it contains many sites for proteolytic attack in its peptide sequence 
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(Taylor et al., 2010). In order to overcome this flaw, yet retain the anti-aggregational 
properties of the inhibitor, Taylor and colleagues designed a retro-inverso version of 
the OR2 inhibitor (Figure 1.7.), named RI-OR2 (Ac-rGffvlkGr-NH2) to transform it into 
a peptidomimetic (Taylor et al., 2010). Previous studies have demonstrated that 
retro-inverso peptides are able to maintain a topology, potency and selectivity 
similar to those of their “parent” molecule, and also have an improved bioavailability 
profile due to their enhanced stability to proteolysis (Chorev and Goodman, 1993; 
Chorev and Goodman, 1995). Additional studies suggest that retro-inverso peptide 
exhibit good blood-brain barrier (BBB) permeability (Taylor et al., 2000) and 
membrane translocation properties (Nickla et al., 2010). 
 
The approach to develop a proteolytically stable retro-inverso peptide was achieved 
by replacing the natural L-amino acids with D-enantiomers (Poduslo et al., 1999; 
Findeis et al., 1999), and also by reversing the peptide bonds (Chorev and Goodman, 
1993; Chorev and Goodman, 1995). Taylor and colleagues also retained the 
positioning of the two solubilising flanking residues, rG- and -Gr, and replaced the C-
terminal amide group of OR2 with an N-terminal acetyl group in RI-OR2. This N-
terminal acetyl group, CH3CONH, has close chemical properties with CONH2, as both 
are uncharged and unreactive, thus mimicking the original C-terminus of the OR2 
inhibitor. As a result, the three-dimensional shape of the new inhibitor was 
maintained similar to the native molecule enabling the effective interaction between 
the retro inverted “ffvlk” in RI-OR2 peptide and the KLVFF sequence in Aβ (Taylor et 
al., 2010). 
 
Stability experiments using individual proteolytic enzymes, and also exposure to 
human brain extract and blood plasma, confirmed that the RI-OR2 peptide is more 
stable to proteolysis than the OR2 inhibitor (Taylor et al., 2010). Additional studies on 
the RI-OR2 inhibitor demonstrated that the peptide is able to block the formation of 
Aβ oligomers and fibrils as verified by ThT assays, sodium dodecyl sulfate (SDS) 
polyacrylamide gel electrophoresis (PAGE) [SDS-PAGE] separation of stable 
oligomers, and atomic force microscopy (AFM). RI-OR2 was also assessed for cell 
toxicity in cultured SH-SY5Y cells using the MTT and lactate dehydrogenase (LDH) 
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assays, confirming its neuroprotective action against the toxic effects of pre-
aggregated Aβ (Taylor et al., 2010). According to the data obtained by Taylor and 
colleagues (Taylor et al., 2010), the RI-OR2 inhibitor represented a suitable drug-like 
molecule for future development and testing in bioavailability studies and BBB 
penetration experiments. 
 
1.8.4. The RI-OR2-TAT peptide inhibitor 
Further development of the inhibitor was performed by the attachment of a retro-
inverted version of the HIV protein transduction domain ‘TAT’ (Green and 
Loewenstein, 1988) to the RI-OR2 peptide to develop a cell-permeable and brain 
penetrant inhibitor, named RI-OR2-TAT (Ac-rGffvlkGrrrrqrrkkrGy-NH2) (Figure 1.7.) 
(Parthsarathy et al., 2013). The incorporated sequence was attached on the RI-OR2 
inhibitor in such a way as to maintain the protease resistance of the whole molecule, 
yet also to increase its bioavailability in vivo. Initial studies on the RI-OR2-TAT peptide 
determined that the inhibitor is able to interrupt the aggregation pathway at a very 
early point (Parthsarathy et al., 2013) by employing ThT assays, SDS- 
PAGE experiments and AFM (Taylor et al., 2010). However, RI-OR2-TAT showed 
inhibition of Aβ aggregation when present at a relatively high concentration of about 
1:5 molar ratio of inhibitor to Aβ.  
 
Moreover, a fluorescent version of RI-OR2-TAT, named Flu-RI-OR2-TAT, was tested 
for penetration in cultured neuroblastoma cells and demonstrated rapid entry – 
within minutes – into the cells. In contrast, Flu-RI-OR2 stayed mainly in the culture 
medium, indicating that the inverted TAT sequence attached on the RI-OR2 inhibitor 
is an effective transit peptide (Parthsarathy et al., 2013). Similar to previous studies 
that employ TAT as a targeting method into the brain (Dietz and Bahr, 2004; Repici et 
al., 2007; Ramanathan et al., 2001), Flu-RI-OR2-TAT was also able to penetrate across 
the BBB following its peripheral (i.p.) administration in APP/PS1 (APPswe/PS1ΔE9) 
transgenic mice. More specifically, the peptide demonstrated attachment to amyloid 
plaques – with high affinity – and to activated microglial cells. It also reduced β-
amyloid oligomer formation, amyloid plaque load, oxidation and inflammation in the 
brain, and stimulated neurogenesis in the dentate gyrus (DG) of the hippocampus 
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when administrated at 100 nmol / kg / once per day over a period of 21 days 
(Parthsarathy et al., 2013).  
 
To further develop the RI-OR2-TAT peptide inhibitor, Parthsarathy and colleagues 
(Parthsarathy et al., 2013) suggested that the effect of the RI-OR2-TAT inhibitor on 
the level of Aβ oligomerisation might be improved by the optimisation of the peptide 
sequence and/or by the use of an alternative dosing regimen.  
 
 
Figure 1.7. The structures of OR1, OR2, RI-OR2 and RI-OR2-TAT peptide inhibitors. 
Demonstration of the amino acid sequences of the four peptide inhibitors. Uppercase letters 
represent L-amino acids while D-amino acids are in lowercase. There is no separate 
enantiomer of glycine (G) amino acid which is shown in uppercase. The direction of peptide 
bonds is indicated by the arrows (adapted from Taylor et al., 2010).  
 
1.8.5. Peptide Inhibitor Nanoparticles 
More recent studies have indicated a growing interest in the use of liposomes as 
carriers of therapeutic agents. The use of nanoliposome devices is an attractive 
strategy for drug delivery due to their remarkable characteristics such as their 
chemical and physical stability - they display good blood circulation times and are 
resistant to hydrolysis (Webb et al., 1995). They also show compatibility with living 
systems, and are biodegradable, since they are readily decomposed by biological 
agents (Torchilin, 2005). More importantly, liposomes can be multi-functionalised on 
their surface and are more efficient at recognising their molecular targets by 
decorating their surface with multi-ligand-nanosystems (Stukel et al., 2010). 
 
Gregori, Taylor and colleagues (Gregori et al., 2017) have attached the RI-OR2-TAT 
peptide inhibitor onto the surface of synthetic nanoparticle scaffolds to form peptide 
inhibitor nanoparticles (PINPs) (Figure 1.8.). The liposomes were composed of a 1:1 
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ratio of sphingomyelin to cholesterol and the RI-OR2-TAT peptide was covalently 
attached to the surface of the liposome through a PEGylated lipid tail (Gregori et al., 
2017). PINPs demonstrated high potency on the inhibition of Aβ aggregation at 
remarkably low concentrations with 50% inhibition at a molar ratio of about 1:2000 
of liposome-bound peptide to Aβ, and they also rescued cultured human 
neuroblastoma cells from Aβ toxicity. Moreover, PINPS were efficient at crossing an 
in vitro BBB model, and also entered the brains of healthy mice with the C57/BL6 
background, and protected against memory loss in the APPswe (Tg2576) transgenic 
mice model using the novel object recognition task (Gregori et al., 2017). 
 
 
Figure 1.8. Preparation of PINPs. 
PINPs are constructed through ‘click’ chemistry through a C-terminal cysteine residue added 
on the amino acid sequence of the RI-OR2-TAT peptide. The lipids are synthesised using equal 
molar ratio of sphingomyelin and cholesterol. The RI-OR2-TAT peptide is attached on the 
surface of the lipid nanoparticle through a lipid tail composed of DSPE, PEG (polyethylene 
glycol) and MAL (maleimide) (adapted from Gregori et al., 2017). 
 
 
1.9. Scope of the thesis 
A new version of the RI-OR2 peptide was developed by attaching N-
acetylglucosamine (NAG), a stable analogue of glucose, to the RI-OR2 inhibitor, 
developing RI-OR2-NAG inhibitor. NAG, a monosaccharide derived from glucose, will 
be used as a transit molecule of the inhibitor by utilising the glucose transporters 
that are located at the BBB (GLUT1) and on the membranes of neurons (GLUT3) (Bell 
et al., 1990) and the NAG transporter (SLC35A3) expressed at the Golgi apparatus of 
the cells (Abeijon et al., 1996). The resulted peptide inhibitor, named RI-OR2-NAG 
will be tested for inhibition of Aβ aggregation using the ThT assay and for potential 
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toxic effects on cultured SH-SY5Y neuroblastoma cells using the MTS cell 
proliferation assay. 
 
The overarching aim of this project is to compare the anti-aggregational properties 
and potency of the RI-OR2-NAG inhibitor relative to the previously developed RI-
OR2-TAT inhibitor (Parthsarathy et al., 2013). The anti-aggregational properties of 
the two free peptides will be examined using the ThT assay, while the MTS assay will 
be employed to determine the effects of the peptides on the viability of cultured SH-
SY5Y neuroblastoma cells. The two peptides will also be compared for their cell-
penetrating properties using their fluorescent versions. 
 
The hypothesis of this thesis project is that the RI-OR2-TAT, RI-OR2-NAG, and PINPs 
can penetrate a dynamic and intact BBB, and co-localise with major neuronal and 
glial cells following their peripheral administration in WT mice with the C57/BL6 
background. This property of the peptides will be examined using confocal 
microscopy, visualising the cortex, hippocampus and DG of the mouse brains. 
 
The three peptides will also be used in an attempt to study their bio-distribution and 
possible elimination routes in healthy mice. Luminex technology and ELISA systems 
are going to be applied in order to study the accumulation of the peptides in the 
brain, heart, lungs, stomach, liver, spleen, kidneys and small intestines of the mice 




Chapter 2: Experimental Procedures 
 
Unless otherwise stated, chemicals were purchased from Sigma-Aldrich/Sigma® Life 
Science (Dorset, UK) and antibodies were purchased from Abcam® (Cambridge, UK) 
and stored according to manufacturer’s recommendations. 
 
  
2.1. Preparation of peptides 
2.1.1. Peptides and their fluorescent derivatives 
The peptide inhibitors RI-OR2-TAT (Ac-rGffvlkGrrrrqrrkkrGy-NH2), RI-OR2-TAT-Cys 
(Ac-rGffvlkrrrrqrrkkGyc-NH2), RI-OR2-NAG (Ac-rGffvlkGrS(GlcNAc)-NH2), and their 
fluorescent versions, Flu-RI-OR2-TAT (Flu-rGffvlkGrrrrqrrkkrGy-NH2) and Flu-RI-OR2-
NAG (5Flu-rGffvlkGrS(GlcNAc)-NH2) used for the study were custom-made by 
Cambridge Peptides (Birmingham, UK). The purity of these peptides was determined 
as >95 % by HPLC – MS (high performance liquid chromatography – mass 
spectrometry). 
 
2.1.2. Liposomes, peptide-liposomes (PINPs), and their fluorescent derivatives 
2.1.2.1. Preparation of the lipid film 
The PEGylated control liposomes (CL) and PINPs used in the study were custom-
synthesized. The liposomes were composed of a matrix of sphingomyelin (egg, 
chicken)/cholesterol (plant derived) (Avanti® Polar Lipids, Inc., Alabama, USA), at a 
1:1 molar ratio (47.5 molar % each) and mixed with 5 molar % of DSPE–PEG–MAL (1, 
2-distearoyl-sn-glycero-3-phosphoethanolamine-N-poly(ethylene glycol)-maleimide  
(Laysan BIO, Inc., Alabama, USA). Following resuspension of the lipids in chloroform 
(VWR Chemicals, Leighton Buzzard, UK) to the required final volume, the chloroform 
solvent was first removed by evaporation under a gentle stream of nitrogen (N2), 
followed by complete evaporation in vacuo using a round-bottomed flask attached to 
a rotary evaporator (SOGEVAC®, Leybold Vacuum, Valence, France) for about 1 h. 
The resulting lipid film was resuspended in PBS (phosphate buffered saline), pH 7.4, 
vortexed and sonicated until mixed completely. The lipid mixture was then subjected 
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to rapid changes of temperature by performing 5 cycles of freezing in liquid nitrogen 
for 15 sec and thawing at 42°C for 3 min, followed by sonication (U300H ultrasonic 
bath, Ultrawave, Cardiff, UK) for 5 min at 45°C. The lipid nanoparticle mixture was 
then extruded 10 times using a mini extruder (Figure 2.1.) (Avanti® Polar Lipids, Inc. 
from Stratech Scientific Ltd., Suffolk, UK) through a 100 nm nucleopore membrane 
(Whatman®, Little Chalfont, UK) and stored at 4°C for up to two weeks. 
 
 
Figure 2.1.Mini extruder assembly. 
For assembly of the mini extruder, two pre-wet filter supports were placed on the top of each 
of the internal membrane supports (with the O-rings facing up) and the 100 nm nucleopore 
membrane was secured in between them. The whole set up was inserted into the extruder 
outer casing and tightened with the retainer nut which already contains the teflon bearing. 
Once the sealed extruder outer casing was placed on the mini extruder base, the Hamilton 
syringes were attached. 
 
The BODIPY-bound liposomes were designed using the same method, with the 
exception that BODIPY-cholesterol [23-(dipyrrometheneboron difluoride)-24-
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norcholesterol] (Avanti® Polar Lipids, Inc., Alabama, USA) was added at 1 molar % of 
the total cholesterol present in the initial liposome mixture. 
 
2.1.2.2. Attachment of RI-OR2-TAT onto the surface of the nanoliposomes 
In order to covalently link the RI-OR2-TAT peptide to the liposomes by ‘click 
chemistry’, a cysteine residue was incorporated at the C-terminal end of the amino 
acid sequence of the peptide inhibitor, resulting in RI-OR2-TAT-Cys. The peptide was 
added at about 50 % molar ratio of the DSPE–PEG–MAL (in excess) in PBS, and 
incubated for 2 h at 37°C and then overnight (O/N) at RT (room temperature), on an 
end-over-end mixer (Stuart® equipment, Bibby Scientific Ltd., Stone, UK). Any 
unbound peptide was removed through centrifugation on an OptimaTM L-100 XP 
Ultracentrifuge for 1 h at ~257 xg and 4°C [50k RPM (revolutions per minute) using 
the 70.1 Ti rotor] (Beckman Coulter, Inc., High Wycombe, UK). The supernatant was 
removed and the pellet of concentrated PINPs was resuspended in PBS, sonicated 
and vortexed until completely mixed. The final PINPs were stored at 4°C for up to 
two weeks. 
 
The elution of the liposomes was assessed by dynamic light scattering (DLS), while 
the amount of peptide bound to the liposomes was quantified by BCA (bicinchoninic 
acid) assay (Smith et al., 1985). Determination of phospholipid recovery after 
extrusion and centrifugation was performed using the Wako LabAssayTM 
Phospholipid (Choline Oxidase–DAOS) method (Wako Pure Chemical Industries, Ltd. 
from Alpha Laboratories, Eastleigh, UK) (Takayama et al., 1977). 
 
The concentrations of liposomes or peptide liposomes tested in this thesis refer to 
the total lipid content.  
 
2.1.3. BCA assay for protein determination of peptide bound to liposomes 
To determine the concentration of peptide bound to nanolipids, the BCA assay was 
performed using BSA (bovine serum albumin) as a standard. The working solution 
was prepared by mixing 50 parts of BCA solution with 1 part of copper (II) sulphate 
solution. The BSA standards - prepared in PBS - and the PINPs were added in 
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triplicate (5 μl/well) to a 96-well plate (ThermoFisher Scientific Nunc A/S from Life 
Technologies Ltd., Paisley, UK) along with 100 μl/well of working solution. The plate 
was left to stand for 30 min at 37°C, and then read at 562 nm (1.0 s) on a Wallac 
1420 multilabel counter Victor2 plate reader (PerkinElmer®, Massachusetts, USA). 
 
2.1.4. Choline Oxidase – DAOS method for phospholipid determination 
To determine the amount of phospholipid (sphingomyelin) present in PINPs following 
extrusion and centrifugation, the Wako LabAssayTM Phospholipid Assay (Wako Pure 
Chemical Industries, Ltd. from Alpha Laboratories, Eastleigh, UK) was performed. The 
standards were prepared using the ‘Standard Solution’ provided in the kit. The 
‘Colour Reagent’ was prepared by dissolving 1 vial of Chromogen substrate to 50 ml 
Buffer, both provided in the kit. To the plate, 2 μl/well of each standard and test 
peptide solution were added in triplicate, along with 300 μl/well of Colour Reagent. 
The plate was then incubated for 5 min in 37°C and then read at 562 nm (1.0 s) on a 




2.2. Preliminary studies on RI-OR2-NAG peptide 
2.2.1. Aβ deseeding 
Recombinant Aβ42 was purchased from rPeptide (Stratech Scientific Ltd, Suffolk, 
UK). The freeze-dried peptide was dissolved at 1 mg/ml in 0.1 % (v/v) ammonium 
hydroxide (NH4OH) and split into two aliquots in fresh glass vials. Following a 15 min 
incubation at RT, the solution was vortexed at high speed and sonicated at 12 
microns peak to peak for four bursts of 30 sec. The solvent was then evaporated in 
vacuo by centrifugal concentration (Savant ISS110, SpeedVac Concentrator, 
ThermoFisher Scientific from Life Technologies Ltd., Paisley, UK) and the two aliquots 
were stored at -20°C for future use. Prior to use of the peptide in in vitro aggregation 
experiments, each Aβ42 aliquot was resuspended in 0.5 mg/ml trifluoroacetic acid 
(TFA) containing 5 % (v/v) thioanisole; vortexed at low speed and sonicated for 30 
sec in glass vials with a chemically resistant Eppendorf lid (Eppendorf UK Ltd., 
Stevenage, UK). The solvent was then evaporated under a stream of oxygen-free 
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nitrogen (N2) gas and the resulting film was treated with 100 μl of 1,1,1,3,3,3-
hexafluoro-2-propanol (HFIP), vortexed at high speed and sonicated for four bursts of 
30 sec. The solvent was again evaporated in vacuo using the SpeedVac concentrator. 
Following the HFIP treatment, the peptide film was dissolved in 0.5 ml NH4OH, 
vortexed at high speed and sonicated for four bursts of 30 sec and split into 100 μg 
aliquots which were dried in the centrifugal concentrator and stored at -20°C for 
future use. 
 
2.2.2. ThT aggregation assay 
2.2.2.1. Preparation of PB, PBS, and PB-2S solutions 
To prepare and maintain the solutions at pH 7.4, the buffers were prepared in 0.81 % 
(v/v) of 1 M K2HPO4 (dipotassium phosphate monobasic acid) and 0.19 % (v/v) of 1 M 
KH2PO4 (monopotassium phosphate bibasic acid). To PBS and PB-2S (Phosphate 
buffered 2x saline) solutions, 0.15 M and 0.3 M NaCl (sodium chloride) were added 
respectively. The volume of the solutions was made to 100 ml with dH2O. 
 
2.2.2.2. Preparation of ThT dye 
ThT powder was dissolved in PB (phosphate buffer) at a concentration of 15 mM and 
stored in 4°C in dark for a week. This stock solution was further diluted in PB-2S at a 
concentration of 60 μM for the purposes of the experiment. 
 
2.2.2.3. Aβ and peptide treatment preparation 
Aβ42 aliquots (100 μg each) were dissolved in 222 μl PB to yield a concentration of 
100 μM. The peptide inhibitors RI-OR2-TAT and RI-OR2-NAG were prepared in PBS at 
1:1, 1:2, 1:5 and 1:10 final molar ratios of peptide inhibitor to Aβ. 
 
2.2.2.4. Preparation of ThT assay plate 
The assays were conducted in 384-well black with clear-bottom microtiter plates 
(ThermoFisher Scientific Nunc A/S from Life Technologies Ltd., Paisley, UK). Controls 
(100 μM Aβ42, ThT and 50 μM of each peptide inhibitor) and sample conditions were 
added to the plates in triplicate to a final volume of 60 μl/well (Table 2.1.). The ThT 
fluorescence was monitored and read at λex = 442 nm and λem = 483 nm every 10 
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min for 48 h at 37°C following shaking of the plate using a BioTek Synergy 2 plate 
reader (BioTek UK, Swindon, UK).  
 
CONDITIONS 100 μM Aβ42 ThT Peptide inhibitors PB PBS 
Aβ42 control 15 μl 15 μl - - 30 μl 
ThT control - 15 μl - 15 μl 30 μl 
Peptide inhibitor controls - 15 μl 30 μl 15 μl - 
Sample conditions 15 μl 15 μl 30 μl - - 
Table 2.1. Indication of the volumes added for each sample condition to the 384-well plate 
for the aggregation assay. 
 
2.2.2.5. Analysis and statistics of ThT aggregation assay 
The analysis of the aggregation experiment was performed using PRISM GraphPad 
software (GraphPad Software Inc., California, USA). Data collected at 24 h and 48 h 
from three independent experiments were averaged and analysed by applying one-
way analysis of variance (ANOVA) using the post hoc Bonferroni’s multiple 
comparisons test in the case of the control Aβ versus peptide treatment; and 
unpaired t-tests with Welch’s correction [assuming different SDs (standard 
deviations)] for comparison between same concentrations of the RI-OR2-TAT and RI-
OR2-NAG peptides. Outliers were checked using the GraphPad QuickCalcs: outlier 
calculator software (GraphPad Software Inc., California, USA). The analysis of the ThT 
assay is presented in Chapter 3, Sections 3.3.1. as mean ± SEM (standard error of 
mean) and a p value of ≤ 0.05 was considered as statistically significant.  
 
2.2.3. Cell culture and maintenance of SH-SY5Y Human Neuroblastoma cell line 
SH-SY5Y neuroblastoma cells (European Collection of Cell Cultures, Salisbury, UK) 
were habitually cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) with 4.5 
g/L glucose and L-glutamine (BioWhittaker® Lonza by Scientific Laboratory Supplies, 
Nottingham, UK) containing 0.1 % (v/v) FBS (Foetal Bovine Serum), and 0.01 % (v/v) 
PEN – STREP (Penicillin – Streptavidin). The cell cultures were maintained in T-75 flat 
flasks (ThermoFisher Scientific Nunc A/S from Life Technologies Ltd., Paisley, UK) at 
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37°C in a humidified incubator with 5 % CO2 – 95 % room air and the medium was 
changed every other day. The cells were used for a maximum of 20 passages. 
 
To maintain the cells in a viable state, a subculture/splitting process was performed 
twice per week. Following removal of the present growth medium, 5 ml of Trypsin 
EDTA (ethylenediaminetetraacetic acid) (BioWhittaker® Lonza by Scientific 
Laboratory Supplies, Nottingham, UK) were added to the T-75 flask of cells and 
incubated at 37°C for about 3 min until the cells were detached from the bottom of 
the flask. To the trypsinised cells, 10 ml of DMEM medium were added, and the 
solution was collected in a fresh tube and spun at 200 RCF for 3 min (Allegra X-30R 
Centrifuge with the SN 15D rotor, Beckman Coulter, Inc., High Wycombe, UK). The 
supernatant was removed and the pellet of cells was resuspended in 5 ml DMEM 
medium. 0.5 ml of this suspension was transferred to a new T-75 flask with 10 ml of 
fresh DMEM medium and incubated at 37°C in a humidified incubator for future use. 
 
2.2.4. MTS cell proliferation assay 
The MTS proliferation assays were conducted in 96-well plates (Costar®, Corning Inc. 
from Fisher Scientific, Loughborough, UK). Following subculture of SH-SY5Y cells, 
approximately 20,000 cells/well were transferred in a final volume of 100 μl of 
DMEM Medium. The cells were allowed to adhere to the bottom of the wells O/N at 
37°C in a humidified incubator. Following incubation, the medium was replaced by 
either 100 μl of fresh DMEM in the control (untreated) samples, or 100 μl of DMEM 
containing 0.1 μM, 1 μM or 10 μM of RI-OR2-NAG, RI-OR2-TAT, PINPs or CL peptides; 
and the plate was incubated O/N at 37°C in a humidified incubator. To each well 100 
μl of CellTiter96 Aqueous One Solution Cell Proliferation (MTS) assay (Promega, 
Southampton, UK) was added and left to stand for 3 h at 37°C in a humidified 
incubator. The proliferation of the cells was assessed on a Wallac 1420 multilabel 
counter Victor2 plate reader (PerkinElmer®, Massachusetts, USA) at 490 nm (0.1 s). 
 
2.2.4.1. Analysis and statistics of MTS proliferation assay results 
Data collected from three independent experiments were averaged and assessed 
applying one-way ANOVA hypothesis followed by post hoc Bonferroni’s multiple 
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comparison test. Outliers were calculated using the GraphPad QuickCalcs: outlier 
calculator software; and analysis was performed using the PRISM GraphPad software 
(GraphPad Software Inc., California, USA). The results are presented in Chapter 3, 
Section 3.3.2. as mean ± SEM and a p value of ≤ 0.05 was considered as statistically 
significant.    
 
2.2.5. Cell penetration experiments 
The experiments were conducted in 6-well plates (Costar®, Corning Inc. from Fisher 
Scientific, Loughborough, UK) containing autoclaved 22 x 22 mm coverslips 
(SuperFrost®, Menzel-Gläser from Life Technologies Ltd., Paisley, UK) at the bottom 
of each well. Following maintenance of SH-SY5Y cells under standard mammalian cell 
culture conditions and subculture of the cells, approximately 40,000 cells/well were 
added to a final volume of 1.5 ml of DMEM medium. The cells were incubated for 48 
h at 37°C in a humidified incubator to allow their adherence on the coverslips. 
Following incubation, the medium was replaced with either 15 μl PBS in 1.5 ml 
DMEM medium for the control (untreated) cells, or 15 μl of PBS containing the 
tested peptide inhibitor in 1.5 ml DMEM for the treated cells; and incubated for 1 h 
at 37°C in a humidified incubator. The peptide inhibitors tested were fluorescently-
tagged peptides, Flu-RI-OR2-TAT and Flu-RI-OR2-NAG, at 1 μM final concentration in 
DMEM growth medium. The coverslips were then placed onto the surface of 
autoclaved microscopy slides (SuperFrost®, Menzel-Gläser from Life Technologies 
Ltd., Paisley, UK) with a drop of FluoroshieldTM with DAPI histology mounting 
medium, and allowed to dry. The coverslips were then sealed and the penetration of 
the fluorescently labelled peptides was assessed on Zeiss LSM 510 confocal 
microscope (Carl Zeiss Ltd., Cambridge, UK), using multichannel filters and the 63x 






2.3. In vivo studies – C57/BL6 mice 
2.3.1. Ethics statement 
All animal regulated procedures were performed as part of authorised personal and 
project licenses; approved by the UK Home Office in accordance with the UK Animals 
(Scientific Procedures) Act 1986.  
 
2.3.2. Animals 
Wild type (WT) mice from APPswe/PS1ΔE9 breeding with C57BL/6 background were 
single housed a week prior to treatment injection in a temperature-controlled 
holding room (21.5°C ± 1) with 12:12 h light and dark cycle. Food and water were 
available ad libitum.  
 
2.3.3. Drug treatment 
A pilot study was performed using 25 female WT animals of age between 31 – 32 
weeks old. The animals were organised in groups of five for study purposes. The 
groups included a control group – injected with 0.9 % NaCl (vehicle control), and four 
treatment groups injected with Flu-RI-OR2-TAT, Flu-RI-OR2-NAG, BODIPY-PINPs, and 
BODIPY-CL respectively. All animals were injected intraperitoneally (i.p.) at a dose of 
100 nmol/kg for the free peptides and 4 μmol/kg in the case of the liposome-based 
peptides; with administration volume of 10 ml/kg. The dose, administration volume 
and duration of treatment were decided based on a previous study investigating the 
effects of Flu-RI-OR2-TAT on amyloid plaque load and other markers of brain 
pathology using the APP/PS1 transgenic mouse model (Parthsarathy et al., 2013). 
 
2.3.4. Tissue collection 
At the time of injection, 0 h, the animals were housed in a dark room. After 1 h, the 
animals were anaesthetised with 0.107 g/ml urethane at a dose of 0.7 ml/30 g, and 
transcardially perfused using PBS with heparin (20 units/ml). To determine if the 
peptides penetrate the BBB, to measure their intensities in the brain, and determine 
whether they co-localise with specific cells, the brains were recovered, sectioned 
through the sagittal plane and the left hemisphere (LH) was fixed in 4 % (w/v) ice-
cold formaldehyde. Following fixation for 3 days, the formaldehyde-preserved LH 
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was transferred to 30 % (w/v) sucrose in PBS with 0.02 % (w/v) sodium azide (NaN3), 
at 4°C for storage. To determine the distribution and elimination of the peptides, the 
right cerebral hemisphere (RH), along with the heart, lungs, liver, stomach, spleen, 
right and left kidneys, and small intestine were collected and snap-frozen in liquid 
nitrogen, and then stored at -80°C for future use.  
 
 
2.4. Distribution of the peptides 
2.4.1. Tissue homogenisation 
Each tissue collected following the perfusion of the C57/BL6 mice (-80°C storage) was 
weighed and then incubated for 20 min in ice-cold homogenisation buffer (HB) [RIPA 
(Radioimmunoprecipitation assay) buffer with 10 μl/ml protease and phosphatase 
inhibitor cocktail (100x) and 10 μl/ml 0.5 M EDTA solution (100X)] (HaltTM Protease 
and Phospatatase inhibitor cocktail, Thermo Scientific from Fisher Scientific, 
Loughborough, UK) at a concentration of 3 μl/mg of tissue. Each sample tissue was 
then homogenised on ice using the LabGEN 7 series homogenizer (Cole-Parmer® 
Instrument Co. Ltd., London, UK). Following complete homogenization, the blade was 
rinsed with extra 2 μl/mg of tissue HB to a total final concentration of 5 μl/mg of 
tissue. The samples were then sonicated (U300H ultrasonic bath, Ultrawave, Cardiff, 
UK) for 5 min with 30 sec incubation intervals on ice and then maintained at constant 
agitation for 2 h at 4°C. Following incubation, the lysate samples were first 
centrifuged at 4750 RPM for 15 min (Allegra® X-15R Centrifuge with SX4750A 
ARIESTM rotor, Beckman Coulter, Inc., High Wycombe, UK) and the supernatant was 
centrifuged again at 14,000 RPM for further 15 mins (Heraeus Fresco 21 Centrifuge 
with 75003424 ClickSealTM biocontainment rotor, Thermo Scientific from Fisher 
Scientific, Loughborough, UK). The lysate (supernatant) was collected, aliquoted and 
stored at -80°C for future use and the cell debris (pellet) was discarded. 
 
2.4.2. BCA assay for total protein content quantification in tissue 
To determine the total protein content of each tissue lysate, the BCA assay was 
performed (explained in Section 2.1.3.). The BSA standards prepared in HB and tissue 
lysate samples in HB were added at 5 μl/well in triplicate on the 96-well plate.  
39 
 
2.4.3. Concentration of antibodies 
Antibodies used in Luminex experiments of concentration lower than 1 mg/ml were 
concentrated to 1 mg/ml using the Pierce® Concentrator, PES, 3K MWCO, 0.5 ml 
(Thermo Scientific from Fisher Scientific, Loughborough, UK).  The concentration 
sample chamber was pre-rinsed with 500 μl dH2O and centrifuged at 15,000 xg 
(Eppendorf centrifuge 5424 with FA-452411 rotor, Eppendorf UK Ltd., Stevenage, UK) 
until more than 400 μl of filtrate was produced. Any rinsing solution remaining in the 
collection tube and concentration chamber was discarded and the sample antibody 
was added to the concentration chamber. The sample was centrifuged 15,000 xg 
(Eppendorf centrifuge 5424 with FA-452411 rotor, Eppendorf UK Ltd., Stevenage, UK) 
until the desired concentration factor relative to the volume in concentration 
chamber was achieved. 
 
2.4.4. Antibody biotinylation and conjugate purification 
Detection antibodies used in Luminex experiments were biotinylated using the 
Biotin-XX Microscale protein labelling kit (Invitrogen by ThermoFisher Scientific from 
Life Technologies Ltd., Paisley, UK). A 1 M sodium bicarbonate solution was prepared 
by adding 1 ml of dH2O to the vial of sodium bicarbonate provided in the kit; and 
vortexed until the reagent was fully dissolved. This reagent was stored at 3°C for up 
to two weeks, or to -20°C for longer storage. The required volume of antibody at 1 
mg/ml was transferred to a reaction tube along with 1/10 volume of 1 M sodium 
bicarbonate and mixed by pipetting up and down numerous times. To a separate vial 
of biotin-XX (reactive biotin) provided in the kit, 10 μl of dH2O were added and 
completely dissolved by pipetting up and down several times, yielding a 
concentration of 14.93 nmol/μl. The reagent was prepared immediately before use 
and any leftover was discarded. According to the equation (Equation 2.1.) that was 
presented in the kit’s product information, the appropriate volume of reactive biotin 
was added to the reaction tube containing the pH-adjusted antibody and mixed 
thoroughly by pipetting up and down. The reaction mixture was incubated for 15 min 






𝐩𝐫𝐨𝐭𝐞𝐢𝐧 𝐌𝐖) 𝐱𝟏, 𝟎𝟎𝟎] 𝐱𝐌𝐑
𝟏𝟒. 𝟗𝟑
= 𝛍𝐥 𝐫𝐞𝐚𝐜𝐭𝐢𝐯𝐞 𝐛𝐢𝐨𝐭𝐢𝐧 − 𝐗𝐗 𝐭𝐨 𝐚𝐝𝐝 𝐭𝐨 𝐬𝐚𝐦𝐩𝐥𝐞 
Equation 2.1. Equation used to calculate the volume of biotin solution. 
The equation was used to calculate the amount of reactive biotin to be added to the reaction 
tube; where μg protein is the mass of protein to be labelled, protein MW is the molecular 
weight of protein in Da (150,000 in the case of antibodies), MR is the biotin to protein molar 
ratio (MR=18 for antibodies – information provided in the kit), and 14.93 is the concentration 
of reactive biotin stock (adapted from Biotin-XX Microscale protein labelling kit Product 
information). 
 
To remove any unbound biotin from the mixture, protein desalting spin columns 
(ThermoFisher Scientific from Life Technologies Ltd., Paisley, UK) were used. The 
column was inverted to suspend the slurry and the bottom closure was twisted 
initially and removed once the cap was loosened. The column was placed in 1.5 ml 
microcentrifuge collection tube and centrifuged at 1,500 xg (Eppendorf centrifuge 
5424 with FA-452411 rotor, Eppendorf UK Ltd., Stevenage, UK) for 1 min to remove 
excess liquid. To the tube, 400 μl of PBS-T [PBS with 0.05 % (v/v) Tween® 20] were 
added to the top of the column and centrifuged at 1,500 xg  for 1 min. The process of 
buffer exchange was repeated three times. Following exchange of buffer, the column 
was placed in a fresh 1.5 microcentrifuge tube and the biotinylated antibody was 
added to the centre of the compacted resin bed and centrifuged at 1,500 xg for 2 
min and the eluted purified biotinylated antibody was aliquoted and stored 
according to the manufacturer’s recommendations. 
 
2.4.5. BODIPY-PINPs peptide treatment with bee venom 
To break down the phospholipids of the liposome, the PINPs solution was treated 
with 1 mg/ml Phospholipase A2 from honey bee venom (Apis mellifera) at 10 % (v/v) 
of the lipid molarity. The reaction mixture was incubated for 20 min at 37°C and then 




2.4.6. Luminex-bead Immunoassay for tissue-specific peptide distribution 
2.4.6.1. Primary antibody coupling to Luminex beads 
Following vortexing and sonication of 1 vial of Luminex beads (COOH Beads 023 – 5.6 
μm COOH microspheres, 1 ml at 1.25x107 beads/ml) (Biol-Plex®, BIO-RAD 
Laboratories Ltd., Hertfordshire, UK), 33 μl of beads were transferred to a fresh 
coupling tube (FisherbrandTM premium microcentrifuge tubes, Fisher Scientific, 
Loughborough, UK) with 50 μl of triton/activation buffer (Table 2.2.), and centrifuged 
at 10,000 RPM for 1 min (Eppendorf centrifuge 5424 with FA-452411 rotor, 
Eppendorf UK Ltd., Stevenage, UK). The supernatant was removed and the pellet of 
beads was washed using the Triton/activation buffer. To the pellet, 80 μl of 
activation buffer (Table 2.2.) were added and the bead mixture was vortexed and 
sonicated. To the tube, 10 μl of freshly prepared NHS (N-hydroxysuccinimide) buffer 
(Sulfo-NHS, Thermo Scientific from Fisher Scientific, Loughborough, UK) were added 
at 50 mg/ml in dH2O along with 10 μl of fresh EDC [1-ethyl-3-(3-
dimethylamino)propyl carbodiimide, hydrochloride] buffer (PierceTM Premium-Grade 
EDC, Thermo Scientific from Fisher Scientific, Loughborough, UK) at 50 mg/ml in 
dH2O, and the mixture was incubated for 30 min at RT in the dark on an end-over-
end mixer (Stuart® equipment, Bibby Scientific Ltd., Stone, UK). After incubation, 100 
μl of triton/coupling buffer (Table 2.2.) were added and centrifuged for an extra 
minute at 10,000 RPM. The supernatant was then removed and the pellet was 
washed twice with the Triton/coupling buffer as above. The pellet of beads was then 
resuspended in 500 μl of the primary antibody in coupling buffer (Table 2.2.) at final 
concentrations of 1 μg/ml in the case of anti-HIV1 tat [N3] (mouse monoclonal) 
antibody used in the Flu-RI-OR2-TAT peptide detection, and 3 μg/ml in the case of 
anti-O-GlcNAc CTD110.6 (mouse monoclonal) antibody (BioLegend, London, UK) 
used in the Flu-RI-OR2-NAG detection. The solution was then incubated for 2 h at RT 
in the dark in an end-over-end mixer. Following incubation, 100 μl of wash buffer 
(Table 2.2.) were added to the tube and the mixture was centrifuged for 1 min at 
10,000 RPM. The supernatant was removed and the pellet was washed twice with 
the same buffer. The pellet of beads coupled to the primary antibody was then 





Table 2.2. The composition of Luminex bead coupling buffers. 
 
2.4.6.2. Bead-based Luminex Assay Development 
The assay was performed on a 96-well filter plate (MultiScreenHTS BV 1.2 μm filter 
plates, Merck Millipore from Life Technologies Ltd., Paisley, UK). The filter plate was 
initially pre-washed using 100 μl/well PBS-T and the solution was aspirated using a 
vacuum manifold (Dymax 5, Charles Austen Pumps Ltd., Surrey, UK). The primary 
antibody-coupled microspheres were diluted in 1:20 ratio in PBS-T, vortexed to 
remove any doublets and added at 25 μl/well to the plate. The plate was then 
agitated on a microplate shaker (Grant-bio, Grant Instruments Ltd., Cambridge, UK) 
for 5 min in dark and aspirated using the vacuum pump. To each well, 50 μl of 
peptide inhibitor standards were added in triplicate at concentrations ranging from 
0.95 pM to 1 μM (and Blank control) in HB in the case of Flu-RI-OR2-TAT detection, 
and 0.24 nM to 1 μM (and Blank control) in HB in the case of Flu-RI-OR2-NAG 
detection, along with 50 μl of tissue lysates in triplicate at 1:5 volume ratio in HB; and 
the plate was agitated O/N at 3°C in the dark on a rocking shaker (Stuart®, gyro-
rocker SSL3, Bibby Scientific Ltd., Stone, UK). Following incubation, the plate was 
aspirated, washed twice with 150 μl/well PBS-T, and aspirated again using the 
vacuum manifold. To each well, 50 μl of biotinylated secondary antibody, anti-
fluorescein (biotin) (goat polyclonal) antibody, was added at 2 μg/ml in the Flu-RI-
OR2-TAT assay and 0.125 μg/ml in the Flu-RI-OR2-NAG assay, diluted in PBS-T. The 
BUFFERS COMPOSITION 
Activation Buffer 0.1 M Sodium Phosphate monobasic pH 6.1 
Triton/Activation 
Buffer 
0.1 M Sodium Phosphate monobasic pH 6.1 with 0.025 % 
(v/v) Triton X-100 
Coupling Buffer 50 mM MES hydrate of pH 5.0 
Triton/Coupling 
Buffer 
50 mM MES solution [2-(N-morpholino)ethanesulfonic acid)] 
of pH 5.0 with 0.025 % (v/v) Triton X-100 
Wash Buffer PBS with 0.025 % (v/v) Triton X-100 
Blocking/Storage 
Buffer 
PBS, 0.1 % (w/v) BSA, 0.02 % (v/v) Tween® 20 with 0.02 % 
(w/v) sodium azide 
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plate was then agitated for 1 h at RT in the dark and then 50 μl/well of 4 μg/ml 
Streptavidin-RPE (R-phycoerythrin conjugate) (Molecular probes®, Life Technologies, 
Paisley, UK) was added, and the plate was agitated for further 30 min at RT in the 
dark. After incubation, the plate was aspirated, washed twice with 150 μl/well PBS-T, 
and aspirated again. The beads were then resuspended in 100 μl/well PBS-T, and 
agitated on a shaker for 1 min, at high speed, at RT in the dark. Finally, the plate was 
read in a Luminex® 200 xMAPTM Technology plate reader (Luminex Co., Texas, USA) 
using the xPONENT® 3.1 software. A schematic representation of the Luminex assay 
(sandwich reaction in each well) is shown in Figure 2.2. 
 
 
Figure 2.2. Luminex Sandwich Immunoassay. 
Schematic representing the Luminex sandwich assay format. The capture and biotinylated 
detection antibodies are specific for each analyte of interest; streptavidin-RPE acts as a 
reporter molecule. 
 
2.4.7. Luminex peptide-specific assay optimisation 
Prior to the analysis of tissue lysates in Luminex-bead immunoassays, a variety of 
antibody combinations and antibody concentrations were used with fluorescent-
tagged peptide inhibitor standards to optimise each peptide assay following the 
same protocol as presented in Section 2.4.6. The tables below show the antibodies 
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and antibody concentrations used for Flu-RI-OR2-TAT optimisation assays (Table 2.3), 
Flu-RI-OR2-NAG optimisation assays (Table 2.4) and PINPs optimisation assays (Table 
2.5). 
 






anti-HIV1 tat [N3] (mouse 
monoclonal) antibody 
1, 2, 3  
anti-Fluorescein (Biotin) 
(goat polyclonal) antibody 
 0.5, 1, 2 
Table 2.3. Table representing the concentrations (μg/ml) tested for detection and coupling 
antibodies for the Flu-RI-OR2-TAT assay optimisation. 
 








anti-O-GlcNAc CTD110.6 (mouse 
monoclonal) antibody (BioLegend, 
London, UK) 
1, 2, 3  
anti-Fluorescein (Biotin) (goat 
polyclonal) antibody 
 0.125, 0.25, 0.5, 1, 2 
anti-O-Linked N-Acetylglucosamine 
[RL2] (mouse monoclonal) antibody 
1, 2, 3  
Anti-O-GlcNAc RL2 (mouse 
monoclonal) antibody (BioLegend, 
London, UK) 
1, 2, 3  
Table 2.4. Table representing the concentrations (μg/ml) tested for detection and coupling 
antibodies for the Flu-RI-OR2-NAG assay optimisation. 












anti-HIV1 tat [N3] (mouse 
monoclonal) antibody 
1, 2, 3  
anti-Polyethylene glycol [PEG-2-
128] (rabbit monoclonal) 
antibody 
 0.5, 1, 2 
anti-Polyethylene glycol [PEG-B-
47b] (Biotin) (rabbit monoclonal) 
antibody 
 0.5, 1, 2 
Table 2.5. Table representing the concentrations (μg/ml) tested for detection and coupling 
antibodies for the BODIPY-PINPs assay optimisation. 
The same coupling antibody was used for all the detection antibodies tested. 
 
2.4.8. Luminex assay analysis 
Data obtained from the assay optimisation experiments were analysed according to 
the signal to noise ratio (S/N) of each assay to determine the antibody 
concentrations to be used in the peptide detection; and are presented in Chapter 4. 
Analysis of each tissue-specific peptide detection was performed using one-way 
ANOVA hypothesis test followed by post hoc Bonferroni’s multiple comparison test. 
The outliers were calculated using the GraphPad QuickCalcs: outlier calculator 
software (GraphPad Software Inc., California, USA). Data are presented in Chapter 5 
as mean ± SEM of the total amount (moles) of peptide per tissue-specific protein 
content (mg) and a p value of ≤ 0.05 was considered as statistically significant. 
 
2.4.9. Sandwich ELISA immunoassay for tissue-specific BODIPY-PINPs detection 
96-well plates (ThermoFisher Scientific Nunc A/S from Life Technologies Ltd., Paisley, 
UK) were coated with 100 μl/well of diluted anti-HIV1 tat [N3] (mouse monoclonal) 
primary antibody in carbonate-bicarbonate buffer at a concentration of 3 μg/ml and 
left to incubate O/N at 3°C on a rocking shaker (Stuart®, gyro-rocker SSL3, Bibby 
46 
 
Scientific Ltd., Stone, UK). The coating solution was then removed and the plate was 
washed three times with 100 μl/well PBS-T. To the plate, 100 μl/well of blocking 
buffer [5 % (w/v) dry-milk in PBS-T] were added and incubated for 1 h at RT on a 
microplate shaker (Grant-bio, Grant Instruments Ltd., Cambridge, UK) in the dark. 
The blocking buffer was then removed, and 100 μl of BODIPY-PINPs standards 
(treated with bee venom) ranging from 7.81 nM to 1 μM (and blank control) in HB 
were added in triplicate to the plate along with tissue lysates prepared at a 1:5 
volume ratio in HB. The plate was then agitated O/N at 3°C in the dark on a rocking 
shaker. Following incubation, the samples and controls were removed and the plate 
was washed three times with 100 μl/well PBS-T. In each well, 100 μl of diluted anti-
polyethylene glycol [PEG-2-128] (rabbit monoclonal) secondary antibody were added 
to the plate at a concentration of 1 μg/ml, and the plate was incubated for 1 h at RT 
in the dark on a microplate shaker. To each well, 100 μl of Streptavidin-RPE 
(Molecular probes®, Life Technologies, Paisley, UK) was added to the plate and left to 
incubate for 30 min at RT in the dark. The detection solution was then removed and 
the wells were washed three times with 200 μl PBS-T. After washes, the wells were 
filled with 100 μl PBS-T, and the plate was read at λex = 546 λem = 578 nm using an 
average 25 reads/per well on a TECAN infinite M200 pro (Tecan Trading AG, 
Switzerland) plate reader, using Magellan V 7.0 software. A schematic representation 








Figure 2.3. ELISA Sandwich Immunoassay. 
Schematic representing the ELISA sandwich assay format. The primary and biotinylated 
secondary antibodies are specific for each analyte of interest; streptavidin-RPE acts as a 
reporter molecule with three excitation maxima at 496, 546, and 565 nm, and one emission 
maximum at 578 nm. 
 
2.4.10. ELISA peptide-specific assay optimisation 
The following table (Table 2.6) represents the antibodies, and antibody 
concentrations used for the optimisation of the BODIPY-PINPs assay, using only 
peptide standards with and without bee venom treatment, following the same 























anti-HIV1 tat [N3] (mouse 
monoclonal) antibody 
1, 2, 3  
anti-Polyethylene glycol [PEG-
2-128] (rabbit monoclonal) 
antibody 
 0.5, 1, 2, 5 
anti-Polyethylene glycol [PEG-
B-47b] (Biotin) (rabbit 
monoclonal) antibody 
 0.5, 1, 2 
Table 2.6. Table representing the concentrations (μg/ml) tested for primary and secondary 
antibodies for the BODIPY-PINPs assay optimisation. 
The same primary antibody was used for all the secondary antibodies tested. 
 
2.4.11. Sandwich ELISA assay analysis 
Data obtained from the BODIPY-PINPs assay optimisation are presented in Chapter 4, 
while analysis of each tissue-specific peptide detection are presented in Chapter 5. 
The analysis of both optimisation assays and tissue-specific peptide detection assays 
was performed as described in Section 2.4.8. 
 
 
2.5. BBB penetration, intensity and co-localisation study 
2.5.1. Brain sectioning 
Following storage, the brains were transferred to 30 % (w/v) sucrose in PBS O/N, and 
then were snap-frozen with Shandon ENVI-RO-TECHTM freezing spray (ThermoFisher 
Scientific from Life Technologies Ltd., Paisley, UK). Using the Bright model OTF 
cryostat with 5040 microtome (Bright Instruments, Luton, UK), 25 micron (μm) thick 
coronal sections of the brains were cut at anatomical regions of 1.10 mm to -4.04 
mm Bregma (Franklin and Paxinos, 2008) with the first section taken at random and 
then every 12th section afterwards. The brain sections were preserved in cryoprotect 
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solution [30 % (v/v) Ethylene Glycol, 25 % (v/v) Glycerin, and 45 % (v/v) PBS] in a 24-
well plate (Costar®, Corning Inc. from Fisher Scientific, Loughborough, UK) and stored 
at -20°C in the dark until further use. 
 
2.5.2. Microscopy Slides Silanization 
The silanizing reagent for coating of microscopy slides (SuperFrost®, Menzel-Gläser 
from Life Technologies Ltd., Paisley, UK) was prepared using 2 % (v/v) 3-amino-
propylthieoxysilane in acetone. The staining rack holding slides was immersed in 
freshly prepared silanizing solution for 1 min. Following coating, the rack was 
transferred to a tank of water for an extra minute. The slides were then removed and 
allowed to air-dry. 
 
2.5.3. Immunostaining of floating brain tissue sections 
The immunostaining procedure was performed in a fresh 24-well plate (Costar®, 
Corning Inc. from Fisher Scientific, Loughborough, UK) and all solutions were added 
at 1 ml/well. The brain sections stored in cryoprotect solution were initially washed 3 
times in TBS (Tris-buffered saline) of pH 8 for 5 min and then incubated in 1X citrate 
buffer at 90°C for 30 min to retrieve the antigens. Following 3 x 5 min washes, the 
sections were permeabilised for 15 min at RT in 0.3 % (v/v) Triton X-100 in TBS and 
then blocked in 5 % (v/v) goat serum with 1 % (w/v) BSA for 1 h at RT. The primary 
antibodies of interest were then added at 1:500 dilution and incubated O/N in a cold 
room (3°C) and dark on a rocking shaker (Stuart®, gyro-rocker SSL3, Bibby Scientific 
Ltd., Stone, UK). For the co-localisation study the sections were examined using cell-
specific markers for neurons using anti-NeuN (Rabbit polyclonal) antibody, astrocytes 
using anti-GFAP (Rabbit polyclonal) antibody, or activated microglia using anti-Iba-1 
(Rabbit polyclonal) antibody. 
 
The brain sections were then washed 3 times in TBS for 10 min and then stained with 
goat anti-rabbit Alexa Fluor 594 conjugate secondary antibody (AlexaFluor®, 
ThermoFisher Scientific from Life Technologies Ltd., Paisley, UK) at 1:1,000 dilution, 
for 1 h in dark at RT. Following 3 x 10 min washes, the tissue sections were placed on 
silanized slides and allowed to air-dry. The slides were then mounted using 
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FluoroshieldTM with DAPI histology mounting medium and sealed with a coverslip 
(SuperFrost®, Menzel-Gläser from Life Technologies Ltd., Paisley, UK).  
 
All sections were visualised on a Zeiss LSM 880 confocal microscope (Carl Zeiss Ltd., 
Cambridge, UK), using multichannel filters, and the images were merged using the 
Zen lite Blue 2012 software (Carl Zeiss Ltd., Cambridge, UK). For quantification, 3 
digital photographic images per section were taken from the cortex (area close to the 
hippocampal formation), DG and cornus ammonis (CA) region 1 (CA1) (referred to as 
hippocampus) areas with a 40X objective, with a minimum of 15 sections visualised 
per animal. For the cell-specific co-localisation study, images were also taken with a 
63X objective. Image analysis for the BBB penetration and intensity study was 
performed using 8-bit converted images in ImageJ [National Institutes of Health 
(NIH), USA]. Images analysis for the co-localisation study was performed using 8-bit 
separated-channels images in Fiji (Fiji is just ImageJ) (NIH, USA). 
 
2.5.4. Statistics of Immunohistochemical Study 
Collected data obtained from ImageJ for the BBB penetration and intensity study 
were analysed as mean Normalised Intensities (Equation 2.2.) applying one-way 
ANOVA hypothesis test in the case of control versus peptide treatment; and two-way 
ANOVA in case of peptide versus brain region and conditions using the PRISM 
GraphPad software (GraphPad Software Inc., California, USA). Outliers were detected 
using the GraphPad QuickCalcs: outlier calculator software (GraphPad Software Inc., 
California, USA). The tests were then further analysed by post hoc Bonferroni’s 
multiple comparison test and are presented in Chapter 6 as mean ± SEM and a p 










𝐈𝐧𝐭𝐞𝐧𝐬𝐢𝐭𝐲 𝐨𝐟 𝐬𝐚𝐦𝐩𝐥𝐞 − 𝐁𝐥𝐚𝐜𝐤 𝐢𝐧𝐭𝐞𝐧𝐬𝐢𝐭𝐲
𝐖𝐡𝐢𝐭𝐞 𝐢𝐧𝐭𝐞𝐧𝐬𝐢𝐭𝐲 − 𝐁𝐥𝐚𝐜𝐤 𝐢𝐧𝐭𝐞𝐧𝐬𝐢𝐭𝐲
 
Equation 2.2. Normalised Intensity equation. 
Equation applied to normalise the averaged mean values of the intensities for each peptide. 
The “black intensity” was calculated from an image acquired with a shutter in front of the 
camera (i.e. black image – no light). The “white intensity” was calculated from an image 
acquired with the shutter open but no sample present. The two images were acquired using 
the same conditions as for data acquisition. The two values are most commonly represented 
as 0 for black intensity and 255 for white intensity demonstrating the maximum pixel value in 
an 8-bit image (adapted from Vojnovic and Barber, 2005). 
 
2.5.5. Analysis of the Co-localisation study 
8-bit images of separated channels from the images taken by the 63X objective were 
analysed by built-in plugins provided in Fiji (NIH, USA). The images were first 
compared using the “Colocalization Test” plugin to obtain the PSF (Point Spread 
Function) of the image and the Costes’ p-value, where a p-value of ≥0.95 was 
considered statistically significant for colocalization between the two channel 
intensities. The colocalization of the images was also expressed using scatterplots of 
colocalized pixel maps using the “Colocalization Threshold” plugin. Finally, for each 
image, the Pearson’s correlation coefficient (Rr), Manders’ overlap coefficient (R), 
Manders’ colocalization coefficients (M1 and M2), and Manders’ thresholded 
colocalization coefficients (tM1 and tM2) were calculated using the “Coloc2” plugin. 
The qualitative - image based - approaches; and quantitative, including threshold-




Chapter 3: RI-OR2-NAG as a potential peptide inhibitor   
of Aβ aggregation process 
 
3.1. Introduction 
3.1.1. Amyloid aggregation as a target for novel treatments for AD 
Cumulative evidence supports the hypothesis that Aβ oligomerisation and 
fibrillogenesis are the primary and crucial pathogenic events in AD (Hardy and 
Selkoe, 2002). Early nonfibrillar intermediate aggregates, known as soluble 
oligomers, are likely to be the pathogenic components that are at least partly 
responsible for neurodegeneration and neuronal cell death in the brains of affected 
individuals (Klein et al., 2001; Hardy and Selkoe, 2002; Chromy et al., 2003; Bitan et 
al., 2003; Kayed et al., 2003; Kayed et al., 2004; Varvel et al., 2008; Tomic et al., 
2009). Thus, the development of drugs that directly inhibit the very early stages of 
the Aβ aggregation process, rather than the late stages of amyloid fibril formation, is 
now considered to be a viable therapeutic approach for slowing the progression of 
the disease, or even halting the pathogenic events of AD.  
 
3.1.2. Different versions of RI-OR2 peptide as potential inhibitors 
Taylor and colleagues developed a proteolytically stable retro-inverso peptide, RI-
OR2, which demonstrated inhibition of Aβ aggregation and rescued SH-SY5Y 
neuroblastoma cells from Aβ-induced toxicity (Taylor et al., 2010). Parthsarathy and 
colleagues improved the RI-OR2 peptide by attaching a ‘TAT’ transit sequence onto 
its carboxyl terminus, to give RI-OR2-TAT (Parthsarathy et al., 2013). The 
incorporation of the retro-inverted version of the HIV-1 TAT sequence onto the 
peptide was aimed at targeting it into cells and into the brain (Parthsarathy et al., 
2013). The TAT sequence has previously been shown to enable a variety of different 
molecules to cross the BBB (Dietz and Bähr, 2004; Repici et al., 2007); an activity that 
was retained in the retro-inverso version of the TAT sequence (Ramanathan et al., 
2001; Zhang et al., 2009). In our inhibitor, the retro-inverso TAT sequence was 
incorporated so that the protease resistance of RI-OR2 is maintained, which should 
result in good in vivo bioavailability (Parthsarathy et al., 2013).  
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The effects of RI-OR2-TAT on the extent of Aβ aggregation and other associated 
components of AD brain pathology could be improved by using a more brain-
selective delivery mechanism, ideally in combination with a more potent inhibitor. 
An approach that was suggested by Parthsarathy and colleagues to increase the 
potency of RI-OR2-TAT against Aβ aggregation, was to attach the peptide onto the 
surface of lipid nanoparticles, to produce a multivalent inhibitor (Parthsarathy et al., 
2013). The resulting peptide inhibitor nanoparticles (PINPs) (Gregori et al., 2017) 
have been studied as part of this project. Another approach taken here is to use NAG 
as an alternative targeting mechanism to TAT, to develop a new version of the RI-
OR2 aggregation inhibitor. This new peptide inhibitor, RI-OR2-NAG, could potentially 
have an enhanced ability to penetrate across the BBB more selectively than TAT by 
utilising the glucose transporters located at the BBB and nerve cell membranes (Bell 
et al., 1990), and the NAG transporters found at the Golgi complex of cells (Abeijon 
et al., 1996). 
 
In this Chapter, the effect of the RI-OR2-NAG peptide on Aβ aggregation and cell 
proliferation and its ability to penetrate into cells, was examined. The data obtained 
were compared with the RI-OR2-TAT peptide, which has already demonstrated anti-
aggregational properties, no effect on the survival of SH-SY5Y cells, and penetration 
into cultured SH-SY5Y neuroblastoma cells. In the case of the cell proliferation 
experiments, PINPs and CL were also examined.   
 
3.1.3. N-acetylglucosamine 
NAG is a monosaccharide and a derivative of glucose and is abundant at the surface 
of mammalian cells, but is also present in the extracellular matrix, where it is 
involved in insulin signalling, cell cycle control and many other essential processes 
(reviewed by Konopka, 2012). Glucose transporters (GLUT) are structurally 
characterised by twelve membrane-spanning helices with their amino- and carboxy-
terminals exposed on the cytoplasmic side of the biological cell membrane (Oka et 
al., 1990; Hebert and Carruthers, 1992; Cloherty et al., 1995). The glucose 
transporters are expressed in a variety of cell membranes, including barrier tissues 
such as the BBB (GLUT1), and in neurons (GLUT3) (Bell et al., 1990). The NAG 
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transporter (SLC35A3), belongs to the solute carrier (SLC) family 35 nucleotide sugar 
transporters and is characterised by ten transmembrane helices with their C- and N- 
terminals exposed to the cytosol (reviewed by Ishida and Kawakita, 2004). SLC35A3 is 
ubiquitously distributed in tissues as it is found in the Golgi apparatus of mammalian 
cells (Abeijon et al., 1996). 
 
3.1.4. Introduction to the ThT spectroscopic assay 
ThT (Figure 3.1.) is a benzothiazole salt which is used regularly in experimental 
procedures for visualisation and quantification of fibrillization of Aβ and other 
amyloid aggregates. Upon binding to amyloid fibrils, ThT exhibits a shift in its 
excitation maximum (from 385 nm to 450 nm) and emission maximum (from 445 nm 
to 482 nm) (Naiki et al., 1989; LeVine, 1993). ThT is only able to bind to the end-
product of the aggregation process, the mature fibrils, due to the cross-β-structure 
that they display (Naiki et al., 1989; LeVine, 1995). 
 
 
Figure 3.1. The structure of Thioflavin T. 
(Adapted from LeVine, 1993) 
 
The ThT assay measures changes in fluorescence intensity of ThT upon binding to the 
mature fibrils. It can be used to monitor the assembly over time of Aβ into fibrils, 
with this process typically exhibiting sigmoidal growth kinetics (Ferrone et al., 1985; 
Ferrone et al., 1985; Ferrone, 1999). The initial state of this growth is characterised 
as a flat region referred as the lag phase which is followed by a steep transition zone 
known as the growth or elongation phase. Following the latter phase, there is 
another flat region called the plateau phase (Arosio et al., 2015). The lag phase 
corresponds to the early nucleation steps involved in Aβ assembly which occur 
before fibril formation as displayed in the rapid growth phase. In the final plateau 
phase, the monomer concentration is thought to reach an equilibrium where no 
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more assemblies are being formed. It is, however, worth noting that the process of 
Aβ aggregation is ongoing through these phases (Ferrone et al., 1985; Ferrone et al., 
1985; Ferrone, 1999; Cohen et al., 2012). For the assay, synthetic Aβ42 was 
‘deseeded’ so that the starting point for aggregation was as close to monomeric 
peptide as possible in these types of experiments. 
 
3.1.5. Introduction to the cell proliferation assay 
3.1.5.1. SH-SY5Y human neuroblastoma cell line 
The SH-SY5Y cell line that was used for these experiments is a widely used in vitro 
cell model in neuroscience research as it possesses many functional and biochemical 
properties of normal neurons (Biedler et al., 1978; Ross et al., 1983). SH-SY5Y is a 
human-derived cell line that was originally subcloned from the SK-N-SH cell line that 
was isolated from a bone marrow biopsy of a four-year-old female with 
neuroblastoma cancer (Biedler et al., 1973). The homogenous neuroblast-like SH-
SY5Y cell line exhibits proliferative properties for long-term periods thus it can be 
used as a model for neurodegenerative disorders for a variety of studies that can 
include neuronal differentiation, neurotoxicity and neuroprotection. 
 
3.1.5.2. The MTS proliferation and viability assay 
The MTS assay is a colorimetric method that is widely used in proliferation or 
cytotoxicity experiments to determine the number of viable cells. Using a 
colorimetric reaction, the assay measures the potential of cells to bio-reduce the 
MTS tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] into a formazan product 
(Figure 3.2.) which is soluble in the medium solution (Barltrop et al., 1991). The 
reaction occurs through NADPH or NADH which is produced by dehydrogenase 
enzymes present in metabolically active cells (Berridge and Tan, 1993). Thus, the 







Figure 3.2. Structures of MTS tetrazolium and its coloured formazan product. 
 (WWW, Promega) 
 
3.1.6. Determination of cell penetration 
As the initial steps of Aβ aggregation may start inside cells (Friedrich et al., 2010), it is 
of primary importance for the new candidate peptide inhibitors to enter neuronal 
cell and block the very early stages of aggregation. The ‘TAT’ sequence of the RI-OR2-
TAT peptide has previously been shown to be an effective transit peptide, as a 
fluorescent version of this inhibitor, Flu-RI-OR2-TAT, demonstrated rapid entry into 
cultured SH-SY5Y human neuroblastoma cells, within 10 min of incubation, in 
contrast to the fluorescent version of the original RI-OR2 peptide (Taylor et al., 
2010), Flu-RI-OR2, that was not able to enter cells and remained in the culture 




3.2.1. Thioflavin-T assay 
The ThT assays were employed to examine the effects of the RI-OR2-NAG peptide 
inhibitor on Aβ aggregation and fibril formation. The aggregation of Aβ into ThT-
positive amyloid fibrils was monitored by the incubation of the deseeded Aβ peptide 
with inhibitor, in the continuous presence of ThT dye. The fluorescent absorbance of 
ThT-bound fibrils (λex = 442 nm and λem = 483 nm) was recorded every 10 min for a 
period of 48 h on a BioTek Synergy 2 plate reader (BioTek UK, Swindon, UK) at 37°C. 




Data obtained from the ThT aggregation assays for control Aβ versus peptide 
treatment were analysed, using one-way ANOVA and post hoc Bonferroni’s multiple 
comparisons test, whereas unpaired t-tests with Welch’s correction (assuming 
different SDs) were used for comparison between the levels of Aβ aggregation 
obtained at the same concentrations of RI-OR2-TAT and RI-OR2-NAG. Assay data are 
presented as mean ± SEM (n = 3) for 24 h and 48 h incubation periods, and a p-value 
of ≤ 0.05 was considered to be statistically significant. 
 
3.2.2. MTS cell proliferation assay 
Cultured SH-SY5Y human neuroblastoma cells were treated with 0.1, 1, and 10 μM of 
RI-OR2-TAT, RI-OR2-NAG, PINPs and CL for 24 h to determine their effect on cell 
proliferation. In the case of PINPs and CL, the concentrations refer to total lipid 
content. Cell proliferation was assessed using the CellTiter96 Aqueous One Solution 
Cell Proliferation (MTS) assay (Promega, Southampton, UK). Following a 3 h 
incubation, the plate was read at 490 nm (0.1 s) on a Wallac 1420 multilabel counter 
Victor2 plate reader (PerkinElmer®, Massachusetts, USA). 
 
Cell proliferation results were analysed using one-way ANOVA followed by post hoc 
Bonferroni’s multiple comparison test. The results are presented as mean ± SEM (n = 
3) and a p-value of ≤ 0.05 was considered to be statistically significant. 
 
3.2.3. Cell penetration experiment 
Assessment of peptide penetration was performed followed a 1 h incubation of 1 μM 
fluorescently-tagged peptides, Flu-RI-OR2-TAT and Flu-RI-OR2-NAG, with SH-SY5Y 
cultured cells. The cells were visualised on Zeiss LSM 510 confocal microscope (Carl 




3.3.1. RI-OR2-NAG peptide inhibits the formation of Aβ fibrils in vitro 
 
Figure 3.3. Macroscopic aggregation curve of Aβ with RI-OR2-TAT. 
Graph demonstrating the lag phase (0 – 5 h), growth phase (6 – 23 h), plateau phase (24 – 48 
h) of RI-OR2-TAT alone and synthetic Aβ42 alone or in the presence of RI-OR2-TAT peptide at 




Figure 3.4. Macroscopic aggregation curve of Aβ with RI-OR2-NAG. 
Graph demonstrating the lag phase (0 – 5 h), growth phase (6 – 23 h), plateau phase (24 – 48 
h) of RI-OR2-NAG alone and synthetic Aβ42 alone or in the presence of RI-OR2-NAG peptide 
at different molar ratios. 
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Both peptides, RI-OR2-TAT and RI-OR2-NAG, when incubated alone, show no 
tendency to self-aggregate. When Aβ was incubated in the presence of each of these 
peptides, there was a decrease in the ThT fluorescence signal, indicating inhibition of 
Aβ aggregation. The maximum ThT fluorescence signal, representing the point where 
most of the monomeric peptide has been converted into mature fibrils, was 
observed at around 24 h of co-incubation between Aβ and each peptide.  
 
 
Figure 3.5. Inhibition of Aβ fibrils at 24 h by RI-OR2-TAT and RI-OR2-NAG peptides. 
Graph representing the data obtained from the ThT assay at 24 h of incubation of Aβ in the 
presence of RI-OR2-TAT and RI-OR2-NAG peptide inhibitors as percentage of aggregation 
(fluorescence signal of ThT-bound Aβ fibrils). The results are presented as mean ± SEM. * 





Figure 3.6. Inhibition of Aβ fibrils at 48 h by RI-OR2-TAT and RI-OR2-NAG peptides. 
Data obtained from the ThT assay at 48 h of incubation of Aβ in the presence of RI-OR2-TAT 
and RI-OR2-NAG peptide inhibitors are represented as percentage of aggregation 
(fluorescence signal of ThT-bound Aβ fibrils). The results are presented as mean ± SEM. * 
denotes p ≤ 0.05, ** denotes p ≤ 0.01, *** denotes p ≤ 0.001, **** denotes p ≤ 0.0001. 
 
The ThT assay results clearly show inhibition of mature Aβ fibril formation by the RI-
OR2-NAG peptide. In the presence of RI-OR2-NAG at 1:1, 1:2, 1:5 and 1:10 molar 
ratios (inhibitor: Aβ), the aggregation of Aβ was significantly decreased at both 24 h 
and 48 h of co-incubation. More importantly, the novel RI-OR2-NAG peptide 
demonstrated a better inhibitory effect than the RI-OR2-TAT peptide, which has 
previously demonstrated inhibition of Aβ fibrilization at 1:1, 1:2, 1:4, and 1:10 molar 
ratios (Parthsarathy et al., 2013). This was further supported by comparing equimolar 
concentrations of the two inhibitory peptides. RI-OR2-NAG demonstrated better 
inhibition than RI-OR2-TAT at 1:2 and 1:5 molar ratios after 24 h of incubation, and at 






3.3.2. RI-OR2-NAG peptide demonstrates no toxic effect on cells 
 
Figure 3.7. The effects of RI-OR2-TAT, RI-OR2-NAG, PINPs and CL on cell proliferation. 
Graph presenting the effect of the test peptides on the proliferation of SH-SY5Y cells following 
24 h incubation, expressed as a percentage relative to control (untreated) cells. Cell 
proliferation was assessed using the MTS assay. The results are expressed as mean ± SEM. * 
indicates p ≤ 0.05. 
 
Exposure to RI-OR2-TAT, RI-OR2-NAG, PINPs and CL alone for 24 h showed no toxic 
effect on SH-SY5Y cells. On the contrary, cells co-incubated with 10 μM CL 
demonstrated a significant increase in proliferation. Even though the rest of the data 
do not show any significant effect, they do suggest a concentration-dependent 
increase in cell proliferation, especially for CL, signifying a possible effect on 









3.3.3. Flu-RI-OR2-NAG penetration into cultured SH-SY5Y neuroblastoma cells 
  
 
Figure 3.8. Flu-RI-OR2-TAT and Flu-RI-OR2-NAG cell penetration. 
Demonstration of cell penetration of the fluorescent peptides Flu-RI-OR2-TAT and Flu-RI-OR2-
NAG into cultured SH-SY5Y neuroblastoma cells. Image 1 demonstrates penetration of Flu-RI-
OR2-TAT, whereas image 2 represents penetration of Flu-RI-OR2-NAG. A, Fluorescein 
(peptide) detection (488 nm); B, DAPI (cell nucleus) detection (405 nm); C, merged image of A 
and B. Scale bars = 20 μm. 
 
Image acquisition of fluorescently labelled RI-OR2-TAT demonstrated penetration of 
the peptide inside the cultured cells at 1 h of incubation. Flu-RI-OR2-NAG, at 1 h of 
incubation, also penetrates inside the cells but not in their nuclei. The fluorescence is 




This Chapter presents preliminary studies on the development of a new Aβ 
aggregation inhibitor peptide as a potential treatment for AD, alongside previously 
studied peptides and PINPs (Gregori et al., 2017). These same inhibitors are 
examined further in the subsequent Chapters of this thesis. 
 
3.4.1. Anti-aggregational properties of RI-OR2-NAG 
Data obtained from the ThT aggregation assays demonstrate inhibition of Aβ 
fibrillization by both RI-OR2-TAT and RI-OR2-NAG (Figures 3.3., 3.4.). RI-OR2-TAT was 
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shown previously to be an effective inhibitor of Aβ aggregation at 1:1, 1:2, 1:4, and 
1:10 molar ratios of peptide inhibitor to Aβ, after 48 h of co-incubation (Parthsarathy 
et al., 2013). In the experiments presented here, the results were analysed at 24 h 
and 48 h incubation when the elongation of Aβ into fibrils reached a maximum (end 
of growth phase and entrance to the plateau phase). At both 24 h and 48 h of co-
incubation (Figures 3.5., 3.6.), RI-OR2-TAT inhibited Aβ aggregation when present at 
a 1:1 molar ratio, while RI-OR2-NAG inhibited aggregation at all ratios tested (i.e. at 
1:1, 1:2, 1:5, 1:10 molar ratios). The difference between the results presented by 
Parthsarathy and colleagues and those presented here may be attributed to the use 
of different batches of Aβ peptide, and possibly variability resulting from slight 
differences in the preparation and de-seeding of the peptides. The Aβ peptide is 
notoriously variable and extremely sensitive, for example, to temperature, which 
influences its aggregation rate.  
 
At 24 h of co-incubation (Figure 3.5.), the presence of RI-OR2-NAG resulted in a 
decrease of around 90% in fibril formation when incubated at 1:1 and 1:2 molar 
ratios of inhibitor to Aβ, and around 62% when incubated at 1:5 and 1:10 molar 
ratios. At 48 h of co-incubation (Figure 3.6.), the presence of RI-OR2-NAG resulted in 
85% inhibition of fibril formation at 1:1 molar ratio, and 75% inhibition at 1:2 molar 
ratio. At 1:5 and 1:10 molar ratios, these values were deceased to 42% and 54% 
inhibition, respectively. Statistical comparison between equal concentrations of RI-
OR2-TAT and RI-OR2-NAG showed that the RI-OR2-NAG peptide exhibits a better 
inhibitory effect than RI-OR2-TAT at 1:2 and 1:5 molar ratios of inhibitor to Aβ at 24 h 
incubation, and at 1:2 molar ratio at 48 h incubation.  
 
In future studies, the effects of RI-OR2-NAG on early Aβ oligomer formation should 
also be examined. Examples of previously employed techniques for oligomer 
detection include the “double-antibody” approach using 6E10 – 6E10 (Yang et al., 
2005; Ward et al., 2000), 4G8 – 4G8 (LeVine, 2004), and 3D6 – 3D6 (82E1 – 82E1) (Xia 
et a., 2009), based on the multiple epitopes available for these antibodies on 
multimeric/oligomeric Aβ. Parthsarathy and colleagues tested the RI-OR2-TAT 
peptide in a 6E10-6E10 sandwich immunoassay (Taylor et al., 2010), for its ability to 
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inhibit oligomeric forms of Aβ. RI-OR2-TAT induced a reduction in immunoassay 
signal at 2:1 and 1:1 molar ratios of inhibitor relative to Aβ42, at 4 h and 8 h of 
incubation, indicating inhibition of oligomer formation (Parthsarathy et al., 2013). A 
similar type of study could be employed in the case of RI-OR2-NAG. 
 
3.4.2. The effect of RI-OR2-NAG on cultured neuroblastoma cells 
Data from the MTS cytotoxicity assay indicate no toxic effect on SH-SY5Y 
neuroblastoma cells of any of the peptides (RI-OR2-TAT and RI-OR2-NAG) or 
nanoliposomes (PINPs and CL) under the conditions tested (Figure 3.7.). Similarly, the 
RI-OR2-TAT peptide has previously shown no toxic effect on cultured SH-SY5Y cells, 
as demonstrated by MTS and LDH assays, except when incubated at a higher 
concentration of 200 μM (Taylor et al., 2010). 
 
Interestingly, the presence of 10 μM CL resulted in a significant 18% increase in cell 
viability (Figure 3.7.), which can be attributed to the control liposomes added to the 
cell culture medium. The presence of cholesterol and sphingomyelin in CL may have 
supplemented the lipid content of the medium, favouring the growth of the cells 
(Savonnière et al., 1996). Even though the other conditions did not demonstrate any 
significant effect, the data do show an increase in the viability of the cells when 
incubated with the peptides, including the RI-OR2-NAG peptide with its glucose 
derivative. This is an interesting observation because previous studies on APP/PS1 
transgenic mice have shown that RI-OR2-TAT administration, at 100 nmoles/kg/once 
per day over 21 days, results in a substantially increased number of young nerve cells 
in the dentate gyrus (DG) of the hippocampus (Parthsarathy et al., 2013). It is 
possible that this peptide rescues the neuronal stem cells present in this region of 
the brain from the toxic effects of Aβ, but a directly stimulatory effect on the viability 
of these cells is also possible. One of the aims of this present study is to determine 





3.4.3. Penetration of RI-OR2-NAG into cultured neuroblastoma cells 
RI-OR2-TAT was previously assessed using cultured SH-SY5Y cells for its penetration 
properties. The fluorescence signal of the fluorescein-tagged peptide, Flu-RI-OR2-
TAT, was detected inside cells following a 10 min incubation with 1 μM concentration 
of the peptide, in contrast with fluorescently-labelled RI-OR2 peptide which 
remained in the culture medium (Parthsarathy et al., 2013). Confocal imaging of cells 
exposed to Flu-RI-OR2-TAT and Flu-RI-OR2-NAG revealed a build up of fluorescence 
inside the cells following 1 h incubation with 1 μM of these peptides (Figure 3.8.). 
The RI-OR2-TAT fluorescence was observed throughout all cell compartments, 
whereas fluorescence from the RI-OR2-NAG peptide was detected in the cytoplasm, 
close to the nucleus of the cells. This is possibly explained by the location of the NAG 
transporters in the Golgi apparatus of the cells. 
 
There was, however, a definite difference between the intracellular fluorescence 
intensity levels of the two peptides, with Flu-RI-OR2-TAT being more intense that Flu-
RI-OR2-NAG. This could be due to different levels of fluorescence output from the 
peptides themselves or to slower diffusion of the RI-OR2-NAG peptide into the cells, 
via the glucose transporters located in the cell membrane. Further experiments 
would be required to investigate these possibilities, including staining of the Golgi 
apparatus inside the cells (Terasaki et al., 2001) to evaluate co-localisation of the RI-
OR2-NAG peptide in this region of the cell, and time-course experiments to assess 




Understanding the pathological and molecular events that lead to the initiation of Aβ 
aggregation and its accumulation, is crucial for the development of effective 
treatments for AD. This Chapter presented three anti-aggregation peptides, with 
more focus on a novel peptide, RI-OR2-NAG, as possible treatments for the disease. 
Taking everything into consideration, the RI-OR2-NAG peptide appears to be a better 
inhibitor of Aβ aggregation than the RI-OR2-TAT peptide, as it induced better 
inhibitory properties at lower concentrations in the presence of Aβ. It also showed 
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no toxic effects on cultured cells. The data presented in this Chapter show 
encouraging results for future development of RI-OR2-NAG as a potential therapeutic 
agent for AD.   
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Chapter 4: Peptides Detection - Assay Development 
 
4.1. Introduction 
4.1.1. The importance of assay development 
Determination of analyte concentration and distribution is a core and fundamental 
practice in the process of drug discovery and development. Various measurement 
systems and analytical methods can be designed to evaluate the effects of a target 
substance on processes of interest, including those at cellular, biochemical and 
molecular levels. These procedures allow the qualitative assessment or quantitative 
measurement of the investigative molecule in biological samples.  
 
In this Chapter, the development and optimisation of peptide-specific assays is 
explored using both Luminex technology and conventional ELISA systems. The 
optimised assays were subsequently used for the quantitative estimation of Flu-RI-
OR2-TAT, Flu-RI-OR2-NAG and BODIPY-PINPs in tissues collected from WT mice with 
C57/BL6 background. Data from the actual tissue-specific peptide detection are 
presented in Chapter 5. 
 
4.1.2. Luminex Technology 
The Luminex analyser utilises a combination of technologies, including flow 
cytometry, bead microspheres, lasers, avalanche photodiodes (APDs) and a 
photomultiplier tube, to deliver a multilateral platform for developing and 
performing sensitive and specific immunoassays.  
 
Based on uniquely identifiable microsphere bead sets, the Luminex system allows 
detection of target analytes in samples. Currently there are 100 bead sets available, 
with each set being internally dyed with red and infrared fluorophores of varying 
intensities. This precise colour code system provides a unique characteristic or 
‘spectral signature’ for each bead set, for its specific identification. Thus, monoplex 
and multiplex assays can be performed using the Luminex system, which offers 
simultaneous detection of up to 100 analytes in a single well or reaction.  
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There are two inbuilt lasers in the Luminex analyser; a red laser which excites the 
internal classification dyes of the beads at a wavelength of 635 nm, and a green laser 
which excites a reporter molecule attached on the surface of the beads, via the 
biological molecule, at a wavelength of 532 nm. The fluorescent intensity emitted by 
the coded beads is then measured by the APDs, which identify and classify the bead 
set. The emission intensity of the reporter molecule is measured by the 
photomultiplier tube, determining the level of analyte captured onto the 
microspheres and generating a quantifiable measurement. In these assays, 
biotinylated detection antibodies and 4 μg/ml of STREP-RPE were used as the 
detection - reporter system (refer to Figure 2.2.).  
 
4.1.3. The reporter system 
STREP is a bacterial-derived protein with extremely high affinity for binding to biotin 
(Green, 1975). The crystal structure of the two bound molecules was first reported in 
1989 by Hendrickson and colleagues (Hendrickson et al., 1989) and Weber and 
colleagues (Weber et al., 1989). Due to the remarkably strong non-covalent 
interaction of these two molecules, this complex is extensively used in science. RPE, 
on the other hand, is an intensely bright phycobiliprotein derived from red algae 
(Ficner and Huber, 1993), with absorption maxima at 496, 546 and 565 nm, and 
fluorescence emission maximum at 578 nm. 
 
By applying a biotinylated antibody as detection, RPE and other labelled streptavidin 
complexes have been widely used as a detection - reporter system to localise 
antigens on cells and tissues, and to detect biomolecules in immunoassays.  
 
4.1.4. Luminex-bead sandwich immunoassay  
For the purposes of this project, Luminex-bead sandwich immunoassays were 
developed for each peptide. The analytes of interest, in this case the fluorescently-
labelled peptides, were captured using analyte-specific antibodies conjugated on a 
particular bead set. The captured analytes were then detected by employing 
biotinylated antibodies specific to each peptide. STREP-RPE (reporter molecule) was 
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4.2.1. Flu-RI-OR2-TAT peptide Luminex assay development 
A Luminex assay for detection of the RI-OR2-TAT peptide was developed by utilising 
the ‘TAT’ sequence of the peptide and the fluorescein molecule attached to the 
peptide as epitope recognition sites. For the optimisation of the Flu-RI-OR2-TAT 
detection assay, 1, 2, and 3 μg/ml of anti-HIV1 tat [N3] primary antibody were 
coupled to the beads. For detection, 0.5, 1 and 2 μg/ml of anti-fluorescein (biotin) 
secondary antibody were used. STREP-RPE at 4 μg/ml was added as the reporter 
molecule. A range of peptide concentrations (244 pM to 1 μM, and a blank control) 
diluted in HB were tested and the intensities and signal to noise ratios for each 
capture and detection combination were compared. 
 
4.2.2. Flu-RI-OR2-NAG peptide Luminex assay development 
Similar to the development of the Flu-RI-OR2-TAT Luminex assay, the Flu-RI-OR2-
NAG assay was generated by exploiting the ‘NAG’ sequence on the peptide and the 
fluorescein molecule attached. In order to develop an assay for detection of the Flu-
RI-OR2-NAG peptide, three different primary antibodies were coupled to the surface 
of the Luminex beads, at concentrations of 1, 2, 3 μg/ml. The captured peptide was 
detected using anti-fluorescein (biotin) secondary antibody concentrations of 0.125, 
0.25, 0.5, 1, 2 μg/ml, followed by the 4 μg/ml STREP-RPE reporter system. Flu-RI-
OR2-NAG peptide concentrations diluted in HB ranging from 1.95 nM to 1 μM, and a 
blank control, were tested in the antibody titration experiments, and the signal to 
noise ratios of each antibody combination were compared. 
 
4.2.3. BODIPY-PINPs peptide ELISA assay development 
An ELISA assay was developed for detection of PINPs. Two biotinylated antibodies 
were tested as candidate detection components: anti-polyethylene glycol [PEG-B-
47b] (biotin) (rabbit monoclonal) antibody at concentrations of 0.5, 1, and 2 μg/ml; 
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and anti-polyethylene glycol [PEG-2-128] (rabbit monoclonal) antibody at 0.5, 1, 2, 
and 5 μg/ml. In each case, anti-HIV1 tat [N3] antibody was employed as the capture 
antibody, at concentrations of 1, 2, and 3 μg/ml (similar to those employed for the 
Flu-RI-OR2-TAT Luminex assay). Bee venom-treated BODIPY-PINPs were added at a 
concentration range of 15.63 nM to 1 μM, diluted in HB, along with blank controls. 
 
4.2.4. Signal to noise ratio 
The developed assays for the three peptides were analysed based on the S/N ratio 
which is defined as the ratio of MFI (Median Fluorescent Intensity) signal power to 
the background signal. The data obtained from the S/N ratio are plotted against each 
peptide concentration examined, and are also presented in tables in this Chapter’s 









Figure 4.1. Flu-RI-OR2-TAT Luminex assay optimisation – Coupling 1 μg/ml. 
Luminex beads coupled with 1 μg/ml anti-HIV1 tat [N3] antibody were reacted with HB blank 
controls and Flu-RI-OR2-TAT concentration ranges: (A) 244 pM to 1 μM, (B) 244 pM to 
15.63 nM, and (C) 244 pM to 1953 pM. Biotinylated detection anti-fluorescein (biotin) 
antibody of 0.5, 1, and 2 μg/ml and 4 μg/ml STREP-RPE were used as the detection – reporter 
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system for the assay. The figure presents the mean ± SEM (n = 3) of median fluorescent 
intensity (MFI) signal. 
 
 
Figure 4.2. Signal to noise ratios of Flu-RI-OR2-TAT assay optimisation – Coupling 1 μg/ml. 
The figure presents the signal to noise ratios of the MFI values obtained from the 
antibody titrations for development of the Flu-RI-OR2-TAT Luminex assay. Luminex 
beads coupled with 1 μg/ml anti-HIV1 tat [N3] antibody were reacted with HB blank 
controls and Flu-RI-OR2-TAT peptide (244 pM to 1 μM). Biotinylated detection anti-
fluorescein (biotin) antibody at 0.5, 1, and 2 μg/ml and 4 μg/ml STREP-RPE were used 
as detection – reporter system for the assay. The figure represents the mean ± SEM 






Detection antibody (μg/ml) 
0.5 1 2 
1000 75.39 131.35 156.16 
250 53.99 143.33 157.42 
62.5 47.89 118.23 85.33 
15.63 39.59 49.31 41.07 
7.81 36.80 33.46 27.32 
3.91 20.85 20.04 13.95 
1.95 11.79 9.19 8.22 
0.98 7.59 7.40 7.14 
0.49 4.63 4.91 4.05 
0.24 2.92 3.12 2.89 
0 1 1 1 
Table 4.1. Flu-RI-OR2-TAT signal to noise raw MFI values – Coupling 1 μg/ml. 
Table presenting the raw MFI values of the signal to noise ratio results of 1 μg/ml anti-HIV1 
tat [N3] antibody coupled to Luminex microspheres and detected with 0.5, 1, and 2 μg/ml of 













Figure 4.3. Flu-RI-OR2-TAT Luminex assay optimisation – Coupling 2 μg/ml. 
Luminex beads coupled with 2 μg/ml anti-HIV1 tat [N3] antibody were reacted with HB blank 
controls and Flu-RI-OR2-TAT concentration ranges: (A) 244 pM to 1 μM, (B) 244 pM to 
15.63 nM, and (C) 244 pM to 1953 pM. Biotinylated detection anti-fluorescein (biotin) 
antibody of 0.5, 1, and 2 μg/ml and 4 μg/ml STREP-RPE were used as the detection – reporter 
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system for the assay. The figure presents the mean ± SEM (n = 3) of median fluorescent 
intensity (MFI) signal. 
 
 
Figure 4.4. Signal to noise ratios of Flu-RI-OR2-TAT assay optimisation – Coupling 2 μg/ml. 
The figure presents the signal to noise ratios of the MFI values obtained from the antibodies 
titration for the development of the Flu-RI-OR2-TAT Luminex assay. Luminex beads coupled 
with 2 μg/ml anti-HIV1 tat [N3] antibody were reacted with HB Blank controls and Flu-RI-
OR2-TAT peptide (244 pM to 1 μM). Biotinylated detection anti-Fluorescein (Biotin) antibody 
of 0.5, 1, and 2 μg/ml and 4 μg/ml STREP-RPE were used as detection – reporter system for 

















Detection antibody (μg/ml) 
0.5 1 2 
1000 81.38 129.18 143.45 
250 79.73 96.95 119.93 
62.5 32.82 72.08 62.18 
15.63 35.03 34.52 27.24 
7.81 31.53 30.64 19.20 
3.91 15.87 10.79 10.30 
1.95 10.22 7.73 7.01 
0.98 7.29 7.09 7.41 
0.49 5.04 5.22 4.81 
0.24 3.18 2.84 2.74 
0 1 1 1 
Table 4.2. Flu-RI-OR2-TAT signal to noise raw MFI values – Coupling 2 μg/ml. 
Table representing the raw MFI values of the signal to noise ratio results of 2 μg/ml anti-HIV1 
tat [N3] antibody coupled to Luminex beads and detected with 05, 1, and 2 μg/ml of anti-













Figure 4.5. Flu-RI-OR2-TAT Luminex assay optimisation – Coupling 3 μg/ml. 
Luminex beads coupled with 3 μg/ml anti-HIV1 tat [N3] antibody were reacted with HB blank 
controls and Flu-RI-OR2-TAT concentration ranges: (A) 244 pM to 1 μM, (B) 244 pM to 
15.63 nM, and (C) 244 pM to 1953 pM. Biotinylated detection anti-fluorescein (biotin) 
antibody of 0.5, 1, and 2 μg/ml and 4 μg/ml STREP-RPE were used as the detection – reporter 
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system for the assay. The figure presents the mean ± SEM (n = 3) of median fluorescent 
intensity (MFI) signal. 
 
 
Figure 4.6. Signal to noise ratios of Flu-RI-OR2-TAT assay optimisation – Coupling 3 μg/ml. 
The figure represents the signal to noise ratios of the MFI values obtained from the 
antibodies titration for the development of the Flu-RI-OR2-TAT Luminex assay. Luminex beads 
coupled with 3 μg/ml anti-HIV1 tat [N3] antibody were reacted with HB Blank controls and 
Flu-RI-OR2-TAT peptide (244 pM to 1 μM). Biotinylated detection anti-Fluorescein (Biotin) 
antibody of 0.5, 1, and 2 μg/ml and 4 μg/ml STREP-RPE were used as detection – reporter 

















Detection antibody (μg/ml) 
0.5 1 2 
1000 80.97 96.18 111.05 
250 60.88 91.97 134.66 
62.5 39.63 63.65 65.66 
15.63 30.67 31.53 29.63 
7.81 28.73 20.39 16.34 
3.91 17.97 11.72 9.00 
1.95 9.32 8.04 7.19 
0.98 8.61 8.41 6.56 
0.49 7.80 5.02 4.90 
0.24 5.65 2.84 2.78 
0 1 1 1 
Table 4.3. Flu-RI-OR2-TAT signal to noise raw MFI values – Coupling 3 μg/ml. 
Table showing the raw MFI values of the signal to noise ratio results of 3 μg/ml anti-HIV1 tat 
[N3] antibody coupled to Luminex microspheres and detected with 0.5, 1 and 2 μg/ml of anti-
fluorescein antibody, as demonstrated in Figure 4.6. 
 
Analysis of the measured MFI signals of the Flu-RI-OR2-TAT antibody titration 
experiments involving nine different combinations of capture (anti-HIV1 tat [N3]) and 
detection (anti-fluorescein (biotin)) antibodies, revealed that Luminex beads coated 
with 1 μg/ml of capture antibody and detected using 2 μg/ml of biotinylated 
secondary antibody (Figure 4.1.) gave the best signal to noise ratios (Figure 4.2., 
Table 4.1.) and sensitivity of peptide detection. This antibody combination was used 
to investigate the distribution of the Flu-RI-OR2-TAT peptide in various mouse 




4.3.2. Flu-RI-OR2-NAG peptide Luminex assay development 




Figure 4.7. Anti-O-linked N-acetylglucosamine [RL2] antibody titration. 
Luminex microspheres coupled with (A) 1 μg/ml, (B) 2 μg/ml and (C) 3 μg/ml of anti-O-linked 
N-acetylglucosamine [RL2] antibody were reacted with HB blank controls and Flu-RI-OR2-
NAG peptide concentrations ranging from 15.63 nM to 1 μM. Biotinylated detection using the 
anti-fluorescein (biotin) antibody at 0.5, 1, and 2 μg/ml and 4 μg/ml STREP-RPE reporter were 
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used as the detection – reporter system for the assay. The figure represents the mean ± SEM 
(n = 3) of MFI signals obtained at these antibody concentrations. 
 
The MFI signals detected using the anti-O-linked N-acetyglucosamine [RL2] antibody 
as coupling molecule and the anti-Fluorescein (Biotin) antibody as detection 
molecule did not generate very high MFI signals in any of the combinations tested 

























Figure 4.8. Anti-O-GlcNAc RL2 (mouse monoclonal) antibody titration. 
Luminex beads coupled with (A) 1 μg/ml, (B) 2 μg/ml and (C) 3 μg/ml of anti-O-GlcNAc RL2 
(mouse monoclonal) antibody were reacted with HB blank controls and Flu-RI-OR2-NAG 
peptide concentrations ranging from 15.63 nM to 1 μM. Biotinylated detection using the anti-
fluorescein (biotin) antibody at 0.5, 1, and 2 μg/ml and 4 μg/ml STREP-RPE reporter molecule 
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were used as the detection – reporter system for the assay. The figure represents the mean ± 
SEM (n = 3) of MFI signals obtained for these antibody combinations. 
 
The MFI signals detected using the anti-O-GlcNAc RL2 (mouse monoclonal) antibody 
as coupling molecule were improved compared to the signals observed using the 
anti-O-Linked N-Acetylglucosamine [RL2] antibody. However, the MFI signals 
generated in this assay are not as high as in the assay developed for detection of the 
Flu-RI-OR2-TAT assay. 
 




Figure 4.9. Anti-O-GlcNAc CTD110.6 (mouse monoclonal) antibody – Coupling 1 μg/ml. 
Luminex beads coupled with 1 μg/ml of anti-O-GlcNAc CTD110.6 (mouse monoclonal) 
antibody were reacted with HB blank controls and Flu-RI-OR2-NAG concentration ranges (A) 
1.95 nM to 1 μM and (B) 1.95 nM to 15.63 nM. Biotinylated detection anti-fluorescein (biotin) 
antibody of 0.125, 0.25, 0.5, 1, and 2 μg/ml and 4 μg/ml STREP-RPE were used as detection – 
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reporter system for the assay. The figure represents the mean ± SEM (n = 3) of MFI signals 
obtained for these antibody concentrations. 
 
 
Figure 4.10. Signal to noise ratios of Flu-RI-OR2-NAG assay optimisation – Coupling 1 
μg/ml. 
The figure represents the signal to noise ratios of the MFI values obtained from the 
antibodies titration for the development of the Flu-RI-OR2-NAG Luminex assay. Luminex 
beads coupled with 1 μg/ml anti-O-GlcNAc CTD110.6 (mouse monoclonal) antibody were 
reacted with HB Blank controls and Flu-RI-OR2-NAG peptide (1.95 nM to 1 μM). Biotinylated 
detection anti-Fluorescein (Biotin) antibody of 0.125, 0.25, 0.5, 1, and 2 μg/ml and 4 μg/ml 
STREP-RPE reporter molecule were used as detection – reporter system for the assay. The 














Detection antibody (μg/ml) 
0.125 0.25 0.5 1 2 
1000 55.70 63.08 13.01 15.59 13.99 
250 49.74 56.53 11.78 8.86 7.13 
62.5 30.26 17.40 4.57 4.47 3.87 
15.63 5.87 3.28 2.01 1.63 1.32 
7.81 2.09 1.70 0.85 0.65 0.87 
3.91 1.65 1.35 0.70 0.58 0.76 
1.95 1.30 1.13 0.62 0.48 0.82 
0 1 1 1 1 1 
Table 4.4. Flu-RI-OR2-NAG signal to noise raw MFI values – Coupling 1 μg/ml. 
Table showing the raw MFI values of the signal to noise ratio results for 1 μg/ml anti-O-
GlcNAc CTD110.6 (mouse monoclonal) antibody coupled to Luminex bead and detected by 
















Figure 4.11. Anti-O-GlcNAc CTD110.6 (mouse monoclonal) antibody – Coupling 2 μg/ml. 
Luminex beads coupled with 2 μg/ml of anti-O-GlcNAc CTD110.6 (mouse monoclonal) 
antibody were reacted with HB blank controls and Flu-RI-OR2-NAG concentration ranges (A) 
1.95 nM to 1 μM and (B) 1.95 nM to 15.63 nM. Biotinylated anti-fluorescein antibody at 
0.125, 0.25, 0.5, 1, and 2 μg/ml and 4 μg/ml STREP-RPE were used as detection – reporter 





Figure 4.12. Signal to noise ratios of Flu-RI-OR2-NAG assay optimisation – Coupling 2 
μg/ml. 
The figure shows the signal to noise ratios of the MFI values obtained from the antibodies 
titration for the development of the Flu-RI-OR2-NAG Luminex assay. Luminex beads coupled 
with 2 μg/ml anti-O-GlcNAc CTD110.6 (mouse monoclonal) antibody were reacted with HB 
Blank controls and Flu-RI-OR2-NAG peptide (1.95 nM to 1 μM). Detection with biotinylated 
anti-Fluorescein antibody of 0.125, 0.25, 0.5, 1, and 2 μg/ml, and 4 μg/ml STREP-RPE reporter 
molecule were used as detection – reporter system for the assay. The figure represents the 

















Detection antibody (μg/ml) 
0.125 0.25 0.5 1 2 
1000 82.70 101.82 18.43 21.38 16.25 
250 85.96 90.98 16.51 16.65 11.76 
62.5 45.48 43.50 7.05 5.44 3.70 
15.63 4.78 2.48 2.21 1.91 1.60 
7.81 2.26 1.59 1.16 0.79 0.89 
3.91 1.83 1.27 0.76 0.56 0.85 
1.95 1.30 1.20 0.65 0.50 0.90 
0 1 1 1 1 1 
Table 4.5. Flu-RI-OR2-NAG signal to noise raw MFI values – Coupling 2 μg/ml. 
Table representing the raw MFI values of the signal to noise ratio results of 2 μg/ml anti-O-
GlcNAc CTD110.6 (mouse monoclonal) antibody coupled to Luminex microspheres and 
detected by 0.125, 0.25, 0.5, 1 and 2 μg/ml of anti-Fluorescein (Biotin) antibody as 















Figure 4.13. Anti-O-GlcNAc CTD110.6 (mouse monoclonal) antibody – Coupling 3 μg/ml. 
Luminex beads coupled with 3 μg/ml of anti-O-GlcNAc CTD110.6 (mouse monoclonal) 
antibody were reacted with HB Blank controls and Flu-RI-OR2-NAG concentrations ranges (A) 
1.95 nM to 1 μM and (B) 1.95 nM to 15.63 nM. Biotinylated anti-Fluorescein antibody of 
0.125, 0.25, 0.5, 1, and 2 μg/ml and 4 μg/ml STREP-RPE were used as detection – reporter 




Figure 4.14. Signal to noise ratios of Flu-RI-OR2-NAG assay optimisation – Coupling 3 
μg/ml. 
The figure demonstrated the signal to noise ratios of the MFI values obtained from the 
antibodies titration for the development of the Flu-RI-OR2-NAG Luminex assay. Luminex 
beads coupled with 3 μg/ml anti-O-GlcNAc CTD110.6 (mouse monoclonal) antibody were 
reacted with HB Blank controls and Flu-RI-OR2-NAG peptide (1 μM to 1.95 nM). Biotinylated 
anti-fluorescein antibody of 0.125, 0.25, 0.5, 1, and 2 μg/ml, and 4 μg/ml STREP-RPE reporter 
molecule were used as detection – reporter system for the assay. The figure represents the 

















Detection antibody (μg/ml) 
0.125 0.25 0.5 1 2 
1000 141.60 134.35 21.59 18.09 12.73 
250 110.40 120.43 18.05 10.71 9.01 
62.5 67.95 44.18 7.19 4.55 3.38 
15.63 4.70 4.60 2.64 1.87 1.43 
7.81 2.80 2.00 1.31 0.96 1.05 
3.91 2.10 1.45 0.89 0.62 0.95 
1.95 1.40 1.15 0.70 0.51 1.05 
0 1 1 1 1 1 
Table 4.6. Flu-RI-OR2-NAG signal to noise raw MFI values – Coupling 3 μg/ml. 
Table representing the raw MFI values of the signal to noise ratio results at 3 μg/ml anti-O-
GlcNAc CTD110.6 (mouse monoclonal) antibody coupled to Luminex beads and detected by 
0.125, 0.25, 0.5, 1, and 2 μg/ml anti-fluorescein (biotin) antibody, as demonstrated in Figure 
4.14. 
 
The anti-O-GlcNAc CTD110.6 (mouse monoclonal) antibody to the Flu-RI-OR2-NAG 
peptide gave much higher signals than the two previous antibodies tested, and so 
this was the capture system chosen for the study of this peptide in mouse tissues 
(Chapter 5, Section 5.3.2.). In order to decide on the best combination of anti-O-
GlcNAc CTD110.6 capture and anti-Fluorescein detection antibody concentrations, 
the signal to noise ratio of each antibody combination was examined. The best signal 
was obtained using the capture antibody at 3 μg/ml and the detection antibody at 
0.125 μg/ml (Figures 4.13., 4.14., Table 4.6.).  
 
4.3.3. BODIPY-PINPs peptide ELISA assay development 
The original idea was to develop and optimise a Luminex-bead immunoassay for 
detection of the BODIPY-PINPs peptide by utilising the ‘TAT’ sequence of the peptide 
attached to the liposome and the ‘PEG’ molecule of the lipid tail as possible epitope 
detection sites. Administration of the peptide into live organisms will presumably 
result at some stage in the breakdown of the liposome and release of the free 
peptide, possibly following its delivery to the brain. The BODIPY-PINPs were treated 
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with bee venom to break up the nanoliposome membrane so that the peptide 
molecule, still attached covalently to lipid, would be released and could be detected 
and measured. This system might also allow detection of the peptide-lipid 
combination that would be present in the mouse tissues examined in Chapter 5.  
 
Unfortunately, development of a Luminex assay for detection of the peptide-lipid 
component of the BODIPY-PINPs was not feasible as the tested antibody system was 
not generating any signal at all. Thus, an attempt was made to develop an ELISA 










Figure 4.15. Anti-polyethylene glycol [PEG-B-47b] (biotin) antibody titration. 
Microtiter ELISA plates coated with (A) 1 μg/ml, (B) 2 μg/ml and (C) 3 μg/ml of anti-HIV1 tat 
[N3] antibody were reacted with HB blank controls and BODIPY-PINPs concentrations over 
the range of 15.63 nM to 1 μM, with biotinylated detection using anti-polyethylene glycol 
[PEG-B-47b] (biotin) antibody at 0.5, 1, and 2 μg/ml, and 4 μg/ml STREP-RPE as the detection 
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– reporter system. The figure shows mean ± SEM (n = 3) of fluorescent intensity (FI) signals 
for these antibody combinations. 
 
The mean FI data observed from using the anti-polyethylene glycol [PEG-B-47b] 
(biotin) antibody as the detection molecule for this assay showed poor sensitivity, in 
great contrast to the large dose-dependent MFI signals obtained for the optimised 
Flu-RI-OR2-TAT and Flu-RI-OR2-NAG peptide assays. An alternative detection 
antibody, anti-polyethylene glycol [PEG-2-128] (rabbit monoclonal) antibody, was 






















Figure 4.16. Anti-polyethylene glycol [PEG-2-128] antibody titration. 
Microtiter ELISA plates coated with (A) 1 μg/ml, (B) 2 μg/ml and (C) 3 μg/ml of anti-HIV1 tat 
[N3] antibody were reacted with HB blank controls and BODIPY-PINPs concentrations over 
the range of 15.63 nM to 1 μM, with biotinylated detection using anti-polyethylene glycol 
[PEG-2-128] (biotin) antibody at 0.5, 1, 2 and 5 μg/ml, and 4 μg/ml STREP-RPE as the 
detection – reporter system. The figure shows mean ± SEM (n = 3) of fluorescent intensity (FI) 






Figure 4.17. Signal to noise ratios of PINPs assay optimisation. 
The figure demonstrated the signal to noise ratios of the mean FI values obtained from the 
antibodies titration for the development of the PINPs ELISA assay. Microtiter ELISA plates 
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coated with (A) 1 μg/ml, (B) 2 μg/ml and (C) 3 μg/ml of anti-HIV1 tat [N3] antibody were 
reacted with HB blank controls and BODIPY-PINPs concentrations over the range of 15.63 nM 
to 1 μM, with biotinylated detection using anti-polyethylene glycol [PEG-2-128] (biotin) 
antibody at 0.5, 1, 2 and 5 μg/ml, and 4 μg/ml STREP-RPE as the detection – reporter system. 
The figure shows mean ± SEM (n = 3) of fluorescent intensity (FI) signal to noise ratios for 
these antibody combinations. 
 
Comparing the two antibodies used as detection molecules in the process of 
developing an assay for the BODIPY-PINPs, the anti-polyethylene glycol [PEG-2-128] 
antibody demonstrated higher mean FI values. Even though this assay did not 
generate very high signals compared to the assay developed for detection of the Flu-
RI-OR2-TAT, an attempt was made to use the combination of 3 μg/ml anti-HIV1 tat 
[N3] antibody as the capture reagent and 1 μg/ml of anti-polyethylene glycol [PEG-2-
128] antibody as the detection molecule (Figure 4.16. – C), in the effort to investigate 
the bio-distribution of BODIPY-PINPs in the mouse tissues collected (Chapter 5, 
Section 5.3.3.). Even though the raw mean FI signals demonstrate higher readings 
using alternative combinations, this system shows a better ratio of the signal’s 
strength relative to background, even at the lowest concentration of peptide tested 




This Chapter has explored the development and optimisation of Luminex assays for 
detection of the Flu-RI-OR2-TAT and Flu-RI-OR2-NAG peptides; and an ELISA assay for 
detection of the BODIPY-PINPs peptide. These assays were used in the following 
Chapter (Chapter 5) to examine the bioavailability and distribution of these peptides 
in several different mouse tissues, 1 h after their peripheral administration, although 
it was realised that the ELISA assay for BODIPY-PINPs may not be fit for this purpose. 
 
4.4.1. Luminex versus ELISA assays 
Immunoassays have allowed major advances in laboratory research and diagnostics, 
and have been widely employed in the process of drug development. They permit 
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specific and sensitive detection of numerous different analytes in biological samples, 
and have become a routine part of clinical and pharmaceutical investigations. ELISA 
assays have been long used as the main tool to detect and quantify analytes in 
biological samples. However, as discussed by Baker and colleagues (Baker et al., 
2012), they have multiple limitations that are mostly associated with the technical 
application of the method. Examples of these limitations include the relatively large 
amounts of sample required for binding to the available antibody sites; and the non-
specific binding and increased background effects seen due to the large surface area 
of the plate wells, and the hydrophobic binding of capture antibody to the solid 
phase of the wells (Baker et al., 2012). 
 
The new and emerging Luminex technology has overcome some of the limitations 
mentioned above by increasing the flexibility of the assays, allowing reduced 
amounts of antibody and sample volumes to be employed, and delivering a lower 
cost system (Baker et al., 2012). Most importantly, the Luminex platform has enabled 
multiplexing applications from a single sample, in contrast to ELISA assays that are 
limited to detection of one analyte in each reaction. 
 
4.4.2. Luminex assays detecting the Flu-RI-OR2-TAT and Flu-RI-OR2-NAG peptides 
The development of a Luminex assay for the quantification of Flu-RI-OR2-TAT was 
effectively performed using a combination of antibodies that bind to the available 
‘TAT’ and fluorescein antigen sites of the peptide. The developed Flu-RI-OR2-TAT 
assay demonstrated efficient and sensitive detection of this peptide, down to 
picomolar concentration levels. 
 
The Flu-RI-OR2-NAG assay was developed by utilising the ‘NAG’ site of the peptide 
and, in a similar way to the Flu-RI-OR2-TAT assay, the fluorescein molecule attached 
to the peptide. This Luminex assay was optimised to detect nanomolar 
concentrations of the free peptide in HB. Even though this range would be 
considered sensitive enough for most applications, it may not be sufficient for 
quantifying the Flu-RI-OR2-NAG peptide in mouse tissue samples where peptide 
penetration is particularly low. However, this was examined in detail in the following 
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Chapter (Chapter 5). Further optimisation and validation of this assay, including the 
use of alternative antibodies for the NAG site, or different antibodies that target 
fluorescein, may improve the sensitivity of the Flu-RI-OR2-NAG assay. 
 
4.4.3. ELISA assay for detection of BODIPY-PINPs 
The original idea was to develop and optimise a Luminex assay for quantification of 
the BODIPY-PINPs peptide by employing the ‘TAT’ sequence of the free peptide and 
the PEG molecule of the lipid tail. Unfortunately, this was not possible, and an 
alternative ELISA assay was developed.  
 
There are a few possible reasons that can be offered as to why the BODIPY-PINPs 
Luminex assay did not work, although it should be noted that none of these 
explanations was proven experimentally: 
1. The phospholipase A2 from honey bee venom may not have broken down the 
cholesterol and sphingomyelin lipid membranes of the BODIPY-PINPs very 
effectively. If the liposomes remained largely intact, this would obstruct the 
interaction of the antibodies with their corresponding antigen binding sites.  
2. Even if the phospholipase A2 was effective at breaking down the lipid 
membranes, the disintegrated free lipids would be viscous and so could 
readily adhere to the filters present at the bottom of the assay plate wells, so 
interfering with the Luminex reaction. 
3. Monoclonal or polyclonal antibodies can be used for developing an 
immunoassay system. However, polyclonal antibodies are more commonly 
used as the capture component because they bind through multiple antigenic 
sites and so can effectively capture more of the analyte molecule than 
monoclonal antibodies which only recognise one single epitope of the analyte 
molecule. In the BODIPY-PINPs assay, both of the antibodies used for capture 
and detection were monoclonal, and the use of polyclonal antibodies was not 
explored. 
4. Tween® 20 was used at 0.05 % (v/v) concentration in the wash buffer of the 
assays. However, Tween® 20 and other polyoxyethylene detergents can 
interfere with immunoassays when used with anti-PEG products as the 
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detergent itself contains PEG polymers which may interfere with binding of 
the antibodies to their correct antigen sites (Saifer et al., 2014).  
5. When designing a sandwich immunoassay it is important to consider that the 
capture and detection antibodies must recognize two different non-
overlapping epitopes. More specifically, the epitope recognised by the 
detection secondary antibody should not be altered or interfered with by 
binding of the antigen to the capture antibody. In the case of the BODIPY-
PINPs assay, both epitope sites are located on the C-terminal end of the 
peptide which, considering also the viscous properties and the size of the 
lipids, may have affected the binding of the anti-PEG antibodies to their 
epitope sites. 
6. Poor biotinylation of the anti-polyethylene glycol [PEG-2-128] (rabbit 
monoclonal) antibody may offer an explanation. This antibody was supplied 
at a concentration of 0.593 mg/ml preserved in 0.01 % sodium azide, and 
constituted in 40 % Glycerol, 0.05 % BSA, and 59 % PBS. For optimal 
biotinylation, it is suggested to use 1 mg/ml of antibody in a buffer that does 
not contain primary amines or carriers such as BSA. The BSA and glycerol 
present as antibody constituents may have interfered with biotinylation of 
the antibody. Additionally, the anti-polyethylene glycol [PEG-2-128] antibody 
initially underwent a buffer exchange step and was then concentrated to 
1 mg/ml prior to biotin-labelling. It is possible that some of the interfering 
components were not completely removed from the mixture during this 
buffer exchange step, and also that some of the antibody was lost. Equally 
important, the purification process that follows biotinylation of the antibody 
usually yields 60 – 90 % of purified labelled protein, thus, there is the 
possibility that some of the labelled antibody was lost through this process 
also.  
 
These limitations would apply to both the Luminex-bead and ELISA immunoassays 
for the BODIPY-PINPs and can reasonably explain the failure to develop a suitable 
Luminex assay for this system. However, a low sensitivity ELISA was developed for 
detecting the peptide-lipid component of the BODIPY-PINPs and it was decided to 
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attempt to employ this assay for examination of the bioavailability and distribution 




The development of diagnostic methods is extremely important in research and 
especially in the process of discovering candidate drugs for the treatment of various 
diseases. This Chapter has presented the development, optimisation and suggestions 
for improvement, of immunoassays for detection of three possible drug-related 
peptides. Equally important, as we are hoping that these drugs will be able to enter 
human clinical trials for treatment of AD, I suggest that further modifications of these 
assays could enable the detection of these peptides in human biological samples (e.g. 
in blood plasma) for investigation of and correlation with various indicators of 
disease. 
 
In this project, these assays were applied in order to investigate the bioavailability 
and distribution of the peptides concerned in the brain, heart, lungs, stomach, liver, 
spleen, right and left kidneys and small intestine in the following Chapter (Chapter 5). 
These tissues were collected from WT mice with C57/BL6 background, one hour after 




Chapter 5: A pilot study to investigate the distribution 
of the peptides 
 
5.1. Introduction 
5.1.1. Pharmacokinetics and pharmacodynamics in drug design and development 
The study of pharmacokinetics and pharmacodynamics in drug design and 
development is crucial. The fields of clinical pharmacology, pharmacokinetics and 
pharmacodynamics are focused on predicting the effects of chemical substances, 
including potential pharmaceutical drugs, in living organisms (Csajka and Verotta, 
2006). Pharmacokinetic studies analyse the effect of the organisms on the drug’s fate 
by examining the route of the drug through the body, whereas pharmacodynamics 
examine the biochemical and physiological effects of drugs on the living organism 
(Meibohm and Derendorf, 1997). 
 
This Chapter is focused on preliminary studies on the pharmacokinetics of the three 
peptide-based inhibitors, RI-OR2-TAT, RI-OR2-NAG, and PINPs. Fluorescent versions 
of these inhibitors were injected intra-peritoneally at a dose of 100 nmol/kg in the 
case of free peptides and 4 μmol/kg (total lipids) for the peptide-decorated 
nanoliposomes, with an administration volume of 10 ml/kg in WT mice with C57/BL6 
background. Tissue samples were removed for analysis after 1 h. 
 
5.1.2. Introduction on pharmacodynamics 
Pharmacodynamics explain the effects of the drug on cellular and molecular 
processes. Tissues differentiate chemical messenger signals through receptors 
located on cell membranes or in the intracellular fluid. Upon binding of an exogenous 
compound to each receptor, a chemical signal is transduced to the cells which 
initiates a downstream response of biological events. The affinity and efficacy of a 
drug is dependent on the chemical structure of the compound relative to the 
receptor, whereas the pharmacologic effect of the drug is associated with the 
duration of binding between the compound (ligand) and receptor (WWW, MSD 
Manual: Professional/Clinical Pharmacology/Pharmacodynamics). Ideally drugs 
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should bind with high affinity on specific receptors to minimize undesirable side-
effects. 
 
5.1.3. Introduction on pharmacokinetics 
Pharmacokinetic studies of a chemical substance involve the analysis of the chemical 
metabolism of a drug in an attempt to determine the journey of the drug in the body 
following its administration up to the time that it is completely eliminated from the 
organism (Csajka and Verotta, 2006). The pharmacokinetic properties of a substance 
are therefore associated with the mechanisms of absorption, bioavailability, 
distribution, metabolism and excretion of the drug, and are greatly affected by the 
route of administration and the dose of the administered drug (Bryant and Knights, 
2014). 
 
5.1.3.1. Route of administration 
In pre-clinical studies, the route of administration of therapeutic substances plays a 
crucial role in determining the pharmacokinetic properties of the drug of interest. 
Based on the target action of the substance, the route of administration can be 
classified as local or systemic. Systemic administration can also be classified as 
enteral where the drug is administered through the gastrointestinal tract or 
parenteral where the application of administration occurs outside of the digestive 
tract (Turner et al., 2011). 
 
Parenteral administration methods are usually preferred in pre-clinical studies 
because of the ease of their application and the beneficial effects they have on the 
bioavailability of the substances as they avoid the first-pass effect of hepatic 
metabolism (Turner et al., 2011). Intravenous administration of substances is the 
most efficient route of delivery as it avoids the absorption process that must occur 
prior to distribution of the drug using alternative parenteral methods. However, as 
application of this method is challenging when using small rodents, the peptides 
investigated in this Chapter were administered intraperitoneally. The intraperitoneal 





Drugs administered non-intravenously need to be absorbed into the circulation to be 
distributed into the tissues. The major factors affecting the absorption of 
administered substances are their physiochemical properties, dosage and 
formulation, and route of administration of the drug. Transcellular movement of 
drugs is facilitated through several processes that include passive diffusion, 
facilitated or active diffusion, active transport and pinocytosis (WWW, MSD Manual: 
Professional/Clinical Pharmacology/Pharmacokinetics). 
 
Absorption of substances following intraperitoneal administration occurs through 
the mesenteric vessels that release blood into the hepatic portal vein and then pass 
through the liver (Lukas et al., 1971). At the site of liver, exogenous substances 
undergo the first pass effect of metabolism (pre-systemic metabolism) whereby the 
concentration/bioavailability of the drug might be reduced in order to be absorbed 
and reach the systemic circulation (Rowland, 1972; Pond and Tozer, 1984). 
Therefore, a disadvantage associated with this method of administration is that 
substances may undergo metabolism through the hepatic system before reaching 
the circulation for distribution (Turner et al., 2011).  
 
5.1.3.3. Bioavailability 
The term bioavailability refers to the percentage fraction of dose that enters the 
systemic circulation and reaches the site of action following administration of a given 
dosage of a drug (Shargel and Yu, 1999). Medicines administered intravenously 
exhibit 100% bioavailability as they remain unchanged and active, whereas drugs 
administered by alternative routes, usually have decreased bioavailability due to 
either incomplete absorption or first-pass metabolism through the hepatic system 
where they are initially metabolised by the liver before entering the general 
circulation (Griffin, 2009). 
 
5.1.3.4. Distribution 
Once in the circulation of the blood, drugs are distributed to the body’s tissues. Each 
organ and tissue receives different amounts of the drug, and also the total time that 
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the drug remains in each tissue and organ varies. These variabilities in the 
distributional properties of a drug are attributed to the differences in blood flow and 
perfusion of organs, tissues and blood-plasma protein binding, regional pH content 
and vascular permeability of tissue and cell membranes. Drugs are more easily 
distributed in highly perfused areas like liver, kidneys and heart, whereas poorly 
vascularized organs such as muscle and fat exhibit slower distribution rates (WWW, 
MSD Manual: Professional/Clinical Pharmacology/Pharmacokinetics). Equally 
important is the degree of binding between the drug and proteins in plasma and 
tissues. When in circulation, drugs can transport freely or bind to various blood 
components. However, only unbound drugs in circulation are free to passively diffuse 
to the site of action. 
 
5.1.3.5. Metabolism and biotransformation 
Metabolism and excretion of drugs occurs concurrently with distribution. As 
mentioned earlier, the liver is the primary organ of drug metabolism. Drugs are 
metabolised by various processes that include oxidation, reduction, hydrolysis and 
conjugation with endogenous substances in order to excrete the substance from the 
organism (WWW, MSD Manual: Professional/Clinical 
Pharmacology/Pharmacokinetics). Most commonly there are two phases in the 
metabolism of drugs; phase I metabolism where the exogenous substances are 
oxidised by the cytochrome P-450 enzyme superfamily (Danielson, 2002), and phase 
II where the drugs are conjugated to water-soluble compounds by UPD-




Drugs are eliminated from the organism following their distribution and metabolism, 
either in an unaltered state as the parent drug or in modified forms as metabolites. 
The major route of elimination is through the urine via the kidneys, which excrete 
water-soluble substances, however, other elimination pathways also exist that 




Most metabolic unbound drug compounds are eliminated through renal filtration in 
the glomerular endothelium and are not reabsorbed back into circulation though 
tubular reabsorption like most water and metabolites (WWW, MSD Manual: 
Professional/Clinical Pharmacology/Pharmacokinetics). On specific occasions, drugs 
and their metabolites combine with bile juices and enter the biliary excretion 
process. Through this process, drugs enter the intestines and can either be excreted 
with any unabsorbed material through the faeces or be reabsorbed into the 
circulation (enterohepatic cycling) though the intestinal mucosa and eventually be 




Brain, heart, lungs, stomach, liver, spleen, right and left kidneys, and small intestinal 
tissues, were collected after 1 h from three groups of mice, each comprised of 5 
animals, which were injected with 100 nmol/kg of Flu-RI-OR2-TATot Flu-RI-OR2-NAG, 
or 4 μmol/kg (total lipids) of BODIPY-PINPs. Tissues were homogenised in 5 μl/mg of 
tissue HB. The total protein content for each lysate was determined using the BCA 
assay. 
 
The tissue-specific distribution of each peptide was then determined by applying the 
developed Luminex-bead assays to investigate the levels of Flu-RI-OR2-TAT and Flu-
RI-OR2-NAG peptides, and the ELISA assay developed for detection of BODIPY-PINPs 
peptide (Chapter 4). The results obtained from the tissue-specific peptide 
distribution are analysed using one-way ANOVA hypothesis followed by Bonferroni’s 
post hoc multiple comparison test and are presented as the total amount (moles) of 
peptide per tissue-specific protein content (mg). 
 
5.2.1. Flu-RI-OR2-TAT tissue-specific peptide distribution 
A Luminex-bead sandwich immunoassay specific for detecting the Flu-RI-OR2-TAT 
peptide was then applied to determine the concentration of the peptide present in 
each tissue of interest. For the assay, 1 μg/ml of anti-HIV1 [N3] antibody was coupled 
to Luminex beads, and bound peptide was detected using 2 μg/ml of anti-fluorescein 
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(biotin) antibody, and 4 μg/ml STREP-RPE, which were applied as the recognition 
element. Analysis of the assay is presented as mean ± SEM (n = 5), and a p-value of ≤ 
0.05 was considered to be statistically significant. 
 
5.2.2. Flu-RI-OR2-NAG tissue-specific distribution 
Similarly to the Flu-RI-OR2-TAT peptide detection, a Luminex assay was applied to 
investigate the amount of Flu-RI-OR2-NAG peptide in the tissue extracts. Luminex 
beads were coupled with 3 μg/ml of anti-O-GlcNAc CTD110.6 (mouse monoclonal) 
antibody and the bound peptide was detected using 0.125 μg/ml of anti-fluorescein 
(biotin) antibody, with 4 μg/ml of STREP-RPE as the recognition system for the assay. 
Analysis of the Flu-RI-OR2-NAG peptide (pmoles) is presented as mean ± SEM (n = 5) 
and a p-value of ≤ 0.05 was considered to be statistically significant. 
 
5.3.3. BODIPY-PINPs tissue-specific peptide distribution 
In order to detect the BODIPY-PINPs peptide in the several tissues collected, an ELISA 
assay was developed, although the sensitivity of this assay is poor compared to the 
Luminex assays developed for the two free peptides. Microtiter plates were coated 
with 3 μg/ml of primary anti-HIV1 tat [N3] antibody, and 1 μg/ml of anti-
Polyethylene glycol [PEG-2-128] (rabbit monoclonal) antibody along with 4 μg/ml 
STREP-RPE were added as the detection – reporter system to measure the 
fluorescence signal of RPE. Analysis of the BODIPY-PINPs peptide (nmoles) is 














5.3.1. Flu-RI-OR2-TAT tissue-specific peptide distribution 
 
Figure 5.1. Protein concentration in tissue extracts from mice injected with Flu-RI-OR2-TAT. 
The figure presents the average total protein content (mg/ml) of tissue extracts prepared 
following i.p. injection of the Flu-RI-OR2-TAT peptide in five WT mice with C57/BL5 
background. Each tissue was homogenised in HB at 5 μl/mg of tissue and analysis of the 
protein concentration was determined with the BCA assay. The results are presented as mean 
± SEM (n = 5). 
 
The total protein content of tissue homogenates (Figure 5.1.) of mice injected with 
100 nmol/kg Flu-RI-OR2-TAT peptide varies from about 6 mg/ml in lungs to about 20 
mg/ml in brains. The precise protein content (mg) of each tissue extract was 





Tissue Homogenate Volume (μl) Tissue-specific protein content (mg) 
Brain 1265 25.60 
Heart 900.4 7.78 
Lungs 1647.9 10.26 
Stomach 2492.2 17.85 
Liver 5543.2 67.36 
Spleen 568.8 7.40 
Right Kidney 955.8 10.21 




Table 5.1. Protein content in tissue extracts injected with Flu-RI-OR2-TAT. 
The table presents the average tissue-specific protein content (mg) of 5 mice injected i.p. with 
100 nmol/kg Flu-RI-OR2-TAT. The amount of protein in each tissue homogenate was 
calculated according to the average volume of tissue extracts prepared in 5 μl/mg HB. 
 
 
Figure 5.2. Flu-RI-OR2-TAT peptide concentration in mouse tissue extracts. 
The figure represents the total amount (fmoles) of Flu-RI-OR2-TAT detected in the tissue 
lysate samples in relation to tissue-specific protein content (mg). Luminex-beads were 
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coupled with 1 μg/ml of anti-HIV1 [N3] antibody, and the bound sample was detected using 2 
μg/ml of anti-fluorescein (biotin) antibody with 4 μg/ml of STREP-RPE as the reporter 
molecule. Results are presented as mean ± SEM (n = 5). * indicates p ≤ 0.05. The levels of Flu-
RI-OR2-TAT peptide were significantly higher in small intestine compared to all tissues except 
stomach. 
 
The results presented (Figure 5.2.) demonstrate that most of the Flu-RI-OR2-TAT 
peptide is found in the small intestine compared to the brain, heart, lungs, liver, 
spleen and kidney tissues, following peripheral administration and distribution of the 
peptide for 1 h. High amounts of the peptide are also located in the stomach tissue 
of the mice. The data indicate that a possible route of excretion of the Flu-RI-OR2-
TAT peptide is the faeces, supported also by the absence of the peptide in the 
kidneys signifying that elimination of the peptide does not occur through the urine. 
However, the assumptions relative to the excretion of the peptide cannot be 
confidently concluded until further investigation of other pharmacokinetic 
parameters including the peptide’s half-life and excretion rate. The exact amount 
(fmoles) of Flu-RI-OR2-TAT was determined by investigating the total protein content 












Total amount of Flu-RI-OR2-
TAT (fmoles) per tissue-specific 
protein content 
Brain 25.60 0.327 8.37 
Heart 7.78 0.149 1.16 
Lungs 10.26 0.223 2.29 
Stomach 17.85 3373.253 60212.57 (60.21 pmoles) 
Liver 67.36 0.637 42.91 
Spleen 7.40 0.048 0.36 
Right 
Kidney 
10.21 0.009 0.09 
Left 
Kidney 
8.85 0.005 0.04 
Small 
Intestine 
34.87 4298.117 149875.34 (149.88 pmoles) 
Table 5.2. Total amount (fmoles) of Flu-RI-OR2-TAT in tissue extracts. 
The table presents the total amount of Flu-RI-OR2-TAT (fmoles) present in each tissue 
homogenate sample by taking into account the tissue-specific protein content (mg).  
 
The total amount of drug recovered in these tissues is approximately 210 pmoles 
(Table 5.2.), from the average 2624 pmoles originally administered in the 5 mice of 
the group (8% recovery). The average original dose was calculated by taking into 
consideration the 100 nmol/kg administered to the mice relative to their body 
weight. There are a few possible reasons for the low recovery of the drug, however, 
it should be noted that none of these has been proven experimentally: 
1. A large amount of the drug dose is in the blood circulation of the mice and 
was removed following the perfusion of the mouse body. 
2. Part of the drug has already been excreted from the organisms through either 
the faeces or urine. 
3. The Flu-RI-OR2-TAT remains at the site of the injection and is not distributed 
around the body; or its distribution is very slow. 
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4. The drug is distributed in other tissues in the mouse body which were not 
examined in this study. 
 
5.3.2. Flu-RI-OR2-NAG tissue-specific distribution 
 
Figure 5.3. Protein concentration in tissue extracts from mice injected with Flu-RI-OR2-
NAG. 
The figure presents the total protein content (mg/ml) of tissue extracts prepared following 
i.p. injection of the Flu-RI-OR2-NAG peptide in five WT mice with C57/BL6 background. Each 
tissue was homogenised in HB at 5 μl/mg of tissue and analysis of the protein concentration 
was determined BCA assay. The results are presented as mean ± SEM (n = 5). 
 
The total protein content of tissue homogenates (Figure 5.3.) of mice injected with 
100 nmol/kg Flu-RI-OR2-TAT peptide varies from about 7 mg/ml in lungs to about 22 
mg/ml in brains. The exact protein content (mg) of each tissue extract was 









Tissue Homogenate Volume (μl) Tissue-specific protein content (mg) 
Brain 1261.8 27.97 
Heart 690.1 7.68 
Lungs 1456.2 9.80 
Stomach 2012.1 17.56 
Liver 5571.2 72.53 
Spleen 462.8 4.75 
Right Kidney 937.3 10.84 




Table 5.3. Protein content in tissue extracts injected with Flu-RI-OR2-NAG. 
The table presents the tissue-specific protein content (mg) of 5 mice injected i.p. with 100 
nmol/kg Flu-RI-OR2-NAG. The amount of protein in each tissue homogenate was calculated 
according to the volume of tissue extract prepared in 5 μl/mg HB. 
 
 
Figure 5.4. Flu-RI-OR2-NAG peptide concentration in mouse tissue extracts. 
The figure represents the total amount (pmoles) of Flu-RI-OR2-NAG detected in the tissue 
lysate inn relation to tissue-specific protein content (mg). Luminex-beads were coupled 3 
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μg/ml of anti-O-GlcNAc CTD110.6 (mouse monoclonal) antibody, and the bound sample was 
detected using 0.125 μg/ml of anti-fluorescein (biotin) antibody with 4 μg/ml of STREP-RPE as 
the reporter molecule. Results are presented as mean ± SEM (n = 5).  
 
Even though statistical analysis of the samples shows no significant difference 
between the distribution of the Flu-RI-OR2-NAG peptide in the mouse tissue extracts 
(Figure 5.4.), high quantities of the peptide were apparently detected in the small 
intestines of the mice, indicating a possible route of clearance, similar to that of the 
Flu-RI-OR2-TAT peptide. Further examination on pharmacokinetic factors, including 
the peptide’s half-life, can accurately determine the exact route of elimination of the 
Flu-RI-OR2-NAG peptide. The exact amount (pmoles) of Flu-RI-OR2-NAG was 










Total amount of Flu-RI-OR2-
NAG (pmoles) per tissue-
specific protein content 
Brain 27.97 28.77 804.70 
Heart 7.68 7.28 55.91 
Lungs 9.80 17.21 168.66 
Stomach 17.56 21.96 385.62 
Liver 72.53 109.73 7958.72 (7.96 nmoles) 
Spleen 4.75 3.57 16.96 
Right 
Kidney 
10.84 23.08 250.19 
Left 
Kidney 
9.10 17.17 156.25 
Small 
Intestine 
30.16 359.08 10829.85 (10.83 nmoles) 
Table 5.4. Total amount (pmoles) of Flu-RI-OR2-NAG in tissue extracts. 
The table represents the total amount of Flu-RI-OR2-NAG (pmoles) present in each 




The total amount of drug recovered in these tissues is approximately 20.63 nmoles 
(Table 5.4.), whereas the original average dose administered in the 5 mice of this 
group was calculated to be only 2.66 nmoles. This indicates an unacceptable over-
recovery of peptide, and suggests that the assay developed for Flu-RI-OR2-NAG 
(Chapter 4, Section 4.3.2.) is not reliable enough to detect the peptide in the mouse 
tissues. The false-positive data obtained from this assay can be attributed to the 
incabability of the Luminex equipment to appropriately detect particular antibodies 
coupled to the microspheres (personal communication with Dr. Kurimun Ismail). 
Even though the pattern of peptide detection may be correct, any assumption 
relative to the actual concentrations calculated, should be made with caution. 
 
5.3.3. BODIPY-PINPs tissue-specific peptide distribution 
 
Figure 5.5. Protein concentration in tissue extracts from mice injected with BODIPY-PINPs. 
The figure presents the total protein content (mg/ml) of tissue extracts prepared following 
i.p. injection of the BODIPY-PINPs peptide in five WT mice with C57/BL6 background. Each 
tissue was homogenised in HB at 5 μl/mg of tissue and analysis of the protein concentration 
was determined BCA assay. The results are presented as mean ± SEM (n = 5). 
 
The total protein content of tissue homogenates (Figure 5.5.) of mice injected with 
μmol/kg BODIPY-PINPs varies from about 6.8 mg/ml in lungs to about 20 mg/ml in 
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brains. The actual protein content (mg) of each tissue extract was determined 
according to the volume of lysate in HB (Table 5.5.).  
 
Tissue Homogenate Volume (μl) Tissue-specific protein content (mg) 
Brain 1304.5 27.20 
Heart 721 7.13 
Lungs 1271.1 9.44 
Stomach 2555.4 17.26 
Liver 6285.5 108.56 
Spleen 545.9 5.97 
Right Kidney 807.4 10.16 
Left Kidney 898.1 10.86 
Small Intestine 3141.2 28.39 
Table 5.5. Protein content in tissue extracts injected with BODIPY-PINPs. 
The table presents the tissue-specific protein content (mg) of 5 mice injected i.p. with 4 
μmol/kg BODIPY-PINPs. The amount of protein in each tissue homogenate was calculated 







Figure 5.6. BODIPY-PINPs peptide concentration in mice tissue extracts. 
The figure represents the total amount (nmoles) of BODIPY-PINPs detected in the tissue lysate 
samples in relation to tissue-specific protein content (mg). 3 μg/ml of primary anti-HIV1 tat 
[N3] antibody were coated on the wells of the plate, and the bound peptide was detected 
using 1 μg/ml of anti-Polyethylene glycol [PEG-2-128] (rabbit monoclonal) antibody. 4 μg/ml 
of STREP-RPE was used as the reporter molecule. Results are presented as mean ± SEM (n = 
5). Significant results relative to the amount (nmoles) of BODIPY-PINPs in the brain extract 
are presented as: ** denoting p ≤ 0.01, *** denoting p ≤ 0.001, **** denoting p ≤ 0.0001; 
while significant results relative to the amount (nmoles) of peptide in the liver extract are 
presented as: ++ indicating p ≤ 0.01, +++ indicating p ≤ 0.001, ++++ indicating p ≤ 0.0001. 
 
Statistical analysis of the BODIPY-PINPs peptide distribution following 1 h incubation 
(Figure 5.6.) shows that most of the peptide is apparently found in the brain and liver 
extracts of the mice, demonstrating significantly higher results compared to the 
heart, lungs, spleen and kidney lysates. High signals were also obtained from the 
small intestine, suggesting also a possible route of peptide elimination. The exact 
amount (nmoles) of Flu-RI-OR2-NAG was determined by investigating the total 












Total amount of FBODIPY-
PINPs (nmoles) per tissue-
specific protein content 
Brain 27.20 3.52 95.74 
Heart 7.13 0.39 2.78 
Lungs 9.44 1.23 11.61 
Stomach 17.26 1.62 27.96 
Liver 108.56 3.52 382.13 
Spleen 5.97 0.69 4.12 
Right 
Kidney 
10.16 1.28 13.01 
Left 
Kidney 
10.86 0.60 6.52 
Small 
Intestine 
28.39 1.79 32.92 
Table 5.6. Total amount (nmoles) of BODIPY-PINPs in tissue extracts. 
The table represents the total amount of BODIPY-PINPs (nmoles) present in each homogenate 
sample compared to the tissue-specific protein content (mg). 
 
The total amount of drug recovered in these tissues is approximately 577 nmoles 
(Table 5.6.). The original average dose administered in 5 mice was calculated to be 
110.8 nmoles in relation to the body weight of the mice. This means that the data 
generated from the assay developed for detection of the BODIPY-PIPs peptide 
(Chapter 4, Section 4.3.3.), are likely to be due to a very high level of background 




Using intravenous administration of Evans Blue, the one-pass blood circulation time 
of mice was investigated, resulting in complete staining of the mouse body at 15 sec 
(Debbage et al., 1998). Perfusion of mice in this study was conducted 1 h following 
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i.p. administration of the peptides or peptide-liposomes, which should provide 
sufficient time for them to be absorbed and enter the circulation of the mice and 
then be distributed throughout the body tissues. 
 
The dosage of the ‘free’ peptides (100 nmol/kg), with administration volume (10 
ml/kg) and duration of treatment (1 h) was decided based on a previous study of Flu-
RI-OR2-TAT where the effects of this peptide on amyloid plaque load and other 
markers of brain pathology were investigated using APP/PS1 transgenic mice 
(Parthsarathy et al., 2013). The administration dose (4 μmol total lipid/kg) of the 
BODIPY-PINPs was formulated using the same administration volume and duration of 
treatment. This particular dose of total lipid was chosen so that the dose expressed 
as concentration of peptide available on the surface of the liposomes (i.e. 100 
nmol/kg or 2.5% of total lipids) is approximately the same as in the experiments with 
the ‘free’ peptides (Gregori et al., 2017). However, I suggest that further 
investigation of the peptides administration dose and duration of treatment can 
provide more in-depth details on the fate of the inibitors within the organism. More 
specifically, determination of the maximum administration dose can improve the 
effects of the peptides in the brain in future studies while also avoiding any side 
effects; whereas investigation on the duration of treatment can provide more 
detailed information on the pharmacokinetic properties of the three peptides. 
 
Following the development of Luminex-bead assays for detection of Flu-RI-OR2-TAT 
and Flu-RI-OR2-NAG peptides and an ELISA assay detecting the levels of BODIPY-
PINPs peptide (Chapter 4), this Chapter presents some preliminary studies on the 
pharmacokinetics of the three peptides of interest. 
 
5.4.1. Flu-RI-OR2-TAT peptide distribution 
The assay developed for the Flu-RI-OR2-TAT peptide (Chapter 4, Section 4.3.1.), 
detecting picomolar concentrations of the peptide, has effectively demonstrated the 
distribution of the peptide within the different tissues collected. Following 
intraperitoneal administration of 100 nmol/kg of Flu-RI-OR2-TAT for 1 h, the peptide 
was mostly found in the small intestines of the mice. High levels of the peptide were 
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also detected in the stomach. This highly skewed distribution and high sensitivity of 
the assay suggest that the data are likely to be reliable. However, the overall 
recovery of the drug is relatively low. This could be due to the majority of the drug 
remaining at, or close to, the site of the injection, or due to accumulation in blood, or 
other tissues not sampled here.  
 
A possible explanation for this distribution is that the peptide is initially absorbed 
though the liver as the primary lymphatic organ located in the abdomen, and 
following the hepatic first-pass effect, the peptide is then distributed throughout the 
mouse body, where it accumulates in the stomach. Following distribution and 
metabolism, the peptide is likely to be secreted into the gastrointestinal tract 
through the bile where it can be excreted though the faeces or reabsorbed back into 
the systemic circulation by the gastric mucosa, resulting in enterohepatic circulation. 
 
This interpretation is supported by the fact that drugs administered to animals that 
have a molecular mass exceeding 600 g/mol (600 Da) are usually eliminated through 
biliary excretion (WWW, MSD Manual: Veterinary/Pharmacology/Pharmacology 
Introduction). Similarly, drugs administered to humans that exceed a molecular mass 
of 300 g/mol and contain both polar and lipophilic amino acid groups in their 
biochemical structure are likely to be excreted in bile into the small intestine and 
then be eliminated from the organism or enter the enterohepatic cycle (WWW, MSD 
Manual: Professional/Clinical Pharmacology/Pharmacokinetics). Both of these 
statements support the above theory regarding the distribution and excretion of the 
peptide, because the molecular mass of Flu-RI-OR2-TAT (~2979 g/mol) exceeds these 
limits mentioned above. 
 
Interestingly, as the primary target tissue of the peptide is the brain, this pilot study 
also demonstrates effective accumulation of Flu-RI-OR2-TAT in the brain, and 
effective penetration of the BBB of WT mice. Even though the mice were perfused 
with saline prior to collection of the samples, there is a possibility that the peptide is 
found within the cerebral blood vessels, rather than in the brain tissue itself. The 
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penetration of the peptides through the BBB and their accumulation in the brain is 
further investigated in Chapter 6. 
 
5.4.2. Flu-RI-OR2-NAG peptide distribution 
The assay developed for Flu-RI-OR2-NAG in Chapter 4, Section 4.3.2. detects 
nanomolar concentrations of the peptide, and given the dose of 100 nmol/kg the 
assay should be sensitive enough to detect this peptide in at least some of the mouse 
tissues sampled. Signals above background were obtained from the tissue extracts, 
especially in the case of the small intestine, which gave the highest signal. As there 
was no observed statistical significance in tissue distribution, and a calculated over-
recovery of the peptide, these results should be interpreted with a great deal of 
caution, and it can only be tentatively concluded that the majority of RI-OR2-NAG is 
found in the small intestine.  
 
Similar to Flu-RI-OR2-TAT, the detection of Flu-RI-OR2-NAG in the small intestine may 
indicate a possible route of excretion. The molecular mass of the Flu-RI-OR2-NAG 
peptide (~1727 g/mol) also exceeds the two limits discussed in the previous section 
(Section 5.4.1.), supporting the possibility that the peptide is secreted through the 
bile into the small intestine where it may undergo elimination or re-absorption into 
the systemic circulation. Additionally, the Flu-RI-OR2-NAG peptide was also detected 
in relatively large amounts in the liver and kidney extracts of the 5 mice examined, 
indicating that it may have been re-absorbed in the circulation, and following further 
distribution and metabolism, it may be partially eliminated through renal excretion. 
 
Notably, the Flu-RI-OR2-NAG peptide may also have been detected in the brain, 
which is the primary target of the peptide’s action, indicating that is able to 
penetrate the BBB, possibly by utilising the glucose (Bell et al., 1990) and N-
acetylglucosamine (Abeijon et al., 1996) transporters located there. This property of 




5.4.3. BODIPY-PINPs peptide distribution 
The development of a suitable assay for sensitive detection of the BODIPY-PINPs 
(Chapter 4, Section 4.3.3.) proved to be very difficult and presented many problems 
and limitations, as discussed in Chapter 4, Section 4.4.3. The very high signals 
obtained with the BODIPY-PINPs peptide ELISA, suggest that there may be 
considerable and unacceptable background interference with this assay. The data 
from this assay are, therefore, not believable. By detection of fluorescence, Chapter 
6 investigates the ability of BODIPY-PINPs to cross the BBB and accumulate in brain 
areas that are predominantly affected in AD. 
 
A small pilot study was also conducted by Quotient Bioresearch (Rushden) Ltd., in 
order to investigate the biodistribution of PINPs in three C57/BL6 mice. The 
cholesterol component of the liposomes decorated with RI-OR2-TAT peptide was 
radioactively labelled (14C), and the peptide-liposomes were administered 
intravenously (tail vein) at the same dose (4 μmol/kg) and volume (10 ml/kg) as the 
study presented in this Chapter.  The amount of radioactivity in various tissues 
(brain, liver, kidneys, lungs, spleen), was assessed using quantitative whole body 
autoradiography (QWBA), and the peptide’s concentration in blood was measured by 
liquid scintillation counter. The results from this study demonstrated that 0.49 %/g of 
the dose was found in the brain and 0.952 %/g in the blood after 15 min of 
administration, supporting the fact that the lipid-peptide does penetrate through the 
BBB (with approximately 50% brain: blood ratio). However, after this 15 min period, 
most of the peptide (92 %/g) was detected in the lungs. At 60 min post-injection, the 
concentration of peptide in several tissues was generally decreased, yet higher 
amounts were still observed in the lungs (Gregori et al., 2017). This effect of the 
peptide was attributed to the clearance of the peptide-liposomes by the 
mononuclear phagocyte system in the lungs and other tissues (spleen, liver) where 
the peptide was also found in large concentrations (Gregori et al., 2017). 
 
The data between this previous study and the one reported here do not appear to be 
compatible. Presumably due to the poor sensitivity and reliability of the BODIPY-
PINPs peptide ELISA assay, but also the difference in the detection element of the 
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peptide could also be a factor.  A major reason also explaining the incompatibility 
between the two studies is the difference in the administration sites. In the Quotient 
study the peptide was administered intravenously resulting in complete bio-
availability in the circulation of the mice, whereas in the study presented in this 
Chapter, the peptides were applied i.p. where they exhibit an initial 
biotransformation (metabolism) prior to their tissue distribution due to the first pass 
effect in the liver. 
 
 Finally, the Quotient study was focused on the lipid component of PINPs rather than 
the peptide component, and so further studies using labelled peptide will be 
required to examine the detailed tissue distribution of the peptide component of the 
PINPs.  
 
5.4.4. General limitations and further considerations on the study 
One of the purposes of this Chapter was to compare the distributions of the three 
peptides in each of the tissues collected. However, due to the limitations of some of 
the assay systems employed, particularly the ELISA system, this was not entirely 
feasible. 
 
Another major confine of the study was the inaccessibility to equipment and lack of 
experience to investigate intravenous application of the peptides, which is difficult in 
mice. For these reasons, a more convenient intraperitoneal administration route was 
employed, where absorption of the peptides is facilitated by the large surface area 
present in the abdominal cavity. Intravenous application of the peptides would have 
enabled immediate administration of unchanged peptides into the circulation, 
avoiding the absorption and first pass metabolism effects that could have decreased 
their bioavailability (Griffin, 2009). For the same reasons, collection of blood samples 
was not accomplished, which could have increased understanding of the distribution, 
bioavailability and elimination of the peptides. As an alternative, the terminal bleed 





As improvements to the study, investigation of alternative administration sites as 
well as variable treatment durations should be undertaken. Intravenous application 
of the peptides would enable comparisons of their bioavailability in tissues, as the 
bioavailability of compounds administered directly in the blood circulation is 100% 
(Shargel and Yu, 1999). It would be particularly interesting to study intranasal 
administration as a possible delivery route for immediate absorption into the brain, 
avoiding the need to penetrate the BBB, which may improve the levels of peptides 
detectable in the brain. Examination of variable durations of treatment can permit 
determination of half-life, elimination rate, clearance and absorption rates of the 




This Chapter has described preliminary experiments that attempt to study the 
biodistribution of Flu-RI-OR2-TAT, Flu-RI-OR2-NAG and BODIPY-PINPs peptides, and 
their possible routes of elimination and excretion. As a result of limitations observed 
in the sensitivity of some of the assays, accurate and reliable estimation of the 
peptide concentrations in tissues was not always possible. However, in the case of 
Flu-RI-OR2-TAT, the pattern of tissue distribution is likely to reflect the actual 
distribution of the peptide in the tissues concerned. Further suggestions on the 
improvement and optimisation of the Flu-RI-OR2-NAG and BODIPY-PINPs assays, as 
well as additional considerations on the study of peptide distribution have been 
proposed in Chapter 4 and in this Chapter, respectively. 
 
To summarise, the Flu-RI-OR2-TAT peptide, 1 h post-injection, shows effective 
distribution around the body of the mice, and possible secretion through the bile into 
the small intestine, where it can either be excreted though the faeces or re-absorbed 
into the circulation. In the case of Flu-RI-OR2-NAG, clear assumptions cannot be 
made due to the over-recovery of the peptide in the assay. However, comparison of 
the distribution pattern within the tissues suggests that the peptide may be excreted 




Signals for all three peptides were detected in the brains of WT mice, suggesting an 
ability to cross the BBB. Penetration across the BBB is of primary importance as 
treatments for AD should be principally targeted to the brain of patients in order to 
minimise or avoid unwanted side-effects. The ability of Flu-RI-OR2-TAT, Flu-RI-OR2-
NAG and BODIPY-PINPs to enter the brain, and their distribution therein, will be 




Chapter 6: Blood-Brain Barrier penetration and 
deposition of the peptides 
 
6.1. Introduction 
Previously published data by Parthsarathy and colleagues (Parthsarathy et al., 2013) 
have shown that the RI-OR2-TAT peptide is able to cross the BBB and bind to amyloid 
plaques and activated microglia cells in the cerebral cortex of APP/PS1 Alzheimer’s 
transgenic mice, followed peripheral administration. Data from the same research 
also demonstrated that the RI-OR2-TAT peptide inhibitor is able to reduce amyloid 
plaque deposition, oxidation and inflammation, yet also stimulate neurogenesis in 
the brains of the same mouse model of AD (Parthsarathy et al., 2013).  
 
In this study, the ability of the peptides to penetrate through the BBB of WT mice 
with a C57/BL6 background following i.p. administration of 100 nmol/kg of free 
peptides, and 4 μmol/kg (total lipids) of peptide-decorated liposomes and 
undecorated control liposomes, was investigated. WT mice have an intact BBB, 
whereas this may not be the case for Alzheimer’s transgenic mice (APP/PS1) where 
the BBB is disrupted and its transport proteins are impaired (Banks, 2012; Erickson 
and Banks, 2013). Thus, with a therapeutic focus, it is of high importance to 
determine whether the peptide inhibitors are able to cross a functioning and integral 
BBB. The accumulation of the peptides was also assessed in brain areas (cortex – 
close to the hippocampal formation, CA1 of the hippocampus, and DG) that are 
pathologically primarily affected in AD. 
 
6.1.1. Introduction on hippocampus, cortex and the dentate gyrus 
6.1.1.1. Cerebral cortex 
The cerebral cortex is the outer layer of neuronal tissue of the brain and has a key 
role in various important brain functions, including memory, thought, consciousness, 
language, attention and perceptual awareness. The two main pathophysiological 
features of AD, the neuritic plaques and neurofibrillary tangles, are mainly found in 
the frontal and temporal lobe structures of the cortex, close to the hippocampus, as 
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well as in other cortical areas of the brain (Morgan, 2011). Additionally, AD brains 
exhibit marked diffused cortical atrophy and enlargement of ventricles (Bird, 2008) 
which both correlate with the reduced weight of the brain in diseased individuals.  
 
6.1.1.2. Hippocampus 
The hippocampus is one of the major components of the brain in humans and 
vertebrates and it is located underneath the cerebral cortex. The hippocampus 
belongs to the limbic system of the brain, which supports a variety of functions and 
emotions. The hippocampus specifically is involved in the stabilisation and unification 
of information between short-term and long-term memory, and is also responsible 
for spatial navigation (Eichenbaum, 2013; Leuner and Gould, 2010). This brain region 
is one of the first sites that suffers damage in AD as it is associated with memory loss 
and disorientation which are primary symptoms of the disease.  
 
The hippocampus of the brain is composed of several compartments that include the 
subiculum complex, the hippocampus proper (CA1, CA2, CA3 and CA4 areas) and the 
DG. Based on the idea that some of the brain areas are more susceptible in AD and 
exhibit neuronal dysfunction from the very early stages of the disease, Padurariu and 
colleagues have demonstrated a significant decrease in neuronal density in the CA1 
and CA3 areas of the hippocampus proper in AD brains, particularly in the CA1 area, 
compared with age-matched control brains (Padurariu, 2012).  
 
6.1.1.3. The dentate gyrus 
The DG is one of the components of the hippocampal formation system along with 
the hippocampus proper and subiculum (Amaral and Lavenex, 2007; Insausti and 
Amaral, 2012), and is involved in the creation of new episodic memories and 
promotes environmental and spatial exploration (Saab et al., 2009). The DG has been 
identified as the sole site of the hippocampal formation system where a population 
of stem cells is located facilitating the process of neurogenesis (Deng et al., 2010; 
Aimone et al., 2010) and indicating a mechanism of plasticity (Derrick, 2007; Saabet 
al., 2009). This region of stem cells was apparently stimulated, or rescued from Aβ 
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toxicity, in the presence of RI-OR2-TAT peptide in transgenic Alzheimer’s mouse 
experiments (Parthsarathy et al., 2013). 
 
6.1.2. Overview of Blood-Brain and Blood-Cerebrospinal Fluid Barriers 
The brain is the most sensitive and tightly controlled tissue in the human body. The 
co-occurrence of the BBB and blood-cerebrospinal fluid barrier (B-CSFB) serves to 
separate the peripheral circulation from the CNS and maintain its homeostasis. The 
anatomical unit of the B-CSFB is epithelial cells of the choroid plexus (Wolburg et al., 
2001) that are responsible for control of the molecular exchange between blood and 
cerebrospinal fluid, while the functional unit of the BBB is the cerebrovascular 
endothelial cells of brain capillaries (Abbott et al., 2010) that control the exchange of 
molecules between the blood and the brain interstitial fluid. 
 
Tight junctions between the epithelial cells and endothelial cells in the B-CSFB and 
BBB, respectively, form semi-permeable barriers that regulate the entry of blood-
borne substances into the CNS, preserving the chemical composition of the brain and 
protecting its functional processes (Spuch and Navarro, 2011). There is also a third 
barrier formed by the avascular arachnoid epithelium that completely encloses all of 
the CNS compartments, however, it is thought that this does not have a significant 
role in nutrient exchange between blood and CNS (Kandel et al., 2000). 
 
The backbone of the tight junctions formed between the endothelial cells in BBB 
consists of the transmembrane proteins occludin, claudins and junctional adhesion 
molecules, and are responsible for interacting with other cytoplasmic proteins (Tietz 
and Engelhardt, 2015). More precisely, occludin plays a crusial role in the function of 
the BBB as it is involved in the redox regulation (Blasig et al., 2011) and stability 
(Medina et al., 2000) of the tight junctions. Claudin-3 and claudin-5 are involved in 
the formation of the tight junctions and the integrity of the BBB (Luissint et al., 
2012); whereas the junctional adhesion molecules facilitate the assaembly of the 




More specifically, the BBB is comprised of a complex of capillary endothelial cells, 
pericytes (Balabanov and Dore-Duffy, 1998; Armulik et al., 2010), astrocytes (Abbott, 
2002) and extracellular matrix that act as a diffusion barrier for transport of 
substances in and out of the brain and aid communication between the CNS and 
periphery (Banks, 2012). Figure 6.1. illustrates the potential routes by which 
nutrients, minerals, molecules and ions are transported across the BBB. 
 
 
Figure 6.1. Possible routes of molecular transport across the BBB. 
Transport pathways “a” to “f” are used commonly used to move solute molecules across the 
BBB, while pathway “g” is used to transport monocytes, macrophages and drugs (including 
liposome-based drugs). The transport of molecules is regulated by the tight junctions of 
endothelial cells and endogenous transporters (Chen and Liu, 2012 – adapted from Abbott et 
al., 2006). 
 
Only certain molecules with lipophilic and polar properties can diffuse to the CNS 
from the blood. It has actually been reported that approximately 98% of small 
molecules and almost all macromolecules do not cross the BBB (Pardridge, 2005). 
Due to the highly restrictive properties of the BBB, the transport of therapeutic 





6.1.3. Blood-Brain Barrier and drug delivery 
One of the huge challenges in the development of effective drugs for AD is the 
presence of the BBB. As a compartment of the CNS, the BBB creates a strictly 
controlled and unique extracellular fluid environment by the presence of multiple 
endothelium interacting cells, which function as an anatomical, metabolic and 
transport barrier to the free movement of solute molecules between blood and brain 
(Begley, 2004). For this reason, various potential drugs have failed to proceed to 
clinical trials, despite the advances in drug discovery, as insufficient quantities were 
transferred to the CNS, so having little impact on the disease even though they were 
proven to be effective at their site of action in vitro (Begley, 2004; Spuch and 
Navarro, 2011). 
 
Consequently, alternative strategies have been employed including the use of 
prodrugs, direct administration of drugs into the brain, and modulations of the BBB 
by osmotic opening of tight junctions to overcome the limitation of BBB permeability 
(Begley, 2004; Banks, 2012). Amongst these, nanotechnology-based approaches are 
considered effective for significant delivery of drugs to the CNS. 
 
6.1.4. Targeted delivery of nanoliposomes through the Blood-Brain Barrier 
Nanoparticles are currently widely used in diagnostics and therapeutics as they 
possess important and unique features of which the most apparent are given below 
(Gelperina et al., 2005; Tassa et al., 2010). 
1. Nanoparticles are developed using both biocompatible and biodegradable 
materials. 
2. They are characterised by high stability both in circulation and shelf life. 
3. Nanoparticles can be multi-functionalised by attaching various ligands to their 
surface. 
4. Drugs can be incorporated on their surface or in the core of the particle to 
avoid degradation, improve bioavailability, and minimise any potential side 
effects by reducing the dosing frequency. 
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5. The nanoparticle/drug system can be incorporated though various 
administration routes and can be applied in solid dosage forms (Schmidt and 
Bodmeier, 1999; Sham et al., 2004; Tsapis et al., 2002). 
 
Among these promising delivery systems, liposomes have been developed as 
nanomedical devices that, further to the above described features, are also 
characterised by their unique compatibility with both hydrophobic and hydrophilic 
drugs, low toxic effect, avoidance of immune system activation and targeted delivery 
of drugs to the site of action (Chen et al., 2010). Their naturally occurring outer layer 
increases permeability across membranes and biological barriers, while specifically 
sphingomyelin and cholesterol stabilize the liposomal structure (Szoka and 
Papahadjopoulos, 1980). Hydrophilic agents may be entrapped inside the aqueous 
core or attached on the surface, while hydrophobic drugs can be loaded into the 
phospholipid bilayer (Spuch and Navarro, 2011). Finally, the addition of PEG on the 
surface of the nanoliposomes prevents vesicle aggregation, increases stability and 
bioavailability, and provides “stealth properties” to the device which extend the 
blood circulation time of the liposomes as it makes them invisible to the 
mononuclear phagocyte system that is responsible for the rapid clearance of 





Five animals were injected i.p. with either 100 nmol/kg Flu-RI-OR2-TAT or Flu-RI-OR2-
NAG; or 4 μmol/kg BOIPY-PINPs or BODIPY-CL peptides. After 1 h, the LH of the 
brains was collected, fixed in 4 % (w/v) formaldehyde, and coronally sliced (25 
micron) at anatomical regions 1.10 mm to -4.04m bregma. The brain slices were 
stained with anti-NeuN, anti-GFAP and anti-Iba-1 antibodies and counterstained with 
DAPI. All brain sections were visualised with confocal microscopy, and 3 digital 
images per animal were taken at 40X objective from the cortex, DG and CA1 region 




Analysis of the images’ intensities was performed using Image J software and by 
applying one-way ANOVA in the case of control (injected with vehicle) versus peptide 
treatment; and two-way ANOVA in the case of peptide versus brain region. The data 
were further analysed using the post hoc Bonferroni’s multiple comparison test and 







6.3.1. Confocal Images of peptides and vehicle control 
6.3.1.1. Flu-RI-OR2-TAT peptide 
 
Figure 6.2. Confocal images of Flu-RI-OR2-TAT in cortex. 
Brain sections stained with markers for astrocytes (anti-GFAP), activated microglia (anti-Iba-
1), and neurons (anti-NeuN), and counterstained with DAPI (nucleus). Ch1 refers to the green 
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fluorescence of the peptide, Ch2 is DAPI nucleus staining, Ch3 is the neuronal cell marker, and 
Merged refers to the merged images of Ch1, Ch2 and Ch3. Scale Bar = 20 μm. 
 
Figure 6.3. Confocal images of Flu-RI-OR2-TAT in dorsal dentate gyrus. 
Brain sections stained with markers for astrocytes (anti-GFAP), activated microglia (anti-Iba-
1), and neurons (anti-NeuN), and counterstained with DAPI (nucleus). Ch1 refers to the green 
fluorescence of the peptide, Ch2 is DAPI nucleus staining, Ch3 is the neuronal cell marker, and 




Figure 6.4. Confocal images of Flu-RI-OR2-TAT in ventral dentate gyrus. 
Brain sections stained with markers for astrocytes (anti-GFAP), activated microglia (anti-Iba-
1), and neurons (anti-NeuN), and counterstained with DAPI (nucleus). Ch1 refers to the green 
fluorescence of the peptide, Ch2 is DAPI nucleus staining, Ch3 is the neuronal cell marker, and 





Figure 6.5. Confocal images of Flu-RI-OR2-TAT in CA1 region of the hippocampus. 
Brain sections stained with markers for astrocytes (anti-GFAP), activated microglia (anti-Iba-
1), and neurons (anti-NeuN), and counterstained with DAPI (nucleus). Ch1 refers to the green 
fluorescence of the peptide, Ch2 is DAPI nucleus staining, Ch3 is the neuronal cell marker, and 




6.3.1.2. Flu-RI-OR2-NAG peptide 
 
Figure 6.6. Confocal images of Flu-RI-OR2-NAG in cortex. 
Brain sections stained with markers for astrocytes (anti-GFAP), activated microglia (anti-Iba-
1), and neurons (anti-NeuN), and counterstained with DAPI (nucleus). Ch1 refers to the green 
fluorescence of the peptide, Ch2 is DAPI nucleus staining, Ch3 is the neuronal cell marker, and 





Figure 6.7. Confocal images of Flu-RI-OR2-NAG in dorsal dentate gyrus. 
Brain sections stained with markers for astrocytes (anti-GFAP), activated microglia (anti-Iba-
1), and neurons (anti-NeuN), and counterstained with DAPI (nucleus). Ch1 refers to the green 
fluorescence of the peptide, Ch2 is DAPI nucleus staining, Ch3 is the neuronal cell marker, and 





Figure 6.8. Confocal images of Flu-RI-OR2-NAG in ventral dentate gyrus. 
Brain sections stained with markers for astrocytes (anti-GFAP), activated microglia (anti-Iba-
1), and neurons (anti-NeuN), and counterstained with DAPI (nucleus). Ch1 refers to the green 
fluorescence of the peptide, Ch2 is DAPI nucleus staining, Ch3 is the neuronal cell marker, and 





Figure 6.9. Confocal images of Flu-RI-OR2-NAG in CA1 region of the hippocampus. 
Brain sections stained with markers for astrocytes (anti-GFAP), activated microglia (anti-Iba-
1), and neurons (anti-NeuN), and counterstained with DAPI (nucleus). Ch1 refers to the green 
fluorescence of the peptide, Ch2 is DAPI nucleus staining, Ch3 is the neuronal cell marker, and 







Figure 6.10. Confocal images of BODIPY-PINPs in cortex. 
Brain sections stained with markers for astrocytes (anti-GFAP), activated microglia (anti-Iba-
1), and neurons (anti-NeuN), and counterstained with DAPI (nucleus). Ch1 refers to the green 
fluorescence of the peptide, Ch2 is DAPI nucleus staining, Ch3 is the neuronal cell marker, and 





Figure 6.11. Confocal images of BODIPY-PINPs in dorsal dentate gyrus. 
Brain sections stained with markers for astrocytes (anti-GFAP), activated microglia (anti-Iba-
1), and neurons (anti-NeuN), and counterstained with DAPI (nucleus). Ch1 refers to the green 
fluorescence of the peptide, Ch2 is DAPI nucleus staining, Ch3 is the neuronal cell marker, and 





Figure 6.12. Confocal images of BODIPY-PINPs in ventral dentate gyrus. 
Brain sections stained with markers for astrocytes (anti-GFAP), activated microglia (anti-Iba-
1), and neurons (anti-NeuN), and counterstained with DAPI (nucleus). Ch1 refers to the green 
fluorescence of the peptide, Ch2 is DAPI nucleus staining, Ch3 is the neuronal cell marker, and 





Figure 6.13. Confocal images of BODIPY-PINPs in CA1 region of the hippocampus. 
Brain sections stained with markers for astrocytes (anti-GFAP), activated microglia (anti-Iba-
1), and neurons (anti-NeuN), and counterstained with DAPI (nucleus). Ch1 refers to the green 
fluorescence of the peptide, Ch2 is DAPI nucleus staining, Ch3 is the neuronal cell marker, and 





6.3.1.4. BODIPY-Control Liposomes 
 
Figure 6.14. Confocal images of BODIPY-CL in cortex. 
Brain sections stained with markers for astrocytes (anti-GFAP), activated microglia (anti-Iba-
1), and neurons (anti-NeuN), and counterstained with DAPI (nucleus). Ch1 refers to the green 
fluorescence of the peptide, Ch2 is DAPI nucleus staining, Ch3 is the neuronal cell marker, and 





Figure 6.15. Confocal images of BODIPY-CL in dorsal dentate gyrus. 
Brain sections stained with markers for astrocytes (anti-GFAP), activated microglia (anti-Iba-
1), and neurons (anti-NeuN), and counterstained with DAPI (nucleus). Ch1 refers to the green 
fluorescence of the peptide, Ch2 is DAPI nucleus staining, Ch3 is the neuronal cell marker, and 





Figure 6.16. Confocal images of BODIPY-CL in ventral dentate gyrus. 
Brain sections stained with markers for astrocytes (anti-GFAP), activated microglia (anti-Iba-
1), and neurons (anti-NeuN), and counterstained with DAPI (nucleus). Ch1 refers to the green 
fluorescence of the peptide, Ch2 is DAPI nucleus staining, Ch3 is the neuronal cell marker, and 





Figure 6.17. Confocal images of BODIPY-CL in CA1 region of the hippocampus. 
Brain sections stained with markers for astrocytes (anti-GFAP), activated microglia (anti-Iba-
1), and neurons (anti-NeuN), and counterstained with DAPI (nucleus). Ch1 refers to the green 
fluorescence of the peptide, Ch2 is DAPI nucleus staining, Ch3 is the neuronal cell marker, and 




6.3.1.5. Vehicle control 
 
Figure 6.18.Confocal images of vehicle control in cortex. 
Brain sections stained with markers for astrocytes (anti-GFAP), activated microglia (anti-Iba-
1), and neurons (anti-NeuN), and counterstained with DAPI (nucleus). Ch1 refers to the 
background fluorescence of the vehicle control peptide, Ch2 is DAPI nucleus staining, Ch3 is 
the neuronal cell marker, and Merged refers to the merged images of Ch1, Ch2 and Ch3. 




Figure 6.19. Confocal images of vehicle control in dorsal dentate gyrus. 
Brain sections stained with markers for astrocytes (anti-GFAP), activated microglia (anti-Iba-
1), and neurons (anti-NeuN), and counterstained with DAPI (nucleus). Ch1 refers to the 
background fluorescence of the vehicle control peptide, Ch2 is DAPI nucleus staining, Ch3 is 
the neuronal cell marker, and Merged refers to the merged images of Ch1, Ch2 and Ch3. 





Figure 6.20. Confocal images of vehicle control in ventral dentate gyrus. 
Brain sections stained with markers for astrocytes (anti-GFAP), activated microglia (anti-Iba-
1), and neurons (anti-NeuN), and counterstained with DAPI (nucleus). Ch1 refers to the 
background fluorescence of the vehicle control peptide, Ch2 is DAPI nucleus staining, Ch3 is 
the neuronal cell marker, and Merged refers to the merged images of Ch1, Ch2 and Ch3. 





Figure 6.21. Confocal images of vehicle control in CA1 region of the hippocampus. 
Brain sections stained with markers for astrocytes (anti-GFAP), activated microglia (anti-Iba-
1), and neurons (anti-NeuN), and counterstained with DAPI (nucleus). Ch1 refers to the 
background fluorescence of the vehicle control peptide, Ch2 is DAPI nucleus staining, Ch3 is 
the neuronal cell marker, and Merged refers to the merged images of Ch1, Ch2 and Ch3. 




6.3.2. Total mean normalised intensity of the peptides 
 
Figure 6.22. Total mean normalised intensity of the peptides in brain. 
The figure illustrates the total mean normalised intensity of the peptides in the cortex, CA1 
and DG areas of the brain 1 h after peripheral administration (10 ml/kg) of 100 nmol/kg of 
free peptides and 4 μmol/kg of peptide-decorated and undecorated liposomes. The graph is 
presented as mean ± SEM (n = 5). Control mice were injected with 0.9 % NaCl (vehicle 
control). * indicates p ≤ 0.05 compared to control. 
 
One hour after peripheral administration of the peptides or peptide-liposomes, all of 
them demonstrated penetration across the BBB and deposition into the mouse 
brains, compared to the control mice that were injected with vehicle control. The 
BODIPY-PINPs peptide demonstrates significantly higher levels in the brain compared 
to the vehicle control indicating that attachment of the peptide to the nanoliposome 
device facilitates the transport of the peptides across the BBB, supported also by the 







6.3.3. Mean normalised peptide intensities in each brain region 
 
Figure 6.23. Normalised intensities of the peptides in each brain region. 
The figure represents the mean normalised intensities of (A) Flu-RI-OR2-TAT, (B) Flu-RI-OR2-
NAG, (C) BODIPY-PINPs and (D) BODIPY-CL in the cortex, DG and CA1 of the hippocampus, 
compared to the vehicle control (normalised based on the brain region). The peptides were 
administered at 100 nmol/kg for the free peptides and 4 μmol/kg for the liposome peptides. 
The figure represents the mean ± SEM (n=5). *** indicates p ≤ 0.001, **** indicates p ≤ 
0.0001 compared to control. 
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All the peptides show deposition into the various brain regions compared to the 
vehicle control. The BODIPY-PINPs peptide demonstrates highly significant results 
compared to the control peptide for all the regions examined. 
 
6.3.4. Mean normalised regional intensities of each peptide 
Figure 6.24. Normalised regional intensities of each peptide. 
The figure represents the intensities in each brain region examined for (A) Flu-RI-OR2-TAT, (B) 
Flu-RI-OR2-NAG, (C) BODIPY-PINPs, and (D) BODIPY-CL compared to the vehicle control 
regional intensities (normalised based on the average of the vehicle control). The peptides 
were administered at 100 nmol/kg for the free peptides and 4 μmol/kg for the liposome 
peptides. The figure represents the mean ± SEM (n=5) and statistical analysis was performed 
between control versus treatment; and region vs region for each condition. *** indicates p ≤ 
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0.001 (control vs treatment), **** indicates p ≤ 0.0001 (control vs treatment), + indicates p ≤ 
0.05 (region vs region), +++ indicates p ≤ 0.001 (region vs region), ° indicates p ≤ 0.05 (region 
vs region). 
 
The peptides demonstrate increased fluorescence compared to the vehicle control 
for each brain region. Comparison between the brain regions for each peptide 
treatment show significant differences for the BODIPY-PINPs peptide that exhibit 
increased deposition in the cortex of the brains relevant to the dentate gyrus and the 
CA1 of the hippocampus. Significant difference is also observed in the control 






6.3.5. Comparison of the peptides in dorsal and ventral dentate gyrus 
 
Figure 6.25. Normalised peptide and regional intensities in dorsal and ventral dentate 
gyrus. 
The figure represents the normalised (A) peptide intensities (normalised based on the brain 
region) and (B) regional intensities (normalised based on the average of the vehicle control) 
in dorsal and ventral DG of the mice brains. The figure is presented as mean ± SEM (n=5). 
 
The first figure demonstrates the differences in the deposition of the peptides in the 
dorsal and ventral DG of the mouse brains. Even though no significant difference was 
observed, the free peptides were found mostly in the ventral DG whereas the 
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liposome-bound peptides were found more in the dorsal DG of the brain. The second 
figure shows a comparison between the peptide differences in each DG 
compartment. Comparison of the peptides’ intensities in the dorsal DG demonstrates 
that the BODIPY-PINPs peptide is found in increased levels compared to the other 
peptides, in contrast to the ventral DG where the Flu-RI-OR2-TAT peptide seemed to 
be present at higher levels than the other peptides examined. 
 
6.3.6. Deposition of the peptides in the brains (Percentage normalised intensities) 
 
 
Figure 6.26. Percentage normalised intensities of the peptides in brain. 
The figure demonstrates pie charts of the percentage total mean intensity of the (A) Flu-RI-
OR2-TAT, (B) Flu-RI-OR2-NAG, (C) BODIPY-PINPs and (D) BODIPY-CL in the cortex, dorsal and 
ventral DG and CA1 of the hippocampus. 
 
The mean normalised intensities of the four peptides were calculated as percentages 
and presented as pie charts. With respect to the DG, the peptide intensities were 
correlated to the longitudinal plane of the sections and are presented as dorsal and 
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ventral DG. All of the peptides seem to be deposited at higher levels in the cortex of 
the brains relative to the other brain regions examined. Similar intensity levels are 




One major problem associated with the treatment of various neurodegenerative 
diseases, including AD, is the inability of potential drugs to penetrate across the BBB 
and accumulate in the brain in sufficient amounts to achieve the desired effect 
(Begley, 2004). This Chapter presents the ability of our candidate peptides to 
penetrate across the BBB and accumulate in major brain areas that are primarily 
involved in the pathology of AD. The Flu-RI-OR2-TAT, Flu-RI-OR2-NAG and BODIPY-
PINPs peptides all demonstrated BBB passage and were found in the cortex, 
hippocampus and dentate gyrus areas of the brain. 
 
6.4.1. Flu-RI-OR2-TAT brain deposition 
The Flu-RI-OR2-TAT peptide was previously investigated in a BBB penetration study 
using APP/PS1 Alzheimer’s transgenic mice (Parthsarathy et al., 2013). However, as 
the BBB in AD, and in these mice, is disrupted (Banks, 2012; Erickson and Banks, 
2013), it was decided to investigate whether the peptide is able to cross an integral 
and functional BBB. The Flu-RI-OR2-TAT peptide indeed demonstrated penetration of 
the intact BBB in WT mice when they were examined 1 h after i.p. administration. 
 
Flu-RI-OR2-TAT was found in the cortex of the mouse brains, which is possibly the 
primary region of the brain where amyloid plaques are observed. The Flu-RI-OR2-TAT 
peptide was also detected in similar amounts (based on intensity quantification) in 
the hippocampus and the DG of the brain. Even though the number of young 
neurons present in the DG was not calculated in this project, the fact that the 
peptide was detected in this brain region further supports the data observed by 
Parthsarathy and colleagues where the peptide stimulated neurogenesis 
demonstrating the ability to reverse the toxic effect of Aβ in the brain (Parthsarathy 
et al., 2013). 
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In the case of the hippocampus, there is a particular interest in the CA1 area, which 
has demonstrated significant neurodegeneration in the initial stages of the disease, 
as demonstrated by Padurariu and colleagues (Padurariou et al., 2012). Flu-RI-OR2-
TAT was found in both in the CA1 and DG regions of the brain, indicating that this 
peptide may be able to prevent neuronal dysfunction in the CA1 region of the 
hippocampus as well. 
 
The accumulation of the peptide in cellular sites and vascular capillaries is further 
investigated in Chapter 7. 
 
6.4.2. BODIPY-PINPs brain deposition 
The BODIPY-PINPs peptide demonstrates significant results in the BBB penetration 
study, demonstrating that the attachment of the peptide on the liposome results in 
an improved peptide inhibitor. For comparison purposes, I have also included 
undecorated control liposomes, which in general show limited penetration and 
deposition in the brain, indicating that the RI-OR2-TAT peptide on the liposome 
facilitates the transport of the peptide across the BBB and accumulation in the brain. 
 
A similar study on the BBB penetration properties of PINPs was performed using an 
artificial BBB model composed of a hCMEC/D3 cell monolayer where the PINPs 
demonstrated enhanced permeability compared to undecorated control liposomes 
(Gregori et al., 2017). This study, further supports the fact that the BODIPY-PINPs are 
able to cross the BBB, an ability that is maintained from the initial free RI-OR2-TAT 
peptide (Parthsarathy et al., 2013). 
 
Similar to the Flu-RI-OR2-TAT peptide, the BODIPY-PINPs were located more in the 
cortex of the brain compared to the CA1 area of the hippocampus and DG. As 
previously explained, this supports the idea that the peptide can facilitate the 
generation of young new neuronal cells in the brain, and protect against neuronal 
dysfunction and amyloid plaque formation in the diseased brains, so providing a 




6.4.3. Flu-RI-OR2-NAG brain deposition 
The results obtained from study investigating the ability of the Flu-RI-OR2-NAG 
peptide to cross the BBB demonstrate that the peptide can penetrate into the brain, 
although with much lower efficacy compared to the Flu-RI-OR2-TAT and BODIPY-
PINPs peptides. These results show that the peptide potentially utilises the N-
acetylglucosamine transporters on neuronal cells and the glucose transporters at the 
BBB, but the NAG moiety on the peptide is not as effective as a transport modulator 
as the HIV1 virus TAT sequence that was previously incorporated onto the RI-OR2 
peptide. 
 
The Flu-RI-OR2-NAG peptide also seems to locate more into the cortex of the brains. 
The localisation of the peptide in CA1 of the hippocampus, and the DG, however, 
suggest that this peptide could be useful therapeutically, and possibly stimulate 
neurogenesis and protect against neuronal damage in a similar way to RI-OR2-TAT 
and PINPs. 
 
The efficacy of the Flu-RI-OR2-NAG peptide, including its ability to penetrate across 
the BBB, could be improved by attaching the peptide onto the surface of synthetic 
nanoliposomes, in a similar way to the PINPs, to generate a more effective 
multivalent peptide.  
 
6.4.4. Comparison of the dorsal-ventral DG peptide deposition 
The variety of processes controlled by the hippocampus, including not only 
involvement in episodic memory and spatial navigation (Eichenbaum, 2013; Leuner 
and Gould, 2010), but also implementation of emotional responses (Bannerman et 
al., 2004), changes in hormonal levels (Lathe, 2001) and detection of novel stimuli 
(Knight, 1996), have been related to different regions along the longitudinal axis of 
the hippocampus. Several studies on the dorsal and ventral regions of the 
hippocampus have demonstrated that the areas are functionally heterogeneous. The 
dorsal portion of the hippocampus is involved in learning and spatial memory, 
whereas the ventral region is involved in emotion, behaviour and anxiety (Amaral 
and Witter, 1989; Moser and Moser, 1998; Fanselow and Dong, 2010). 
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As the DG is part of the hippocampal formation it should not be considered as a 
homogeneous structure, as variations in the cellular content of the DG can be 
associated with the differential properties of the dorsoventral axis of the 
hippocampus (Fanselow and Dong, 2010).  A study by Fuster-Matanzo and colleagues 
demonstrated that the functional differences between the two DG poles are linked 
to the time variation of the appearance of cognitive and behavioural decline 
symptoms in various neurodegenerative diseases (Fuster-Matanzo et al., 2011). 
Similarly, Kheirbek and Hen suggested that the granule cells present in the DG may 
contribute to different functions associated with learning and emotion (Kheirbek and 
Hen, 2011). 
 
Based on these studies I decided to investigate whether the peptides are extensively 
deposited in either of the two poles of the DG. The results obtained from our study 
demonstrated that the Flu-RI-OR2-TAT and Flu-RI-OR2-NAG peptides are found 
mainly in the ventral DG, whereas the BODIPY-PINPs are found more in the dorsal 
DG. These differences between the peptides suggest the RI-OR2-TAT and RI-OR2-
NAG peptides can improve the behavioural changes that occur in patients with AD; 
while PINPs peptide can recover the cognitive deficits of the disease. However, as the 
peptides are detected in both regions of the dorsoventral axis of the DG (Figure 
6.25.), this outcome suggests that the peptides may affect both of these functional 
processes of the hippocampus. Further investigation of the distribution of these 
peptides within the DG, along with behavioural tests that involve APP/PS1 transgenic 




The results generated from this study demonstrate that Flu-RI-OR2-TAT, Flu-RI-OR2-
NAG and BODIPY-PINPs are able to cross an intact and functional BBB and 
accumulate in the cortex and hippocampus of the brain, regions that are primarily 




A main restriction of this study is the limited number of animals used, which also 
explains the large error bars in some of the graphs presented. However, the pattern 
observed in the total normalised intensities of the peptides correlates with other 
studies presented in this thesis, or published by our research group. Examples 
include the ability of Flu-RI-OR2-TAT to penetrate across the BBB in APP/PS1 
transgenic mice (Parthsarathy et al., 2013), or an artificial BBB in the case of PINPs 
(Gregori et al., 2017). Additionally, the lower fluorescence intensity observed with 
the Flu-RI-OR2-NAG peptide compared to the Flu-RI-OR2-TAT peptide was also 
observed in the cell penetration experiments presented in Chapter 3, Section 3.3.3. 
 
One major finding of this Chapter is that the liposome-attached RI-OR2-TAT peptide 
has an enhanced ability to cross the BBB compared to the RI-OR2-TAT free peptide 
and control undecorated liposomes. Moreover, focusing on the therapeutic abilities 
of the peptides, their accumulation in the DG of the brain suggests that they may be 
able to stimulate neurogenesis in diseased brains, or reverse the toxic effects of Aβ 
on neuronal stem cells, as well as improving both cognition and memory. This finding 
also correlates with the ability of the peptides to enhance cell viability and 





Chapter 7: Co-localisation of peptides with neuronal 
and glial markers 
 
7.1. Introduction 
7.1.1. The study of co-localisation 
The study of co-localisation can provide basic evidence on the structural and 
functional characteristics of two antigens of interest. The co-existence of a signal at a 
particular pixel location when examining multichannel fluorescence microscopy 
images provides an initial clue of spatial overlap between the two fluorescent 
antigens (Zinchuk et al., 2007). 
 
There are many techniques used to identify the co-localisation of two biological 
phenomena, which can be divided into qualitative and quantitative methods. The 
qualitative approach involves the presentation of a merged image where co-
localisation is demonstrated by the colour change on colocalised pixels between two 
fluorescent channels. The quantitative approach involves the statistical analysis of 
the degree of co-localisation where the frequency of coincidental objects and the 
interdependence of the two different channels is calculated (Manders et al., 1993). 
 
7.1.2. Introduction on co-localisation analysis 
Qualitative analysis can provide initial insights into co-localisation estimation. 
Merged fluorescent images, colocalised pixel maps and scatterplots of pixel 
intensities of each channel’s image demonstrate to some degree the co-localisation 
of two objects (Dunn et al., 2011). On the other hand, quantitative co-localisation 
analysis results in the generation of multiple coefficients that describe the degree of 
co-localisation between two objects (Demandolx and Davoust, 1997). These 
coefficients estimate the degree of co-localisation using specially developed 




7.1.2.1. Pearson’s correlation coefficient (Rr) 
Pearson’s correlation coefficient is widely used in pattern recognition and 
determines the covariance and correlation of signal intensities between the two 
channels. Pearson’s coefficient is not sensitive to the intensity of the background nor 
to the intensity of the overlapping signals. Statistical values of Pearson’s coefficient 
ranges from -1 to 1, where 0 indicates no significant or random correlation, -1 
indicates total negative correlation and 1 refers to total positive correlation 
(Manders et al., 1992; Manders et al., 1993; Zinchuk et al., 2007; Dunn et al., 2011). 
 
7.1.2.2. Costes’ p-value 
The Costes’ method calculates the Pearson’s correlation coefficient of the two 
channel images and then tests the result in trials where the channel 1 image is 
compared to the channel 2 image with scrambled pixel values. This process occurs 
200 times to stimulate random overlap between the two images. The Costes’ p-value 
is then generated, indicating the probability of real co-localisation in the original 
image. In this study, the test must be passed at 95% confidence level to proceed to 
further statistical analysis using alternative methods (Costes et al., 2004). 
 
7.1.2.3. Manders’ overlap coefficient (R) 
Manders’ overlap coefficient refers to the overlap of signals between the two 
channels and therefore represents the true degree of co-localisation. Manders’ 
overlap coefficient is sensitive to the differences in background intensities but not to 
the overlapping pixel intensities. Its values range from 0 to 1, where 0 means no 
overlapping pixels, and 1 indicates high co-localisation (Manders et al., 1992; 
Manders et al., 1993; Zinchuk et al., 2007; Dunn et al., 2011). 
 
7.1.2.4. Manders’ colocalization coefficients (M1 and M2) 
M1 and M2 colocalization coefficients demonstrate the input of each channel’s 
image to the pixels of interests. More specifically, M1 describes the number of above 
background pixels in the channel 1 image that overlap with above background pixels 
in the channel 2 image. Respectively, M2 refers to the number of above background 
pixels in channel 2 image that overlap with above background pixels in channel 1 
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image. Thus, M1 and M2 are not sensitive to overlapping pixel intensities but they 
are sensitive to background intensity. The coefficients’ values range from 0 to 1 and 
can be expressed as a percentage where a value of 1 in both channels indicates 100% 
co-localisation (Manders et al., 1992; Manders et al., 1993; Zinchuk et al., 2007; Dunn 
et al., 2011).  
 
7.1.2.5. Manders’ thresholded colocalization coefficients (tM1 and tM2) 
This method of analysis is based on Costes’ p-value. Following determination of the 
p-value, the method generates a scatterplot from the two analysed images and a 
regression line between the two channels pixel distribution. The Pearson’s 
correlation coefficient is calculated for all colocalised pixels on the regression line; 
until the Pearson’s value reaches 0 indicating the threshold values for each channel 
of certain images. Following determination of the threshold, the M1 and M2 values 
are calculated yet, this time the pixels below threshold are ignored (Manders et al., 
1993; Dunn et al., 2011). 
 
7.1.2.6. Scatterplots 
Two-dimensional scatterplots can also be generated by computer software upon 
analysis of co-localisation and demonstrate the distribution of the pixels according to 
each image examined. The pixels intensity scale for the channel 1 image is presented 
on the x-axis whereas the pixels intensity of the channel 2 image is represented on 
the y-axis. Each pixel’s intensity value is used as point coordinate on the graph. Thus, 








Figure 7.1. Example of a 2D scatterplot. 
The figure demonstrates (A) an example of a scatterplot designed by the alignment of pixels 
from two fluorescent images, and (B) the four quadrants of a scatterplot. The red quadrant 
indicates channel 1 pixels below threshold and channels 2 pixels above threshold. The green 
quadrant demonstrates channel 1 and channel 2 pixels below threshold. The blue quadrant 
shows channel 1 pixels above threshold and channel 2 pixels below threshold. The yellow 
quadrant indicates channel 1 and channel 2 pixels above threshold. The regression line 
reflects the ratio of the fluorescence between the two channels’ pixels (WWW, Image J: 
Colocalization analysis).   
 
7.1.3. Introduction to neuronal cells 
7.1.3.1. Neurons 
Neurons are the basic component of signalling in the brain that process information 
through electrical signals or action potentials by the formation of synapses between 
two neuronal cells. They are composed of the cell body (soma), dendrites, and an 
axon that ends at the presynaptic terminals. The cell body of the neurons is 
responsible for the metabolic processes associated with the cell while the dendrites 
and the axon are responsible for signal transmission. More specifically, the many 
dendrites on the soma of the neuron are responsible for receiving incoming 
information, whereas the axon transmits the signal to the synapse to communicate 




7.1.3.2. Glial cells 
Macroglial and microglial cells of the brain are responsible for the structural and 
metabolic support of the neurons and maintenance of CNS homeostasis (Jessen and 
Mirsky, 1980). The macroglial cells are classified as astrocytes, oligodendrocytes, 
ependymal cells and radial glia. Astroglial cells support the metabolic balance of 
extracellular ions and are involved in the exchange of substances in the brain by 
assisting the BBB endothelial cells (Abbott, 2002). On the other hand, ependymal 
cells form the epithelial layer that surrounds the choroid plexus, thus maintaining the 
B-CSFB. Oligodendrocytes are responsible for the production of myelin that shields 
and protects the neuronal axons and the formation of action potentials. Finally, 
radial glia facilitate the migration of new neurons formed in the hippocampus and 
have been also identified as precursor cells of both neurons and glial cells (Campell 
and Gotz, 2002; Steindler, 2012). 
 
As specialised macrophages, microglia are associated with the immune functioning of 
the CNS. They present antigens on their cell-surface and secrete cytokines (Eglitis and 
Mezey, 1997), and are involved in phagocytic procedures protecting neurons in the 
CNS and interfering with the progression of various diseases (Wake et al., 2013). 
Adult microglial cells have been identified to regulate synaptic elimination, cell 
death, neurogenesis and neuronal surveillance and plasticity (Eyo and Dailey, 2013). 
Thus, microglial deficiency may result in several psychiatric but also neurological 
disorders (Wake et al., 2013), including AD. 
 
7.1.4. Neuronal and glial cells markers 
7.1.4.1. anti-GFAP: Astrocytes 
Antibodies specific towards glial fibrillary acidic protein (GFAP) have been used as 
markers for astrocytes. GFAP is a class-III intermediate filament that provides 
support to the astroglia by the formation of a network that controls their function, 




7.1.4.2. anti-Iba-1: Activated Microglia 
Ionized calcium binding adaptor molecule 1 (Iba-1) mRNA is specifically expressed in 
microglia (Imai et al., 1996; Ito et al., 1998), thus antibodies targeting this protein 
have been used in immunocytochemical and immunohistochemical studies to 
identify activated microglial cells. This macrophage-specific calcium binding protein 
embodies the actin-bundling activity and is involved in the membrane disruption and 
phagocytic properties of activated microglia (Ohsawa et al., 2004).  
 
7.1.4.3. anti-NeuN: Neurons 
Antibodies recognising Neuronal Nuclei (NeuN) protein have been widely used in 
immunohistochemistry as a tool to identify neurons in the CNS (Mullen et al., 1992). 
NeuN has been identified as Fox-3, a protein that is expressed exclusively in neurons 
and is involved in the regulation of mRNA alternative splicing and neuronal cell 
differentiation (Kim et al., 2009). 
 
In this Chapter, brain sections from WT mice were stained with anti-GFAP, anti-Iba-1, 
and anti-NeuN antibodies and counterstained with DAPI, and visualised on a Zeiss 
LSM confocal microscope and images of the sections were acquired using the 63X 
objective. The analysis of co-localisation is presented, with both qualitative and 




Fluorescent images acquired using confocal microscopy were converted into 8-bit 
images and analysed for co-localisation between neuronal cell markers (red – 
Channel 1) and fluorescent peptides (green – Channel 2) using plugins in Image J 
software. The “Colocalization Test” was used to obtain the Costes’ p-value. The 
“Colocalization Threshold” was used to generate a colocalised pixel map and a 
scatterplot of colocalization of the two channels. Finally, the “Coloc 2” plugin was 
used to calculate the Pearson’s correlation coefficient (Rr), Manders’ overlap 
coefficient (R), Manders’ colocalization coefficients (M1 and M2), and Manders’ 




7.3.1. Co-localisation of Flu-RI-OR2-TAT with cell markers in cortex, DG and 
hippocampus 
7.3.1.1. Evaluation of co-localisation with astrocytes (anti-GFAP) 
 
Figure 7.2. Co-localisation of Flu-RI-OR2-TAT with astrocytes in cortex. 
The figure illustrates the (A) confocal image analysed, (B) pixel map where colocalised pixels 
are shown as white. SB = 10 μm. 
 
 
Figure 7.3. Scatterplot of colocalised pixel map of Flu-RI-OR2-TAT with astrocytes in cortex. 
The scatterplot illustrates the threshold of the red channel on x-axis and the threshold of the 
green channel on y-axis. The intensity of a given pixel in channel 1 is used as an x-coordinate 
whereas the corresponding pixel’s intensity in channel 2 is represented as the y-coordinate. 




The scatterplot results demonstrate that there is some co-localisation between the 
fluorescent intensities of the Flu-RI-OR2-TAT peptide and the astrocytes in the cortex 




Figure 7.4. Co-localisation of Flu-RI-OR2-TAT with astrocytes in dentate gyrus. 
The figure illustrates the (A) confocal image analysed, (B) pixel map where colocalised pixels 
are shown as white. SB = 10 μm. 
 
 
Figure 7.5. Scatterplot of colocalised pixel map of Flu-RI-OR2-TAT with astrocytes in 
dentate gyrus. 
The scatterplot illustrates the threshold of the red channel on x-axis and the threshold of the 
green channel on y-axis. The intensity of a given pixel in channel 1 is used as an x-coordinate 
whereas the corresponding pixel’s intensity in channel 2 is represented as the y-coordinate. 




Similar to the cortex of the brain, the scatterplot shows that the Flu-RI-OR2-TAT 
peptide co-localises with astrocytes in the DG of the hippocampal formation.  
 
 
Figure 7.6. Co-localisation of Flu-RI-OR2-TAT with astrocytes in hippocampus. 
The figure illustrates the (A) confocal image analysed, (B) pixel map where colocalised pixels 
are shown as white. SB = 10 μm. 
 
 
Figure 7.7. Scatterplot of colocalised pixel map of Flu-RI-OR2-TAT with astrocytes in 
hippocampus. 
The scatterplot illustrates the threshold of the red channel on x-axis and the threshold of the 
green channel on y-axis. The intensity of a given pixel in channel 1 is used as an x-coordinate 
whereas the corresponding pixel’s intensity in channel 2 is represented as the y-coordinate. 
The regression line of fluorescence ratio is also presented. 
 
Even though there is some association between the peptide and astrocytes in the 
hippocampus of the brain, the degree of co-localisation is not as high as in the cortex 
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and DG, as the coordinates of the fluorescent intensities locate further away from 




Cortex Dentate Gyrus Hippocampus 
Costes’ p-value 1 1 1 
Pearson’s Rr value 0.505 0.535 0.357 
Manders’ R value 0.599 0.586 0.347 
Manders’ M1 coefficient 0.785 0.874 0.908 
Manders’ M2 coefficient 0.978 0.901 0.896 
Manders’ tM1 coefficient 0.413 0.544 0.548 
Manders’ tM2 coefficient 0.624 0.603 0.510 
Table 7.1. Co-localisation coefficients of Flu-RI-OR2-TAT with astrocytes. 
The table demonstrates the Costes’ p-value obtained from “Colocalization Test”, and the 
Pearson’s correlation coefficient, Manders’ overlap coefficient, Manders’ colocalization 
coefficients M1 and M2, and Manders’ thresholded coefficients tM1 and tM2 obtained from 
“Coloc2”. 
 
As all of the conditions examined demonstrate a Costes’ p-value of 1 I conclude that 
there is co-localisation between the Flu-RI-OR2-TAT peptide and astrocytes in the 
cortex, DG and hippocampus of the brain. Examination of the thresholded Manders’ 
coefficients suggest that there is 41% overlap of astrocyte intensity with the peptide, 
whilst 62% pixels of the peptide intensity overlap with the astrocyte intensity in the 
cortex. In the DG, 54% of the red pixels (astroglia) overlap with the green pixels (Flu-
RI-OR2-TAT), whereas 60% of the peptide’s pixels overlap with the astroglial pixels. 
Finally, in the hippocampus, about 55% of the astroglial pixels co-localise with the 





7.3.1.2. Evaluation of co-localisation with activated microglia (anti-Iba-1) 
 
Figure 7.8. Co-localisation of Flu-RI-OR2-TAT with activated microglia in cortex. 
The figure illustrates the (A) confocal image analysed, (B) pixel map where colocalised pixels 
are shown as white. SB = 10 μm. 
 
 
Figure 7.9. Scatterplot of colocalised pixel map of Flu-RI-OR2-TAT with activated microglia 
in cortex. 
The scatterplot illustrates the threshold of the red channel on x-axis and the threshold of the 
green channel on y-axis. The intensity of a given pixel in channel 1 is used as an x-coordinate 
whereas the corresponding pixel’s intensity in channel 2 is represented as the y-coordinate. 
The regression line of fluorescence ratio is also presented. 
 
Examination of the scatterplot of colocalised pixels between the activated microglia 
and Flu-RI-OR2-TAT peptide in the cortex, indicates that there is co-localisation 




Figure 7.10. Co-localisation of Flu-RI-OR2-TAT with activated microglia in dentate gyrus. 
The figure illustrates the (A) confocal image analysed, (B) pixel map where colocalised pixels 
are shown as white. SB = 10 μm. 
 
 
Figure 7.11. Scatterplot of colocalised pixel map of Flu-RI-OR2-TAT with activated microglia 
in dentate gyrus. 
The scatterplot illustrates the threshold of the red channel on x-axis and the threshold of the 
green channel on y-axis. The intensity of a given pixel in channel 1 is used as an x-coordinate 
whereas the corresponding pixel’s intensity in channel 2 is represented as the y-coordinate. 
The regression line of fluorescence ratio is also presented. 
 
The scatterplot of colocalised pixels between the Flu-RI-OR2-TAT peptide and 





Figure 7.12. Co-localisation of Flu-RI-OR2-TAT with activated microglia in hippocampus. 
The figure illustrates the (A) confocal image analysed, (B) pixel map where colocalised pixels 
are shown as white. SB = 10 μm. 
 
 
Figure 7.13. Scatterplot of colocalised pixel map of Flu-RI-OR2-TAT with activated microglia 
in hippocampus. 
The scatterplot illustrates the threshold of the red channel on x-axis and the threshold of the 
green channel on y-axis. The intensity of a given pixel in channel 1 is used as an x-coordinate 
whereas the corresponding pixel’s intensity in channel 2 is represented as the y-coordinate. 
The regression line of fluorescence ratio is also presented. 
 
Comparison of the scatterplot showing the co-localisation between the Flu-RI-OR2-
TAT and activated microglia in the hippocampus indicates that the peptide does co-






Cortex Dentate Gyrus Hippocampus 
Costes’ p-value 1 1 1 
Pearson’s Rr value 0.616 0.687 0.599 
Manders’ R value 0.605 0.635 0.539 
Manders’ M1 coefficient 0.848 0.896 0.948 
Manders’ M2 coefficient 1 0.991 0.988 
Manders’ tM1 coefficient 0.660 0.711 0.681 
Manders’ tM2 coefficient 0.877 0.868 0.775 
Table 7.2. Co-localisation coefficients of Flu-RI-OR2-TAT with activated microglia. 
The table demonstrates the Costes’ p-value obtained from “Colocalization Test”, and the 
Pearson’s correlation coefficient, Manders’ overlap coefficient, Manders’ colocalization 
coefficients M1 and M2, and Manders’ thresholded coefficients tM1 and tM2 obtained from 
“Coloc2”. 
 
The Costes’ coefficient demonstrates 100% co-localisation of the Flu-RI-OR2-TAT 
peptide with activated microglia in the cortex, DG and hippocampus of the brain. 
Examination of the thresholded Manders’ coefficients demonstrate that 88% of the 
peptide co-localises with activated microglia in the cortex, 87% in the DG, and about 
78% in the hippocampus. On the other hand, in the cortex, 66% of the activated 
microglia pixels co-localise with the pixels of the peptide, 71% of red pixels (activated 
microglia) co-localise with green pixels (Flu-RI-OR2-TAT) in the DG, whereas in the 





7.3.1.3. Evaluation of co-localisation with neurons (anti-NeuN) 
 
Figure 7.14. Co-localisation of Flu-RI-OR2-TAT with neurons in cortex. 
The figure illustrates the (A) confocal image analysed, (B) pixel map where colocalised pixels 
are shown as white. SB = 10 μm. 
 
 
Figure 7.15. Scatterplot of colocalised pixel map of Flu-RI-OR2-TAT with neurons in cortex. 
The scatterplot illustrates the threshold of the red channel on x-axis and the threshold of the 
green channel on y-axis. The intensity of a given pixel in channel 1 is used as an x-coordinate 
whereas the corresponding pixel’s intensity in channel 2 is represented as the y-coordinate. 
The regression line of fluorescence ratio is also presented. 
 
The scatterplot of colocalised pixels of Flu-RI-OR2-TAT and neurons in the cortex of 
the brain indicates that, even though there is co-localisation between the two 




Figure 7.16. Co-localisation of Flu-RI-OR2-TAT with neurons in dentate gyrus. 
The figure illustrates the (A) confocal image analysed, (B) pixel map where colocalised pixels 
are shown as white. SB = 10 μm. 
 
 
Figure 7.17. Scatterplot of colocalised pixel map of Flu-RI-OR2-TAT with neurons in dentate 
gyrus. 
The scatterplot illustrates the threshold of the red channel on x-axis and the threshold of the 
green channel on y-axis. The intensity of a given pixel in channel 1 is used as an x-coordinate 
whereas the corresponding pixel’s intensity in channel 2 is represented as the y-coordinate. 
The regression line of fluorescence ratio is also presented. 
 
The scatterplot of colocalised pixels between the Flu-RI-OR2-TAT and neurons in the 





Figure 7.18. Co-localisation of Flu-RI-OR2-TAT with neurons in hippocampus.  
The figure illustrates the (A) confocal image analysed, (B) pixel map where colocalised pixels 
are shown as white. SB = 10 μm. 
 
 
Figure 7.19. Scatterplot of colocalised pixel map of Flu-RI-OR2-TAT with neurons in 
hippocampus.  
The scatterplot illustrates the threshold of the red channel on x-axis and the threshold of the 
green channel on y-axis. The intensity of a given pixel in channel 1 is used as an x-coordinate 
whereas the corresponding pixel’s intensity in channel 2 is represented as the y-coordinate. 
The regression line of fluorescence ratio is also presented. 
 
The scatterplot of colocalised pixels demonstrates that even though there is some 
co-localisation between the Flu-RI-OR2-TAT peptide and neurons in the 
hippocampus, there are also a lot of neurons that do not correlate with the peptide’s 





Cortex Dentate Gyrus Hippocampus 
Costes’ p-value 1 1 1 
Pearson’s Rr value 0.262 0.247 0.325 
Manders’ R value 0.374 0.595 0.595 
Manders’ M1 coefficient 0.811 0.838 0.788 
Manders’ M2 coefficient 0.975 0.992 0.985 
Manders’ tM1 coefficient 0.171 0.166 0.222 
Manders’ tM2 coefficient 0.239 0.130 0.236 
Table 7.3. Co-localisation coefficients of Flu-RI-OR2-TAT with neurons.  
The table demonstrates the Costes’ p-value obtained from “Colocalization Test”, and the 
Pearson’s correlation coefficient, Manders’ overlap coefficient, Manders’ colocalization 
coefficients M1 and M2, and Manders’ thresholded coefficients tM1 and tM2 obtained from 
“Coloc2”. 
 
Even though the Costes’ p-value indicates that the Flu-RI-OR2-TAT peptide co-
localises with some neurons in the cortex, DG, and hippocampus of the brain, 
examination of the thresholded Manders’ coefficients indicate that the correlation of 
the two channels is low. In the cortex and hippocampus, 24 % of the peptide 
overlaps with neurons, whereas in the DG, only 13% of the peptide overlaps with the 
red pixels. Comparing the percentages of overlap between the red pixels (neurons) 
and green pixels (Flu-RI-OR2-TAT peptide), there is 17% overlap in the cortex and DG, 




7.3.2. Co-localisation of Flu-RI-OR2-NAG with cell markers in cortex, DG and 
hippocampus 
7.3.2.1. Evaluation of co-localisation with astrocytes (anti-GFAP) 
 
Figure 7.20. Co-localisation of Flu-RI-OR2-NAG with astrocytes in cortex. 
The figure illustrates the (A) confocal image analysed, (B) pixel map where colocalised pixels 
are shown as white. SB = 10 μm. 
 
 
Figure 7.21. Scatterplot of colocalised pixel map of Flu-RI-OR2-NAG with astrocytes in 
cortex. 
The scatterplot illustrates the threshold of the red channel on x-axis and the threshold of the 
green channel on y-axis. The intensity of a given pixel in channel 1 is used as an x-coordinate 
whereas the corresponding pixel’s intensity in channel 2 is represented as the y-coordinate. 




The scatterplot comparing the Flu-RI-OR2-NAG peptide and astrocytes co-localisation 
in cortex demonstrates weak co-localisation of the peptide with the cell marker as 
the slope of the regression line shifts towards the red pixels of the astrocytes.  
 
 
Figure 7.22. Co-localisation of Flu-RI-OR2-NAG with astrocytes in dentate gyrus. 
The figure illustrates the (A) confocal image analysed, (B) pixel map where colocalised pixels 
are shown as white. SB = 10 μm. 
 
 
Figure 7.23. Scatterplot of colocalised pixel map of Flu-RI-OR2-NAG with astrocytes in 
dentate gyrus. 
The scatterplot illustrates the threshold of the red channel on x-axis and the threshold of the 
green channel on y-axis. The intensity of a given pixel in channel 1 is used as an x-coordinate 
whereas the corresponding pixel’s intensity in channel 2 is represented as the y-coordinate. 




Similar to the previous scatterplot, weak correlation is observed between the Flu-RI-
OR2-NAG peptide and astrocytes in the DG of the hippocampal formation. 
 
 
Figure 7.24. Co-localisation of Flu-RI-OR2-NAG with astrocytes in hippocampus. 
The figure illustrates the (A) confocal image analysed, (B) pixel map where colocalised pixels 
are shown as white. SB = 10 μm. 
 
 
Figure 7.25. Scatterplot of colocalised pixel map of Flu-RI-OR2-NAG with astrocytes in 
hippocampus. 
The scatterplot illustrates the threshold of the red channel on x-axis and the threshold of the 
green channel on y-axis. The intensity of a given pixel in channel 1 is used as an x-coordinate 
whereas the corresponding pixel’s intensity in channel 2 is represented as the y-coordinate. 
The regression line of fluorescence ratio is also presented. 
 
Even though the slope of the regression line comparing the fluorescent intensities of 
Flu-RI-OR2-NAG peptide and astrocytes in the hippocampus is higher than the grade 
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of correlation in cortex and DG, there is no strong co-localisation observed between 




Cortex Dentate Gyrus Hippocampus 
Costes’ p-value 1 1 1 
Pearson’s Rr value 0.644 0.426 0.630 
Manders’ R value 0.700 0.327 0.623 
Manders’ M1 coefficient 0.584 0.626 0.901 
Manders’ M2 coefficient 0.999 0.939 0.976 
Manders’ tM1 coefficient 0.031 0.537 0.727 
Manders’ tM2 coefficient 0.073 0.725 0.728 
Table 7.4. Co-localisation coefficients of Flu-RI-OR2-NAG with astrocytes. 
The table demonstrates the Costes’ p-value obtained from “Colocalization Test”, and the 
Pearson’s correlation coefficient, Manders’ overlap coefficient, Manders’ colocalization 
coefficients M1 and M2, and Manders’ thresholded coefficients tM1 and tM2 obtained from 
“Coloc2”. 
 
The Costes’ p-value demonstrates that all of the peptides co-localise with astrocytes 
in the cortex, DG and hippocampus of the brain. The thresholded Manders’ 
coefficients demonstrate that 7% of the Flu-RI-OR2-NAG peptide co-localises with 
astrocytes in the cortex and 73% in the DG and hippocampus. On the other hand, 3% 
of astrocytes co-localise with the Flu-RI-OR2-NAG peptide in the DG, 54% in the DG 




7.3.2.2. Evaluation of co-localisation with activated microglia (anti-Iba-1) 
 
Figure 7.26. Co-localisation of Flu-RI-OR2-NAG with activated microglia in cortex. 
The figure illustrates the (A) confocal image analysed, (B) pixel map where colocalised pixels 
are shown as white. SB = 10 μm. 
 
 
Figure 7.27. Scatterplot of colocalised pixel map of Flu-RI-OR2-NAG with activated 
microglia in cortex. 
The scatterplot illustrates the threshold of the red channel on x-axis and the threshold of the 
green channel on y-axis. The intensity of a given pixel in channel 1 is used as an x-coordinate 
whereas the corresponding pixel’s intensity in channel 2 is represented as the y-coordinate. 
The regression line of fluorescence ratio is also presented. 
 
The scatterplot showing the correlation of Flu-RI-OR2-NAG peptide and activated 
microglia in the cortex of the brain, demonstrates strong overlap between the two 




Figure 7.28. Co-localisation of Flu-RI-OR2-NAG with activated microglia in dentate gyrus. 
The figure illustrates the (A) confocal image analysed, (B) pixel map where colocalised pixels 
are shown as white. SB = 10 μm. 
 
 
Figure 7.29. Scatterplot of colocalised pixel map of Flu-RI-OR2-NAG with activated 
microglia in dentate gyrus. 
The scatterplot illustrates the threshold of the red channel on x-axis and the threshold of the 
green channel on y-axis. The intensity of a given pixel in channel 1 is used as an x-coordinate 
whereas the corresponding pixel’s intensity in channel 2 is represented as the y-coordinate. 
The regression line of fluorescence ratio is also presented. 
 
Investigation of co-localisation of the Flu-RI-OR2-NAG peptide and activated 





Figure 7.30. Co-localisation of Flu-RI-OR2-NAG with activated microglia in hippocampus.  
The figure illustrates the (A) confocal image analysed, (B) pixel map where colocalised pixels 
are shown as white. SB = 10 μm. 
 
 
Figure 7.31. Scatterplot of colocalised pixel map of Flu-RI-OR2-NAG with activated 
microglia in hippocampus. 
The scatterplot illustrates the threshold of the red channel on x-axis and the threshold of the 
green channel on y-axis. The intensity of a given pixel in channel 1 is used as an x-coordinate 
whereas the corresponding pixel’s intensity in channel 2 is represented as the y-coordinate. 
The regression line of fluorescence ratio is also presented. 
 
Examination of the scatterplot demonstrates that the Flu-RI-OR2-NAG peptide co-







Cortex Dentate Gyrus Hippocampus 
Costes’ p-value 1 1 1 
Pearson’s Rr value 0.691 0.530 0.419 
Manders’ R value 0.714 0.453 0.373 
Manders’ M1 coefficient 0.975 0.758 0.724 
Manders’ M2 coefficient 0.915 0.966 0.932 
Manders’ tM1 coefficient 0.788 0.681 0.496 
Manders’ tM2 coefficient 0.755 0.841 0.688 
Table 7.5. Co-localisation coefficients of Flu-RI-OR2-NAG with activated microglia. 
The table demonstrates the Costes’ p-value obtained from “Colocalization Test”, and the 
Pearson’s correlation coefficient, Manders’ overlap coefficient, Manders’ colocalization 
coefficients M1 and M2, and Manders’ thresholded coefficients tM1 and tM2 obtained from 
“Coloc2”. 
 
The Costes’ p-values demonstrates true co-localisation between the Flu-RI-OR2-NAG 
peptide and activated microglia in the cortex, DG and hippocampus of the brain. 
Evaluation of the thresholded Manders’ values indicate the 76% of the peptide co-
localises with activated microglia in the cortex, 84% in the DG and 69% in the 
hippocampus of the brain. With respect to the fluorescence of the red channel, 79% 
of activated microglia co-locate with the peptide in the cortex, 68% in the DG, and 






7.3.2.3. Evaluation of co-localisation with neuronal nuclei (anti-NeuN) 
 
Figure 7.32. Co-localisation of Flu-RI-OR2-NAG with neurons in cortex. 
The figure illustrates the (A) confocal image analysed, (B) pixel map where colocalised pixels 
are shown as white. SB = 10 μm. 
 
 
Figure 7.33. Scatterplot of colocalised pixel map of Flu-RI-OR2-NAG with neurons in cortex. 
The scatterplot illustrates the threshold of the red channel on x-axis and the threshold of the 
green channel on y-axis. The intensity of a given pixel in channel 1 is used as an x-coordinate 
whereas the corresponding pixel’s intensity in channel 2 is represented as the y-coordinate. 
The regression line of fluorescence ratio is also presented. 
 
The scatterplot demonstrates that the fluorescent pixels of the Flu-RI-OR2-NAG 
peptide weakly overlap with the fluorescent pixels of the neurons in the cortex, 
however the slope of the regression line is low due to the abundance of neurons in 




Figure 7.34. Co-localisation of Flu-RI-OR2-NAG with neurons in dentate gyrus. 
The figure illustrates the (A) confocal image analysed, (B) pixel map where colocalised pixels 
are shown as white. SB = 10 μm. 
 
 
Figure 7.35. Scatterplot of colocalised pixel map of Flu-RI-OR2-NAG with neurons in 
dentate gyrus. 
The scatterplot illustrates the threshold of the red channel on x-axis and the threshold of the 
green channel on y-axis. The intensity of a given pixel in channel 1 is used as an x-coordinate 
whereas the corresponding pixel’s intensity in channel 2 is represented as the y-coordinate. 
The regression line of fluorescence ratio is also presented. 
 
Examination of the scatterplot between the Flu-RI-OR2-NAG peptide and neurons in 





Figure 7.36. Co-localisation of Flu-RI-OR2-NAG with neurons in hippocampus. 
The figure illustrates the (A) confocal image analysed, (B) pixel map where colocalised pixels 
are shown as white. SB = 10 μm. 
 
 
Figure 7.37. Scatterplot of colocalised pixel map of Flu-RI-OR2-NAG with neurons in 
hippocampus. 
The scatterplot illustrates the threshold of the red channel on x-axis and the threshold of the 
green channel on y-axis. The intensity of a given pixel in channel 1 is used as an x-coordinate 
whereas the corresponding pixel’s intensity in channel 2 is represented as the y-coordinate. 
The regression line of fluorescence ratio is also presented. 
 
The regression line of the scatterplot comparing the Flu-RI-OR2-NAG peptide and 
neurons in the hippocampus demonstrates that the peptide overlaps with the cell 






Cortex Dentate Gyrus Hippocampus 
Costes’ p-value 1 1 1 
Pearson’s Rr value 0.295 0.100 0.367 
Manders’ R value 0.245 0.146 0.562 
Manders’ M1 coefficient 0.627 0.491 0.644 
Manders’ M2 coefficient 0.939 0.964 0.991 
Manders’ tM1 coefficient 0.416 0.247 0.253 
Manders’ tM2 coefficient 0.480 0.498 0.539 
Table 7.6. Co-localisation coefficients of Flu-RI-OR2-NAG with neurons. 
The table demonstrates the Costes’ p-value obtained from “Colocalization Test”, and the 
Pearson’s correlation coefficient, Manders’ overlap coefficient, Manders’ colocalization 
coefficients M1 and M2, and Manders’ thresholded coefficients tM1 and tM2 obtained from 
“Coloc2”. 
 
The p-values resulted from the Costes’ randomization test demonstrate that the Flu-
RI-OR2-NAG peptide co-localises with neurons in the cortex, DG and hippocampus. 
The results observed from the thresholded Manders’ coefficients indicate that 48% 
of the peptide co-localises with neurons in the cortex, 50% in the DG, and 54% in the 
hippocampus. On the other hand, 42% of neurons co-localise with the Flu-RI-OR2-





7.3.3. Co-localisation of BODIPY-PINPs with cell markers in cortex, DG and 
hippocampus 
7.3.3.1. Evaluation of co-localisation with astrocytes (anti-GFAP) 
 
Figure 7.38. Co-localisation of BODIPY-PINPs with astrocytes in cortex. 
The figure illustrates the (A) confocal image analysed, (B) pixel map where colocalised pixels 
are shown as white. SB = 10 μm. 
 
 
Figure 7.39. Scatterplot of colocalised pixel map of BODIPY-PINPs with astrocytes in cortex. 
The scatterplot illustrates the threshold of the red channel on x-axis and the threshold of the 
green channel on y-axis. The intensity of a given pixel in channel 1 is used as an x-coordinate 
whereas the corresponding pixel’s intensity in channel 2 is represented as the y-coordinate. 
The regression line of fluorescence ratio is also presented. 
 
Investigation of the scatterplot demonstrates weak overlap of the pixel intensities 




Figure 7.40. Co-localisation of BODIPY-PINPs with astrocytes in dentate gyrus. 
The figure illustrates the (A) confocal image analysed, (B) pixel map where colocalised pixels 
are shown as white. SB = 10 μm. 
 
 
Figure 7.41. Scatterplot of colocalised pixel map of BODIPY-PINPs with astrocytes in 
dentate gyrus. 
The scatterplot illustrates the threshold of the red channel on x-axis and the threshold of the 
green channel on y-axis. The intensity of a given pixel in channel 1 is used as an x-coordinate 
whereas the corresponding pixel’s intensity in channel 2 is represented as the y-coordinate. 
The regression line of fluorescence ratio is also presented. 
 
Comparing the regression line from the scatterplot of colocalised pixels of BODIPY-
PINPs and astrocytes demonstrates that the two channels co-localise better in the 





Figure 7.42. Co-localisation of BODIPY-PINPs with astrocytes in hippocampus. 
The figure illustrates the (A) confocal image analysed, (B) pixel map where colocalised pixels 
are shown as white. SB = 10 μm. 
 
 
Figure 7.43. Scatterplot of colocalised pixel map of BODIPY-PINPs with astrocytes in 
hippocampus. 
The scatterplot illustrates the threshold of the red channel on x-axis and the threshold of the 
green channel on y-axis. The intensity of a given pixel in channel 1 is used as an x-coordinate 
whereas the corresponding pixel’s intensity in channel 2 is represented as the y-coordinate. 
The regression line of fluorescence ratio is also presented. 
 
The scatterplot of colocalised pixels between the BODIPY-PINPs peptide and 







Cortex Dentate Gyrus Hippocampus 
Costes’ p-value 1 1 1 
Pearson’s Rr value 0.319 0.558 0.341 
Manders’ R value 0.150 0.492 0.194 
Manders’ M1 coefficient 0.731 0.875 0.795 
Manders’ M2 coefficient 0.881 0.865 0.797 
Manders’ tM1 coefficient 0.578 0.747 0.577 
Manders’ tM2 coefficient 0.641 0.651 0.512 
Table 7.7. Co-localisation coefficients of BODIPY-PINPs with astrocytes. 
The table demonstrates the Costes’ p-value obtained from “Colocalization Test”, and the 
Pearson’s correlation coefficient, Manders’ overlap coefficient, Manders’ colocalization 
coefficients M1 and M2, and Manders’ thresholded coefficients tM1 and tM2 obtained from 
“Coloc2”. 
 
The p-values observed from the Costes’ randomisation test indicate that the BODIPY-
PINPs co-localise with astrocytes in the cortex, DG and hippocampus of the brain. 
Evaluation of the Manders’ thresholded coefficients indicates that 64% of the 
peptide co-locates with astrocytes in the cortex, 65% in the DG and 51% in the 
hippocampus. Relative to the red fluorescent pixels, 58% of the astrocytes co-localise 







7.3.3.2. Evaluation of co-localisation with activated microglia (anti-Iba-1) 
 
Figure 7.44. Co-localisation of BODIPY-PINPs with activated microglia in cortex. 
The figure illustrates the (A) confocal image analysed, (B) pixel map where colocalised pixels 
are shown as white. SB = 10 μm. 
 
 
Figure 7.45. Scatterplot of colocalised pixel map of BODIPY-PINPs with activated microglia 
in cortex. 
The scatterplot illustrates the threshold of the red channel on x-axis and the threshold of the 
green channel on y-axis. The intensity of a given pixel in channel 1 is used as an x-coordinate 
whereas the corresponding pixel’s intensity in channel 2 is represented as the y-coordinate. 
The regression line of fluorescence ratio is also presented. 
 
The scatterplot indicates strong overlap between the BODIPY-PINPs and activated 




Figure 7.46. Co-localisation of BODIPY-PINPs with activated microglia in dentate gyrus. 
The figure illustrates the (A) confocal image analysed, (B) pixel map where colocalised pixels 
are shown as white. SB = 10 μm. 
 
 
Figure 7.47. Scatterplot of colocalised pixel map of BODIPY-PINPs with activated microglia 
in dentate gyrus. 
The scatterplot illustrates the threshold of the red channel on x-axis and the threshold of the 
green channel on y-axis. The intensity of a given pixel in channel 1 is used as an x-coordinate 
whereas the corresponding pixel’s intensity in channel 2 is represented as the y-coordinate. 
The regression line of fluorescence ratio is also presented. 
 
Evaluation of the scatterplot of colocalised pixels demonstrates really strong 
correlation between BODIPY-PINPs and activated microglia in the DG of the 




Figure 7.48. Co-localisation of BODIPY-PINPs with activated microglia in hippocampus. 
The figure illustrates the (A) confocal image analysed, (B) pixel map where colocalised pixels 
are shown as white. SB = 10 μm. 
 
 
Figure 7.49. Scatterplot of colocalised pixel map of BODIPY-PINPs with activated microglia 
in hippocampus. 
The scatterplot illustrates the threshold of the red channel on x-axis and the threshold of the 
green channel on y-axis. The intensity of a given pixel in channel 1 is used as an x-coordinate 
whereas the corresponding pixel’s intensity in channel 2 is represented as the y-coordinate. 
The regression line of fluorescence ratio is also presented. 
 
The scatterplot indicates strong overlap between the BODIPY-PINPs peptide and 







Cortex Dentate Gyrus Hippocampus 
Costes’ p-value 1 1 1 
Pearson’s Rr value 0.701 0.824 0.605 
Manders’ R value 0.698 0.842 0.620 
Manders’ M1 coefficient 0.806 0.923 0.740 
Manders’ M2 coefficient 0.993 0.886 0.988 
Manders’ tM1 coefficient 0.677 0.800 0.642 
Manders’ tM2 coefficient 0.806 0.774 0.758 
Table 7.8. Co-localisation coefficients of BODIPY-PINPs with activated microglia. 
The table demonstrates the Costes’ p-value obtained from “Colocalization Test”, and the 
Pearson’s correlation coefficient, Manders’ overlap coefficient, Manders’ colocalization 
coefficients M1 and M2, and Manders’ thresholded coefficients tM1 and tM2 obtained from 
“Coloc2”. 
 
Evaluation of the p-values from the Costes’ randomization test indicates that there is 
true co-localisation between the BODIPY-PINPs and activated microglia in all of the 
examined regions of the brain. The values resulting from the Manders’ thresholded 
test indicate that 81% of the peptide co-localises with activated microglia in the 
cortex, 75% in the DG and 76% in the hippocampus. On the other hand, 68% of 
activated microglia co-locate with BODIPY-PINPs in the cortex of the brain, 80% in 






7.3.3.3. Evaluation of co-localisation with neurons (anti-NeuN) 
 
Figure 7.50. Co-localisation of BODIPY-PINPs with neurons in cortex. 
The figure illustrates the (A) confocal image analysed, (B) pixel map where colocalised pixels 
are shown as white. SB = 10 μm. 
 
 
Figure 7.51. Scatterplot of colocalised pixel map of BODIPY-PINPs with neurons in cortex. 
The scatterplot illustrates the threshold of the red channel on x-axis and the threshold of the 
green channel on y-axis. The intensity of a given pixel in channel 1 is used as an x-coordinate 
whereas the corresponding pixel’s intensity in channel 2 is represented as the y-coordinate. 
The regression line of fluorescence ratio is also presented. 
 
The scatterplot resulting from the colocalised pixels of the BODIPY-PINPs and 





Figure 7.52. Co-localisation of BODIPY-PINPs with neurons in dentate gyrus. 
The figure illustrates the (A) confocal image analysed, (B) pixel map where colocalised pixels 
are shown as white. SB = 10 μm. 
 
 
Figure 7.53. Scatterplot of colocalised pixel map of BODIPY-PINPs with neurons in dentate 
gyrus. 
The scatterplot illustrates the threshold of the red channel on x-axis and the threshold of the 
green channel on y-axis. The intensity of a given pixel in channel 1 is used as an x-coordinate 
whereas the corresponding pixel’s intensity in channel 2 is represented as the y-coordinate. 
The regression line of fluorescence ratio is also presented. 
 
Similarly to the cortex, comparison of the pixels intensity between the BODIPY-PINPs 





Figure 7.54. Co-localisation of BODIPY-PINPs with neurons in hippocampus. 
The figure illustrates the (A) confocal image analysed, (B) pixel map where colocalised pixels 
are shown as white. SB = 10 μm. 
 
 
Figure 7.55. Scatterplot of colocalised pixel map of BODIPY-PINPs with neurons in 
hippocampus. 
The scatterplot illustrates the threshold of the red channel on x-axis and the threshold of the 
green channel on y-axis. The intensity of a given pixel in channel 1 is used as an x-coordinate 
whereas the corresponding pixel’s intensity in channel 2 is represented as the y-coordinate. 
The regression line of fluorescence ratio is also presented. 
 
Data from the scatterplot comparing the colocalised pixels of BODIPY-PINPs and 







Cortex Dentate Gyrus Hippocampus 
Costes’ p-value 1 1 1 
Pearson’s Rr value 0.085 0.095 0.184 
Manders’ R value 0.102 0.535 0.291 
Manders’ M1 coefficient 0.889 0.826 0.794 
Manders’ M2 coefficient 0.995 0.868 0.972 
Manders’ tM1 coefficient 0.271 0.251 0.263 
Manders’ tM2 coefficient 0.057 0.043 0.240 
Table 7.9. Co-localisation coefficients of BODIPY-PINPs with neurons. 
The table demonstrates the Costes’ p-value obtained from “Colocalization Test”, and the 
Pearson’s correlation coefficient, Manders’ overlap coefficient, Manders’ colocalization 
coefficients M1 and M2, and Manders’ thresholded coefficients tM1 and tM2 obtained from 
“Coloc2”. 
 
The results of the Costes’ randomization test indicates that the BODIPY-PINPs do co-
localise with neurons in the brain. However, evaluation of the Manders’ thresholded 
coefficients demonstrate that 6% of the peptide co-localises with neurons in the 
cortex, 4% in the DG and 24% in the hippocampus. Relative to the channel 1 pixels, 
27% of neurons co-localise with the BODIPY-PINPs in the cortex, 25% in the DG and 




This Chapter presents a co-localisation study of Flu-RI-OR2-TAT, Flu-RI-OR2-NAG and 
BODIPY-PINPs with neuronal and glial cells in the cortex, DG and hippocampus of the 
brain. Previously published data by Parthsarathy and colleagues demonstrated that 
the Flu-RI-OR2-TAT peptide co-localises with activated microglial cells in the brains of 
APP/PS1 transgenic mice (Parthsarathy et al., 2013).  
 
Peripheral administration of 100 nmol/kg of Flu-RI-OR2-TAT and Flu-RI-OR2-NAG 
peptides and 4 μmol/kg of BODIPY-PINPs results in BBB penetration after 1 h, as 
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demonstrated in the previous Chapter (Chapter 6). Here, these peptides and peptide-
nanoparticles showed some co-localisation with astrocytes, activated microglia and 
neurons in the cortex, DG and hippocampus of the brain, in WT mice with C57/BL6 
background. The table below (Table 7.10.) represents a summary of the 
colocalization study. 
 
Brain Region Cell type Flu-RI-OR2-TAT Flu-RI-OR2-NAG BODIPY-PINPs 
Cortex 
Astrocytes High Low Low 
Activated 
microglia 
Moderate High High 
Neurons Moderate Low Low 
DG 
Astrocytes High Low Moderate 
Activated 
microglia 
High Moderate High 
Neurons Low Low Low 
Hippocampus 
(CA1) 
Astrocytes Moderate Moderate Moderate 
Activated 
microglia 
High Moderate Moderate 
Neurons Low Low Low 
Table 7.10. Summary table of colocalisation between peptides and cells. 
The table represents a summary of the colocalization between the three peptides (Flu-RI-
OR2-TAT, Flu-RI-OR2-NAG and BODPY-PINPs) and the cell types (astrocytes, activated 
microglia, neurons) examined in the cortex, hippocampus, and DG of WT mouse brains. 
 
The Flu-RI-OR2-TAT peptide demonstrated some tendency to co-localise with 
activated microglial cells, as indicated in the previous study by Parthsarathy and 
colleagues (Parthsarathy et al., 2013), in all regions of the brain that were 
investigated in this study. The same property was observed with BODIPY-PINPs and 
Flu-RI-OR2-NAG peptides, where they were mainly found inside activated microglia, 
rather than astrocytes and neurons. Activated microglial cells function as immune 
macrophages in the presence of cytotoxic compounds in the brain. This ability is also 
evident when increased concentrations of Aβ are present in the brains of AD 
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patients. More specifically, activated microglial cells tend to cluster around the senile 
plaques in the brain and mediate inflammation pathways by the secretion of 
cytokines and activation of macrophages to aid the clearance of Aβ (Mandrekar and 
Landreth, 2013; Lai and McLaurin, 2012; Solito and Sastre, 2012;). 
 
Previously published work on APP/PS1 mice by Parthsarathy and colleagues 
supported that the presence of the Flu-RI-OR2-TAT peptide inside activated microglia 
is due to the attachment of the peptide to Aβ fibrils, as the activated microglial cells 
are responsible for the active take up of amyloid by phagocytosis resulting in the 
clearance of Aβ from the brain (Paresce et al., 1997). As the Flu-RI-OR2-NAG and 
BODIPY-PINPs were found colocalised with activated microglial cells, there is the 
likelihood that these peptides can retain this property. However, further 
ultrastructural studies and colocalisation examination with an Aβ marker are 
required to confirm this. Additionally, as the peptides co-localise with astrocytes, this 
further supports the fact that the peptides can penetrate across the BBB, since 
astroglial cells are located close to the BBB (Abbott, 2002) and structurally support 
the tight junctions formed by the endothelial cells, controlling the access of 
substances crossing from blood to the CNS. 
 
The mechanism by which the peptides are inserted inside the cells was not 
investigated in this project. With reference to the Flu-RI-OR2-NAG, the peptide was 
formulated with the NAG transit sequence so as the inhibitor can utilise the glucose 
transporters that are located at the BBB (GLUT1) (Bell et al., 1990) to penetrate 
inside the brain, and the GLUT3 transporters on the membrane of neurons (Bell et 
al., 1990) and NAG transporters expressed at the Golgi complex of the cells (Abeijon 
et al., 1996) to penetrate inside cells. On the other hand, the TAT sequence of the RI-
OR2-TAT inhibitor has been widely used as a transit sequence enabling a diversity of 
molcules across the BBB (Dietz and Bahr, 2004; Ramanathan et al., 2001); and this 
activity was also proven to be retained in the retro-inverso version of the TAT 
sequence (Repici et al., 2007; Zhang et al., 2009). However, the exact mechanism by 
which the TAT sequence enables the penetration of compounds inside cells remains 




The results from this study have demonstrated that Flu-RI-OR2-TAT, Flu-RI-OR2-NAG 
and BODIPY-PINPs are found mainly inside or in association with microglial cells, 
rather than astrocytes and neurons in the cerebral cortex, DG and hippocampus of 
the brains of WT mice acutely injected i.p. with 100 nmol/kg of the free peptides and 
4 μmol/kg of the peptide-decorated liposomes, after 1 h. 
 
One of the limitations related to this study is the absence of a vascular marker in the 
brain. Endothelial cells in the brain comprise the microvasculature, which along with 
the astroglial cells, form the BBB in the CNS (Abbott, 2002; Tanapat, 2013). Co-
localisation of the peptides with vascular endothelial cells would further confirm that 
they are able to cross the BBB and deposit in the brain. Additionally, as the 
acquisition of the images (63X objective) for this study was performed at the same 
time as the images acquired for the BBB penetration study (40X objective), the 
sections exhibited partial photobleaching that might have interfered with the 
statistical analysis of the study, even though the majority of the colocalization tools 
employed in this Chapter are independent of the channels’ and background 
intensities. 
 
With a therapeutic focus, the study further supports findings that the peptides can 
cross an intact and functional BBB, as demonstrated previously in Chapter 6. 
Additionally, the ability of the peptides to co-locate with activated microglia indicates 
that they may be involved in the clearance mechanisms responsible for removal of 




Chapter 8: Final discussion and further work 
 
8.1. Background 
AD is the most common neurodegenerative disease, affecting mainly elderly 
individuals, and is characterised by the accumulation of extracellular senile plaques 
containing the Aβ peptide, and intracellular neurofibrillary tangles composed of 
hyperphosphorylated tau protein (Bird, 2008). Currently, AD is considered as an 
epidemic since 46.8 million people worldwide are believed to be affected by the 
disease, or by a related dementia, a number that is expected to increase to 74.7 
million by 2030 and 131.5 million by 2050. It is estimated that a new case of 
dementia occurs every 3.2 sec (WWW, BrightFocus Foundation).  
 
8.1.1. Drugs targeting the Aβ aggregation pathway 
Aβ pathology is a central component in AD. Accumulating research evidence has 
supported the hypothesis that Aβ oligomerisation and fibrillogenesis are crucial and 
primary pathogenic events in AD (Lansbury and Lashuel, 2006; Haass and Selkoe, 
2007; Walsh and Selkoe; 2007). It was originally proposed that the mature end-
products of the Aβ aggregation process, the amyloid fibrils which are present in the 
senile plaques of the brain, are the primary neurotoxic factors that are associated 
with the progression of the disease (Hardy and Allsop, 1991). However, later studies 
on AD have supported the idea that the early nonfibrillar aggregates, known as the 
soluble oligomers, are the main pathogenic components that are partly responsible 
for neurodegeneration and neuronal cell death in the brains of diseased individuals 
(Hardy and Selkoe, 2002). Oligomeric forms of Aβ are now thought to be more toxic 
than the mature fibrils (Klein et al., 2001; Hardy and Selkoe, 2002; Varvel et al., 
2008), consequently resulting in the potent memory and learning deficits (Chromy et 
al., 2003; Bitan et al., 2003) as well as cognitive impairment (Tomic et al., 2009), that 
are the main symptoms of the disease. 
 
Therefore, the invention and development of drugs that directly inhibit the very early 
stages of the aggregation process, rather than the late stages of amyloid fibril 
211 
 
formation, is considered to be a viable therapeutic strategy for slowing or even 
halting the progression of AD. Many studies have been performed in recent years in 
order to develop new drugs that target the formation, clearance or aggregation of 
Aβ, with all of them proven to be ineffective (Mangialasche et al., 2010). Several of 
these inhibitor drugs target the β-secretase (Klaver et al., 2010) and γ-secretase 
(Wolfe, 2008) proteolytic enzymes that are both involved in the production of Aβ 
from the APP protein (LaFerla et al., 2007). Both approaches have resulted in various 
side effects in patients, as both enzymes have substrates other than APP (Gandy, 
2005). 
 
8.1.2. Other approaches used in drug development 
Various other approaches to drug development, such as direct immunisation with 
Aβ, or passive immunisation with anti-Aβ antibodies, have also failed to progress in 
clinical trials, often due to adverse side effects, including activation of brain 
inflammatory responses that result in microhaemorrhages (Sperling et al., 2012) and 
the development of meningoencephalitis (Gilman et al., 2005). In particular, studies 
based on passive immunisation with anti-Aβ antibodies have resulted in the 
development of Bapineuzumab (Johnson and Johnson) and Solanezumab (Elli Lilly), 
both of which failed in late-clinical trials, as they did not demonstrate any improved 
cognition in mild-to-moderate AD (Sperling et al., 2012; WWW, ClinicalTrials.gov). 
One more promising discovery, Curcumin, has demonstrated inhibition of Aβ 
aggregation (Yang et al., 2005), but is unsuitable as a drug candidate because it 
exhibits poor bioavailability and biodistribution. 
 
Currently, four drugs are approved for use in patients with AD. However, the three 
acetylcholinesterase inhibitor drugs Galantamine, Donepezil and Rivastigmine, and 
the NMDA receptor antagonist drug Memantine, temporarily alleviate the symptoms 
of AD but do not have a major impact on disease progression (Inglis, 2002; Areosa et 
al., 2006; Schneider et al. 2011). Consequently, there is an urgent need to develop 
more effective drugs that prevent, delay the onset, slow the progression, or more 




8.1.3. The RI-OR2 peptide-based aggregation inhibitors 
Published data by Parthsarathy and colleagues (Parthsarathy et al., 2013) 
demonstrated that the RI-OR2-TAT peptide inhibits Aβ oligomer and fibril formation, 
as well as blocking their toxic effects in vitro using cultured SH-SY5Y human 
neuroblastoma cells. This peptide inhibitor was also found to cross the BBB and bind 
to amyloid plaques and activated microglial cells in the cerebral cortex of APP/PS1 
Alzheimer’s transgenic mice, following its peripheral administration (100 nmol/kg) 
once per day for 21 days. Data from the same research also showed that the RI-OR2-
TAT peptide inhibitor was able to reduce amyloid deposition, oxidation and 
inflammation, yet also stimulate neurogenesis in the DG of the same mouse model of 
AD (Parthsarathy et al., 2013). 
 
The incorporation of the retro-inverted version of the HIV-1 ‘TAT’ sequence on the 
former developed peptide, RI-OR2 (Taylor et al., 2010), was aimed at targeting the 
peptide into the brain. The TAT sequence has previously been shown to enable a 
variety of different molecules to cross the BBB (Dietz and Bahr, 2004; Ramanathan et 
al., 2001); an activity that was proven to be retained in the retro-inverso version of 
the TAT sequence (Repici et al., 2007; Zhang et al., 2009). In RI-OR2-TAT, the retro-
inverso TAT sequence was integrated so that the protease resistance of the whole 
molecule was maintained (Parthsarathy et al., 2013). 
 
However, one problem associated with the use of the TAT sequence is that the 
peptide is not targeted selectively to the brain, possibly resulting in various adverse 
peripheral side effects. This limitation of the RI-OR2-TAT peptide as well its effect on 
the level of Aβ aggregation could be improved by using a more brain-selective 
delivery mechanism, ideally in a combination with a more potent inhibitor. An 
approach that was suggested by Parthsarathy and colleagues to increase the potency 
of RI-OR2-TAT against Aβ aggregation, was to attach the peptide onto the surface of 
lipid nanoparticles, to produce a multivalent inhibitor (Parthsarathy et al., 2013). The 
resulting PINPs have been studied as part of this project. Another approach taken 
here is to use NAG as an alternative targeting mechanism to TAT, in an attempt to 
develop a new more brain-selective version of the RI-OR2 aggregation inhibitor.  
213 
 
8.2. Findings of the study 
The scope of this PhD thesis project was to develop a new peptide inhibitor, RI-OR2-
NAG, as an alternative anti-aggregation peptide to RI-OR2-TAT. Additionally, this 
project was aiming at determining whether RI-OR2-TAT, RI-OR2-NAG and PINPs, are 
able to penetrate across an intact and functional BBB, and investigate the 
accumulation of the peptides in the brain and distribution in other body tissues of 
WT mice with C57/BL6 background following their peripheral administration.  
 
8.2.1. Penetration across an intact BBB 
The ability of RI-OR2-TAT and PINPs to cross the BBB have been assessed previously. 
Parthsarathy and colleagues have demonstrated that the RI-OR2-TAT peptide was 
able to cross the BBB of APP/PS1 transgenic mice (Parthsarathy et al., 2013). On the 
other hand, PINPs can penetrate an artificial BBB composed of a hCMEC/D3 human 
brain endothelial cells monolayer (Gregori et al., 2017). In this project, RI-OR2-TAT, 
RI-OR2-NAG and PINPs have been shown to penetrate a dynamic and functional BBB, 
1 h after peripheral administration of 100 nmol/kg of the free peptides and 4 
μmol/kg of the PINPs.  
 
The PINPs demonstrated significantly improved results compared to the two free 
peptides, RI-OR2-TAT and RI-OR2-NAG, indicating that the attachment of the RI-OR2-
TAT peptide onto the surface of nanoliposomes favours the penetration of the 
peptide into the brain. This property of the PINPs can be partly attributed to the 
“stealth” characteristics of PEGylated liposomes, and also to the naturally occurring 
outer lipid membrane layer of this type of nanoliposome device that facilitates 
penetration across cell membranes and biological barriers (Szoka and 
Papahadjopoulos, 1980). 
 
In the case of the RI-OR2-NAG peptide, it was believed that incorporation of the NAG 
transit moiety onto the RI-OR2 could possibly target the peptide to the brain more 
effectively and selectively than the TAT transit sequence of the RI-OR2-TAT peptide. 
By utilising the glucose transporters located at the BBB (GLUT1) and on the 
membranes of neurons (GLUT3) (Bell et al., 1990), as well as the NAG transporter 
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(SLC35A3) expressed at the Golgi complex of cells (Abeijon et al., 1996), the RI-OR2-
NAG peptide should penetrate the BBB of the CNS and accumulate inside the brain.  
Even though this study has demonstrated that the RI-OR2-NAG peptide is found 
inside the brain, it was present at lower concentrations than RI-OR2-TAT and PINPs, 
suggesting that NAG-facilitated transport across the BBB is less effective than the 
TAT transit system.  
 
8.2.2. Distribution and excretion of the peptides 
Luminex technology was used to identify the distribution of the peptides in the body 
of WT mice, 1 h following their peripheral administration by i.p. injection. RI-OR2-TAT 
showed a a relatively high concentration in the stomach compared to other tissues of 
the mice, which is possibly due to the primary absorption metabolism by the liver 
and distribution through the general blood circulation. The peptide was also 
detected at significantly higher concentrations in the small intestine, indicating a 
possible mechanism of elimination through bile secretion. The peptide could either 
then be excreted through the faeces or reabsorbed back into the systemic circulation 
by the intestinal mucosa of the small intestine (Roberts et al., 2002). These findings 
are also supported by the detection of the peptide in the liver, and its absence from 
the kidneys.  
 
With respect to RI-OR2-NAG, this peptide was primarily detected in the small 
intestines of the mice, and also in the kidneys. This suggests that the peptide was 
already subjected to bile secretion and possibly reabsorbed by the intestinal mucosa 
into the blood circulation for distribution and elimination through the kidneys by 
urine (Roberts et al., 2002). A similar distribution was observed by the PINPs. 
However, these results should be interpreted with great caution due to the 
limitations in effectively developing sensitive assays for detection of these peptides.  
 
One of the most important findings of this study is, however, that the peptides were 
detected at low levels in the brains of the mice, supporting the idea that they can 




8.2.3. The anti-aggregational properties of the peptides 
Previously published data on RI-OR2-TAT showed that the peptide was able to inhibit 
Aβ aggregation up to a molar ratio of 1:5 (inhibitor to Aβ) as demonstrated by the 
ThT assay (Parthsarathy et al., 2013). On the other hand, Gregori, Taylor and 
colleagues have demonstrated that the attachment of the peptide onto the surface 
of the liposome induced a dramatic improvement in the ability of the peptide to 
inhibit the aggregation process. As demonstrated by ThT data, the peptide inhibited 
50% of the aggregation at a molar ratio of 1:50 of lipid to Aβ, or more specifically at a 
molar ratio of 1:2,000 of RI-OR2-TAT to Aβ, as the surface peptide comprises 2.5% of 
the total lipid (Gregori et al., 2017). More importantly, the peptide demonstrates 
about 25% inhibition even at a molar ratio of 1:5,000 lipid to Aβ or 1:200,000 RI-OR2-
TAT to Aβ (Gregori et al., 2017). 
 
The explanation for this increase in potency of the PINPs peptide relative to the free 
RI-OR2-TAT peptide can be partly attributed to the presence of multiple copies of the 
RI-OR2-TAT peptide on the surface of the nanoliposomes, allowing the simultaneous 
interaction of the peptide with many sites on aggregated Aβ (Figure 8.1.) (Gregori et 
al., 2017). This idea is supported by previous work with tetrameric dendrimers of the 
KLVFF peptide, which are much more potent and effective than the monomer at 
inhibiting Aβ aggregation (Chafekar et al., 2007). Thus, in the case of PINPs, multiple 
copies of the KLVFF sequences should also result in a more potent inhibitor. Another 
possible explanation for the high potency of PINPs could be associated with the 
highly positive electric charge of the TAT region of the peptide. The RI-OR2-TAT 
peptide contains several positively-charged amino acids, and multiple copies of this 
peptide on the surface of the liposomes could help to attract and bind the Aβ 





Figure 8.1. Possible mechanisms of action of PINPs. 
The figure illustrates the possible mechanisms by which the PINPs peptide inhibits the 
aggregation of Aβ. The retro-inverted “ffvlk” peptide of the free RI-OR2-TAT peptide is 
designed to interact with the “KLVFF” sequence(s) of the (A) oligomeric and (C) monomeric 
Aβ. It is also possible that the Aβ interacts with the positively charged TAT sequence of the 
peptide (B), and once captured, the Aβ molecules are inserted into the lipid bilayer of the 
liposomes. 
 
With respect to RI-OR2-NAG, this peptide proved to be a more potent inhibitor of Aβ 
aggregation than RI-OR2-TAT peptide, in the ThT experiments reported here. Even 
though the main binding region (retro-inverted ffvlk) is identical between the two 
free peptides, there is a possibility the the attachment of the NAG sequence to the 
main RI-OR2 peptide enhances the binding affinity of the peptide to the native Aβ by 
altering the conformation of the three-dimentional peptide structure. Consequently, 
the attachment of the RI-OR2-NAG peptide onto the surface of lipid scaffolds would 
possibly result in a better peptide inhibitor than the PINPs, and also exhibit the 
advanced brain and cell penetration properties of the nanoliposomes (Szoka and 
Papahadjopoulos, 1980). However, these hypotheses need to be further examined. 
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8.3. Limitations of the study 
The main limitation of the study is related to the administration of the peptides 
which was performed intraperitoneally. Ideally, the study of drug distribution should 
be conducted by administering the compounds intravenously. In that case, the 
peptides would avoid the first pass metabolism effect and enter the circulation as 
unchanged compounds where they exhibit 100% bioavailability (Shargel and Yu, 
1999) allowing the accurate qualification of distribution and metabolism of the 
peptides. 
 
Another significant limitation of the project is the limited number of animals used in 
the BBB penetration study (Chapter 6). The small number of animals treated with 
each peptide inhibitor has resulted in large error bars during the statistical analysis of 
the experiments, that do not allow the effective comparison on the deposition of the 
peptides within the cortex, hippocampus and DG of the normal brain.  
 
Additionally, another restriction of this study is the likelihood of inaccurate 
quantification of the distribution of some of the peptides in the tissues by the 
immunoassays employed for this purpose (Chapters 4 and 5). The lack of sensitivity 
of the developed assays for the Flu-RI-OR2-NAG and PINPs peptides in particular, has 
probably resulted in fallacious determination of the concentrations of the peptides in 
different tissues. However, the observed pattern of tissue distribution is probably 
accurate for the Flu-RI-OR2-TAT, although comparison between peptides is 
problematic. In general, the Luminex technology is more sensitive compared to other 
assay-based techniques, particularly to the ELISA assay that was used for detection of 
the PINPs peptide. However, there are various potential problems with optimisation 
of an assay for detection of the PINPs peptide, including the adhesion of this lipid-
bound peptide to the Luminex plate filter, poor biotinylation of the detection 





8.4. Future work 
With reference to the limitations of this study, future research should include the 
administration of the peptides intravenously to study the biodistribution of the drugs 
(Shargel and Yu, 1999), as well as other possible routes of administration. Of 
particular interest, is the possibility of intranasal administration of the peptides or 
peptide-liposomes to facilitate immediate absorption into the brain, avoiding also 
the metabolism of the peptides upon absorption by barriers other than the BBB. 
Additionally, examination of variable durations of treatment would provide 
information on the half-life of the peptides, as well as elimination rate and other 
important pharmacokinetic factors. 
 
With respect to the detection of the peptides, alternative antibodies could be tested 
for the Flu-RI-OR2-NAG and BODIPY-PINPs assays, in order to develop more sensitive 




8.5. Final conclusion 
Reflecting on the hypotheses and aims of this thesis project, the RI-OR2-TAT, RI-OR2-
NAG and PINPs peptides proved that are able to cross a dynamic and intact BBB 
(Chapter 6) and were found colocalised with major neuronal and glial cells in the 
cortex, hippocampus and DG of the mouse brains (Chapter 7). Regarding the 
properties of the two free peptides, the RI-OR2-NAG demonstrated more potent 
inhibition of Aβ fibrillogenesis compared to RI-OR2-TAT, showed no toxic effects on 
cultured neuroblastoma cells, yet displayed slower penetration inside cells (Chapter 
3) in contrast to RI-OR2-TAT that has previously shown deposition in cells within 10 
min of incubation (Parthsarathy et al., 2013). 
 
On the other hand, the attempt to study the bio-distribution and possible elimination 
routes of the Flu-RI-OR2-TAT, Flu-RI-OR2-NAG and BODIPY-PINPs peptides was not 
achieved (Chapter 5). The main reason of failing to demonstrate these properties of 
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the peptides was the inaccurate development of detection assays for Flu-RI-OR2-
NAG and BODIPY-PINPs (Chapter 4), as well as my incabability of applying an 
intravenous administration of the peptides. The i.p. administration of the inhibitor 
peptides resulted in their decreased bio-availability due to the “first-pass” effect 
occurring prior their absorption in circulation and tissue distribution. 
 
In conclusion, the attachment of the RI-OR2-TAT peptide onto the surface of lipid 
nanoparticle scaffolds has resulted in the generation of a potent and multivalent 
inhibitor of the Aβ aggregation process which also exhibits improved BBB 
penetration properties. Since the RI-OR2-NAG peptide appears to be a better 
aggregation inhibitor than RI-OR2-TAT, the attachment of RI-OR2-NAG onto 
liposomes could be particularly beneficial. This would confer on the liposome-
attached RI-OR2-NAG peptide the unique features possessed by the nanoliposomes, 
including targeted delivery into the brain, stealth properties to avoid the immune 
system, and increased bioavailability and circulation times.  
 
Finally, we are currently working on a collaborative project with the University of 
Eastern Finland and the University of Rome “La Sapienza”. It has been demonstrated 
that young APP/PS1 mice exhibit epileptic spiking due to the presence and 
accumulation of Aβ in the brain; an effect that is not observed in WT mice 
(Minkeviciene et al., 2009). This project involves the investigation of brain 
biomarkers following i.p. administration of 100 nmol/kg of RI-OR2-TAT peptide once 
per day for 21 days in 3 months old APP/PS1 transgenic mice. More importantly 
though, epileptic electroencephalogram (EEG) recordings of the cortex and 
hippocampus of the mice will be performed to investigate the effects of RI-OR2-TAT 
on normalisation of epileptic EEG. The recordings will be performed once per week 
and compared with a baseline EEG recording in treated and untreated APP/PS1 
transgenic mice.  
 
Of particular interest here, no peptide-based inhibitor targeting the Aβ aggregation 
process has been tested yet in any advanced clinical trial (Taylor et al., 2010; 
Parthsarathy et al., 2013). I believe that our peptide inhibitors, PINPs, RI-OR2-TAT 
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and RI-OR2-NAG, show encouraging results; and further studies and development of 
the peptides will hopefully enable them firstly to enter human clinical trials and 
ultimately to be used as an early-intervention disease-modifying therapy to slow or 
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